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Preamble
The medical profession should play a central role in evalu-
ating the evidence related to drugs, devices, and procedures
for the detection, management, and prevention of disease.
When properly applied, expert analysis of available data on
the benefits and risks of these therapies and procedures can
improve the quality of care, optimize patient outcomes, and
favorably affect costs by focusing resources on the most
effective strategies. An organized and directed approach to a
thorough review of evidence has resulted in the production
of clinical practice guidelines that assist physicians in select-
ing the best management strategy for an individual patient.
Moreover, clinical practice guidelines can provide a foun-
dation for other applications, such as performance measures,
appropriate use criteria, and both quality improvement and
clinical decision support tools.
The American College of Cardiology Foundation
(ACCF) and the American Heart Association (AHA) have
jointly produced guidelines in the area of cardiovascular
disease since 1980. The ACCF/AHA Task Force on
Practice Guidelines (Task Force), charged with developing,
updating, and revising practice guidelines for cardiovascular
diseases and procedures, directs and oversees this effort.
Writing committees are charged with regularly reviewingand evaluating all available evidence to develop balanced,
patient-centric recommendations for clinical practice.
Experts in the subject under consideration are selected by
the ACCF and AHA to examine subject-specific data and
write guidelines in partnership with representatives from
other medical organizations and specialty groups. Writing
committees are asked to perform a literature review; weigh
the strength of evidence for or against particular tests,
treatments, or procedures; and include estimates of expected
outcomes where such data exist. Patient-specific modifiers,
comorbidities, and issues of patient preference that may
influence the choice of tests or therapies are considered.
When available, information from studies on cost is con-
sidered, but data on efficacy and outcomes constitute the
primary basis for the recommendations contained herein.
In analyzing the data and developing recommendations
and supporting text, the writing committee uses evidence-
based methodologies developed by the Task Force (1). The
Class of Recommendation (COR) is an estimate of the size
of the treatment effect, with consideration given to risks
versus benefits as well as evidence and/or agreement that a
given treatment or procedure is or is not useful/effective or
in some situations may cause harm. The Level of Evidence
(LOE) is an estimate of the certainty or precision of the
treatment effect. The writing committee reviews and ranks
evidence supporting each recommendation, with the weight
of evidence ranked as LOE A, B, or C according to specific
definitions that are included in Table 1. Studies are identi-
fied as observational, retrospective, prospective, or random-
ized as appropriate. For certain conditions for which inad-
equate data are available, recommendations are based on
expert consensus and clinical experience and are ranked as
LOE C. When recommendations at LOE C are supported
by historical clinical data, appropriate references (including
clinical reviews) are cited if available. For issues for which
sparse data are available, a survey of current practice among
the clinicians on the writing committee is the basis for LOE C
recommendations, and no references are cited. The schema
for COR and LOE is summarized in Table 1, which also
provides suggested phrases for writing recommendations
within each COR. A new addition to this methodology is
separation of the Class III recommendations to delineate
whether the recommendation is determined to be of “no
benefit” or is associated with “harm” to the patient. In
addition, in view of the increasing number of comparative
effectiveness studies, comparator verbs and suggested
phrases for writing recommendations for the comparative
effectiveness of one treatment or strategy versus another
have been added for COR I and IIa, LOE A or B only.
In view of the advances in medical therapy across the
spectrum of cardiovascular diseases, the Task Force has
designated the term guideline-directed medical therapy
(GDMT) to represent optimal medical therapy as defined by
ACCF/AHA guideline (primarily Class I)–recommended
therapies. This new term, GDMT, will be used herein and
throughout all future guidelines.
B only
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patient populations (and healthcare providers) residing in
North America, drugs that are not currently available in
North America are discussed in the text without a specific
COR. For studies performed in large numbers of subjects
outside North America, each writing committee reviews the
potential influence of different practice patterns and patient
populations on the treatment effect and relevance to the
ACCF/AHA target population to determine whether the
findings should inform a specific recommendation.
The ACCF/AHA practice guidelines are intended to
assist healthcare providers in clinical decision making by
Table 1. Applying Classification of Recommendations and Leve
A recommendation with Level of Evidence B or C does not imply that the recommendation is weak
Although randomized trials are unavailable, there may be a very clear clinical consensus that a
Data available from clinical trials or registries about the usefulness/efficacy in different subp
failure, and prior aspirin use.
†For comparative effectiveness recommendations (Class I and IIa; Level of Evidence A and
treatments or strategies being evaluated.describing a range of generally acceptable approaches to thediagnosis, management, and prevention of specific diseases
or conditions. The guidelines attempt to define practices
that meet the needs of most patients in most circumstances.
The ultimate judgment about care of a particular patient
must be made by the healthcare provider and patient in light
of all the circumstances presented by that patient. As a
result, situations may arise in which deviations from these
guidelines might be appropriate. Clinical decision making
should involve consideration of the quality and availability
of expertise in the area where care is provided. When these
guidelines are used as the basis for regulatory or payer
decisions, the goal should be improvement in quality of care.
vidence
important clinical questions addressed in the guidelines do not lend themselves to clinical trials.
lar test or therapy is useful or effective.
ons, such as sex, age, history of diabetes, history of prior myocardial infarction, history of heart
), studies that support the use of comparator verbs should involve direct comparisons of thel of E
. Many
particu
opulatiThe Task Force recognizes that situations arise in which
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effectively; these areas will be identified within each respec-
tive guideline when appropriate.
Prescribed courses of treatment in accordance with these
recommendations are effective only if followed. Because lack of
patient understanding and adherence may adversely affect
outcomes, physicians and other healthcare providers should
make every effort to engage the patient’s active participation in
prescribed medical regimens and lifestyles. In addition, patients
should be informed of the risks, benefits, and alternatives to a
particular treatment and should be involved in shared decision
making whenever feasible, particularly for COR IIa and IIb,
for which the benefit-to-risk ratio may be lower.
The Task Force makes every effort to avoid actual,
potential, or perceived conflicts of interest that may arise as
a result of industry relationships or personal interests among
the members of the writing committee. All writing com-
mittee members and peer reviewers of this guideline were
required to disclose all such current health care-related
relationships, including those existing 24 months (from
2005) before initiation of the writing effort. The writing
committee chair may not have any relevant relationships
with industry or other entities (RWI); however, RWI are
permitted for the vice chair position. In December 2009, the
ACCF and AHA implemented a new policy that requires a
minimum of 50% of the writing committee to have no
relevant RWI; in addition, the disclosure term was changed
to 12 months before writing committee initiation. The
present guideline was developed during the transition in
RWI policy and occurred over an extended period of time.
In the interest of transparency, we provide full information
on RWI existing over the entire period of guideline devel-
opment, including delineation of relationships that expired
more than 24 months before the guideline was finalized.
This information is included in Appendix 1. These state-
ments are reviewed by the Task Force and all members
during each conference call and meeting of the writing
committee and are updated as changes occur. All guideline
recommendations require a confidential vote by the writing
committee and must be approved by a consensus of the
voting members. Members who recused themselves from
voting are indicated in the list of writing committee mem-
bers, and specific section recusals are noted in Appendix 1.
Authors’ and peer reviewers’ RWI pertinent to this guide-
line are disclosed in Appendixes 1 and 2, respectively.
Comprehensive disclosure information for the Task Force is
also available online at http://www.cardiosource.org/ACC/
About-ACC/Who-We-Are/Leadership/Guidelines-and-
Documents-Task-Forces.aspx. The work of the writing com-
mittee is supported exclusively by the ACCF, AHA, American
College of Physicians (ACP), American Association for Tho-
racic Surgery (AATS), Preventive Cardiovascular Nurses As-
sociation (PCNA), Society for Cardiovascular Angiography
and Interventions (SCAI), and Society of Thoracic Surgeons
(STS), without commercial support. Writing committee
members volunteered their time for this activity. aThe recommendations in this guideline are considered
current until they are superseded by a focused update or the
full-text guideline is revised. Guidelines are official policy of
both the ACCF and AHA.
Jeffrey L. Anderson, MD, FACC, FAHA
Chair, ACCF/AHA Task Force on Practice Guidelines
1. Introduction
1.1. Methodology and Evidence Overview
The recommendations listed in this document are, when-
ever possible, evidence based. An extensive evidence review
was conducted as the document was compiled through
December 2008. Repeated literature searches were per-
formed by the guideline development staff and writing
committee members as new issues were considered. New
clinical trials published in peer-reviewed journals and arti-
cles through December 2011 were also reviewed and incor-
porated when relevant. Furthermore, because of the ex-
tended development time period for this guideline, peer
review comments indicated that the sections focused on
imaging technologies required additional updating, which
occurred during 2011. Therefore, the evidence review for
the imaging sections includes published literature through
December 2011.
Searches were limited to studies, reviews, and other
evidence in human subjects and that were published in
English. Key search words included but were not limited to
the following: accuracy, angina, asymptomatic patients, cardiac
magnetic resonance (CMR), cardiac rehabilitation, chest pain,
chronic angina, chronic coronary occlusions, chronic ischemic
heart disease (IHD), chronic total occlusion, connective tissue
disease, coronary artery bypass graft (CABG) versus medical
therapy, coronary artery disease (CAD) and exercise, coronary
calcium scanning, cardiac/coronary computed tomography angiog-
raphy (CCTA), CMR angiography, CMR imaging, coronary
stenosis, death, depression, detection of CAD in symptomatic
patients, diabetes, diagnosis, dobutamine stress echocardiography,
echocardiography, elderly, electrocardiogram (ECG) and chronic
stable angina, emergency department, ethnic, exercise, exercise stress
testing, follow-up testing, gender, glycemic control, hypertension,
intravascular ultrasound, fractional flow reserve (FFR), invasive
coronary angiography, kidney disease, low-density lipoprotein
(LDL) lowering, magnetic resonance imaging (MRI), medication
adherence, minority groups, mortality, myocardial infarction (MI),
noninvasive testing and mortality, nuclear myocardial perfusion,
nutrition, obesity, outcomes, patient follow-up, patient education,
prognosis, proximal left anterior descending (LAD) disease, physical
activity, reoperation, risk stratification, smoking, stable ischemic
heart disease (SIHD), stable angina and reoperation, stable angina
and revascularization, stress echocardiography, radionuclide stress
testing, stenting versus CABG, unprotected left main, weight
reduction, and women. Appendix 3 contains an list of abbrevi-
tions used in this document.
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the absolute risk difference and number needed to treat or
harm, if they were published and their inclusion was deemed
appropriate, are provided in the guideline, along with
confidence intervals (CIs) and data related to the relative
treatment effects, such as odds ratio (OR), relative risk
(RR), hazard ratio, or incidence rate ratio.
1.2. Organization of the Writing Committee
The writing committee was composed of physicians, car-
diovascular interventionalists, surgeons, general internists,
imagers, nurses, and pharmacists. The writing committee
included representatives from the ACP, AATS, PCNA,
SCAI, and STS.
1.3. Document Review and Approval
This document was reviewed by 2 external reviewers nom-
inated by both the ACCF and the AHA; 2 reviewers
nominated by the ACP, AATS, PCNA, SCAI, and STS;
and 19 content reviewers, including members of the ACCF
Imaging Council, ACCF Interventional Scientific Council,
and the AHA Council on Clinical Cardiology. Reviewers’
RWI information was collected and distributed to the
writing committee and is published in this document
(Appendix 2). Because extensive peer review comments
resulted in substantial revision, the guideline was subjected
to a second peer review by all official and organizational
reviewers. Lastly, the imaging sections were peer reviewed
separately, after an update to that evidence base.
This document was approved for publication by the
governing bodies of the ACCF, AHA, ACP, AATS,
PCNA, SCAI, and STS.
1.4. Scope of the Guideline
These guidelines are intended to apply to adult patients with
stable known or suspected IHD, including new-onset chest
pain (i.e., low-risk unstable angina [UA]), or to adult
patients with stable pain syndromes (Figure 1). Patients
Asymptomatic 
Persons 
Without 
Known IHD
(CV Risk)
Noncardiac 
Chest Pain
New Onset 
Chest Pain
(SIHD; UA/NSTEMI; STEM
Sudden Ca
(VA-
Noninvasive
Testing
*Features of low ri
•Age, 70 y
•Exertional pain 
•Pain not rapidly
•Normal or uncha
•No elevation of 
Figure 1. Spectrum of IHD
Guidelines relevant to the spectrum of IHD are in parentheses. CABG indicates coro
disease; PCI, percutaneous coronary intervention; SCD, sudden cardiac death; SIHD, stabl
angina; UA/NSTEMI, unstable angina/non–ST-elevation myocardial infarction; and VA, ventwho have “ischemic equivalents,” such as dyspnea or arm
pain with exertion, are included in the latter group. Many
patients with IHD can become asymptomatic with appro-
priate therapy. Accordingly, the follow-up sections of this
guideline pertain to patients who were previously symptom-
atic, including those who have undergone percutaneous
coronary intervention (PCI) or CABG.
This guideline also addresses the initial diagnostic ap-
proach to patients who present with symptoms that suggest
IHD, such as anginal-type chest pain, but who are not known
to have IHD. In this circumstance, it is essential that the
practitioner ascertain whether such symptoms represent the
initial clinical recognition of chronic stable angina, reflecting
gradual progression of obstructive CAD or an increase in
supply/demand mismatch precipitated by a change in activ-
ity or concurrent illness (e.g., anemia or infection), or
whether they represent an acute coronary syndrome (ACS),
most likely due to an unstable plaque causing acute throm-
bosis. For patients with newly diagnosed stable angina, this
guideline should be used. Patients with ACS have either
acute myocardial infarction (AMI) or UA. For patients with
AMI, the reader is referred to the “ACCF/AHA Guidelines
for the Management of Patients With ST-Elevation Myo-
cardial Infarction” (STEMI) (2,3). Similarly, for patients
with UA that is believed to be due to an acute change in
clinical status attributable to an unstable plaque or an abrupt
change in supply (e.g., coronary occlusion with myocardial
supply through collaterals), the reader is referred to the
“ACCF/AHA Guidelines for the Management of Patients
With Unstable Angina/non–ST-Elevation Myocardial Infarc-
tion” (UA/NSTEMI) (4,4a). There are, however, patients
with UA who can be categorized as low risk and are addressed
in this guideline (Table 2).
A key premise of this guideline is that once a diagnosis of
IHD is established, it is necessary in most patients to assess
their risk of subsequent complications, such as AMI or
death. Because the approach to diagnosis of suspected IHD
Asymptomatic
(SIHD)
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or Low-Risk 
UA*
(SIHD; PCI/CABG)
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conceptually different and are based on different literature,
the writing committee constructed this guideline to address
these issues separately. It is recognized, however, that a
clinician might select a procedure for a patient with a
moderate to high pretest likelihood of IHD to provide
information for both diagnosis and risk assessment, whereas
in a patient with a low likelihood of IHD, it could be
sensible to select a test simply for diagnostic purposes
without regard to risk assessment. By separating the con-
ceptual approaches to ascertaining diagnosis and prognosis,
the goal of the writing committee is to promote the sensible
application of appropriate testing rather than routine use of
the most expensive or complex tests whether warranted or
not. It is not the intent of the writing committee to promote
unnecessary or duplicate testing, although in some patients
this could be unavoidable.
Additionally, this guideline addresses the approach to
asymptomatic patients with SIHD that has been diagnosed
solely on the basis of an abnormal screening study, rather
than on the basis of clinical symptoms or events such as
Table 2. Short-Term Risk of Death or Nonfatal MI in Patients W
Feature
High Risk
At least 1 of the following
features must be present:
No h
patie
istory Accelerating tempo of ischemic
symptoms in preceding 48 h
Prior M
dise
Prior a
haracteristics
of pain
Prolonged ongoing (20 min)
rest pain
Prolon
res
like
Rest a
res
Noctu
New-o
IV a
pro
with
of C
Clinical findings Pulmonary edema, most likely
due to ischemia
New or worsening mitral
regurgitation murmur
S3 or new/worsening rales
Hypotension, bradycardia, or
tachycardia
Age 75 y
Age 
ECG Angina at rest with transient
ST-segment changes 0.5 mm
Bundle-branch block, new or
presumed new
Sustained ventricular tachycardia
T-wave
Patho
ST-
lea
Cardiac markers Elevated cardiac TnT, TnI, or CK-MB
(i.e., TnT or TnI 0.1 ng/mL)
Slight
MB
Estimation of the short-term risks of death and nonfatal cardiac ischemic events in UA or NSTE
the table is meant to offer general guidance and illustration rather than rigid algorithms.
CABG indicates coronary artery bypass graft; CAD, coronary artery disease; CCS, Canadian
infarction; NTG, nitroglycerin; N/A, not available; TnI, troponin I; TnT, troponin T; and UA/NSTEM
Modified from Braunwald et al. (6).anginal symptoms or ACS. The inclusion of such asymp-tomatic patients does not constitute an endorsement of such
tests for the purposes of screening but is simply an acknowl-
edgment of the clinical reality that asymptomatic patients
often present for evaluation after such tests have been
performed. Multiple ACCF/AHA guidelines and scientific
statements have discouraged the use of ambulatory moni-
toring, treadmill testing, stress echocardiography, stress
myocardial perfusion imaging (MPI), and computed to-
mography (CT) scoring of coronary calcium or coronary
angiography as routine screening tests in asymptomatic
individuals. The reader is referred to these documents for a
detailed discussion of screening, which is beyond the scope
of this guideline (Table 3).
Patients with known IHD who were previously asymptom-
atic or whose symptoms were stable can develop new or
recurrent chest pain or other symptoms suggesting ACS. Just
as in the case of patients with new-onset chest pain, the
clinician must determine whether such recurrent or worsening
pain is consistent with ACS or simply represents symptoms
more consistent with chronic stable angina that do not require
emergent attention. As indicated previously, patients with
A/NSTEMI
ntermediate Risk Low Risk
k features are present, but
st have 1 of the following:
No high- or intermediate-risk features
are present, but patient may have
any of the following:
ipheral or cerebrovascular
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of CAD
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blingual NTG
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in previous 2 wk without
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Increased angina frequency, severity,
or duration
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New-onset angina with onset 2 wk to
2 mo before presentation
N/A
ges
l Q waves or resting
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ps (anterior, inferior, lateral)
Normal or unchanged ECG
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low-risk UA are addressed in the present guideline.
When patients with documented IHD develop recurrent
chest pain, the symptoms still could be attributable to another
condition. Such patients are included in this guideline if there
is sufficient suspicion that their heart disease is a likely source
of symptoms to warrant cardiac evaluation. If the evaluation
demonstrates that IHD is unlikely to cause the symptoms, the
evaluation of noncardiac causes is beyond the scope of this
guideline. If the evaluation demonstrates that IHD is the likely
cause of their recurrent symptoms, subsequent management of
such patients does fall within this guideline.
The approach to screening and management of asymp-
tomatic patients who are at risk for IHD but who are not
known to have IHD is also beyond the scope of this
guideline, but it is addressed in the “ACCF/AHA Guide-
line for Assessment of Cardiovascular Risk in Asymptom-
atic Adults” (5). Similarly, the present guideline does not
apply to patients with chest pain symptoms early after
revascularization by either percutaneous techniques or
CABG. Although the division between “early” and “late”
symptoms is arbitrary, the writing committee believed that
this guideline should not be applied to patients who develop
recurrent symptoms within 6 months of revascularization.
Pediatric patients are beyond the scope of this guideline,
because IHD is very unusual in such patients and is related
primarily to the presence of coronary artery anomalies.
Patients with chest pain syndromes after cardiac transplan-
tation also are not included in this guideline.
1.5. General Approach and Overlap With
Other Guidelines or Statements
This guideline overlaps with numerous clinical practice
guidelines published by the ACCF/AHA Task Force on
Table 3. Associated Guidelines and Statements
Document
uidelines
Chronic Stable Angina: 2007 Focused Update
Valvular Heart Disease
Heart Failure: 2009 Update
STEMI
Assessment of Cardiovascular Risk in Asymptomatic Adults
Coronary Artery Bypass Graft Surgery
Percutaneous Coronary Intervention
Secondary Prevention and Risk Reduction Therapy for Patients With Coronary
Other Atherosclerotic Vascular Disease
UA/NSTEMI: 2007 and 2012 Updates
tatements
NCEP ATP III Implications of Recent Clinical Trials
National Hypertension Education Program (JNC VII)
Referral, Enrollment, and Delivery of Cardiac Rehabilitation/Secondary Preven
Clinical Centers and Beyond: A Presidential Advisory From the AHA
ACCF indicates American College of Cardiology Foundation; AHA, American Heart Association; ATP
Detection, Evaluation, and Treatment of High Blood Pressure; NHLBI, National Heart, Lung andPractice Guidelines; the National Heart, Lung, and BloodInstitute; and the ACP (Table 3). To maintain consistency,
the writing committee worked with members of other
committees to harmonize recommendations and eliminate
discrepancies. Some recommendations from earlier guide-
lines have been updated as warranted by new evidence or a
better understanding of earlier evidence, whereas others that
were no longer accurate or relevant or were overlapping were
modified; recommendations from previous guidelines that
were similar or redundant were eliminated or consolidated
when possible.
Most of the topics mentioned in the present guideline
were addressed in the “ACC/AHA 2002 Guideline Update
for the Management of Patients With Chronic Stable
Angina—Summary Article” (7), and many of the recom-
mendations in the present guideline are consistent with
those in the 2002 document. Whereas the 2002 update dealt
individually with specific drugs and interventions for reduc-
ing cardiovascular risk and medical therapy of angina
pectoris, the present document recommends a combination
of lifestyle modifications and medications that constitute
GDMT. In addition, recommendations for risk reduction
have been revised to reflect new evidence and are now
consistent with the “AHA/ACCF Secondary Prevention
and Risk Reduction Therapy for Patients With Coronary
and Other Atherosclerotic Vascular Disease: 2011 Update”
(8). Also in the present guideline, recommendations and
text related to revascularization are the result of extensive
collaborative discussions between the PCI and CABG
writing committees, as well as key members of the SIHD
and UA/NSTEMI writing committees. In a major under-
taking, the PCI and CABG guidelines were written con-
currently with input from the STEMI guideline writing
committee and additional collaboration with the SIHD
guideline writing committee, allowing greater collaboration
Reference(s) Organization Publication Year
(19) ACCF/AHA 2007
(20) ACCF/AHA 2008
(21) ACCF/AHA 2009
(2,3,22) ACCF/AHA 2009
(5) ACCF/AHA 2010
(9) ACCF/AHA 2011
(10) ACCF/AHA/SCAI 2011
(8) AHA/ACCF 2011
(4,4a) ACCF/AHA 2012
(18,24) NHLBI 2004
(17) NHLBI 2004
rograms at (25) AHA 2011
lt Treatment Panel 3;JNC VII, The Seventh Report of the Joint National Committee on Prevention,
Institute; and SCAI, Society for Cardiovascular Angiography and Interventions.and
tion Pbetween these writing committees on revascularization
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main PCI, multivessel disease revascularization, and hybrid
procedures) (9,10). Section 5 is included as published in
both the PCI and CABG guidelines in its entirety.
In addition to cosponsoring practice guidelines, the
ACCF has sponsored appropriate use criteria (AUC) doc-
uments for imaging testing, diagnostic catheterization, and
coronary revascularization since 2005 (11–16). Practice
guideline recommendations are based on evidence from
clinical and observational trials and expert consensus; AUCs
are complementary to practice guidelines and make every
effort to be concordant with their recommendations. In
general, the recommendations in this guideline and current
AUCs are consistent. Apparent discrepancies usually reflect
differing frameworks or imaging methodologies. Moreover,
where guidelines leave “gaps” (i.e., unaddressed applica-
tions), AUCs can provide additional clinical guidance based
on the best available clinical evidence and use a prospective,
expert consensus methodology (16). Specifically, AUCs
provide detailed indications for testing and procedures to
aid clinical decision making, categorizing each indication as
appropriate, uncertain, or inappropriate. Thus, ACCF
AUCs provide an additional means to identify candidates
for testing or procedures as well as those for whom they
would be inappropriate or for whom the optimal approach
is uncertain. Inappropriate candidates are those for whom
compelling evidence indicates that testing is not indicated
or, in some cases, results in reduced accuracy. Uncertain
indications are those with either published evidence or lack
of expert consensus on testing use.
AUCs also include relevant clinical scenarios not ad-
dressed by these guidelines (11), such as the issue of testing
during follow-up of patients with SIHD with stress echo-
cardiography (15), single-photon emission computed to-
mography (SPECT) MPI (12), CMR, and CCTA (13,14).
These AUC documents address the intervals between test-
ing for various stress imaging indications. As with all
standards documents, ongoing evaluation is required to
update the recommendations on the value, limitations,
timing, costs, and risks of imaging as an adjunct to clinical
assessment during follow-up of patients with established
SIHD. Review of these AUCs is beyond the scope of the
present document, and the reader is referred to the most recent
AUC documents to complement the guidelines provided here.
As the scientific basis of the approach to management of
cardiovascular disease has rapidly expanded, the size and
scope of clinical practice guidelines have grown commen-
surately to a point where they have become too unwieldy for
routine use by practicing clinicians. The most current
national guidelines for management of hypertension (Joint
National Committee VII) (17) and hyperlipidemia (Adult
Treatment Panel III) (18) combined comprise nearly 400
pages. Thus, the writing committee recognized that it
would be unfeasible to produce a document that would be tsimultaneously practical and exhaustive and, therefore, has
tried to create a resource that provides a comprehensive
approach to management of SIHD for which the relevant
evidence is succinctly summarized and referenced. The
writing committee used current and credible meta-analyses,
when available, instead of conducting a systematic review of
all primary literature.
1.6. Magnitude of the Problem
IHD remains a major public health problem nationally and
internationally. It is estimated that 1 in 3 adults in the
United States (about 81 million) has some form of cardio-
vascular disease, including 17 million with coronary heart
disease and nearly 10 million with angina pectoris (26,27).
Among persons 60 to 79 years of age, approximately 25% of
men and 16% of women have coronary heart disease, and
these figures rise to 37% and 23% among men and women
80 years of age, respectively (27).
Although the survival rate of patients with IHD has been
steadily improving (28), it was still responsible for nearly
380,000 deaths in the United States during 2010, with an
age-adjusted mortality rate of 113 per 100,000 population
(29). Although IHD is widely known to be the number 1
cause of death in men, this is also the case for women,
among whom this condition accounts for 27% of deaths
(compared with 22% due to cancer) (30). IHD also accounts
for the vast majority of the mortality and morbidity of
cardiac disease. Each year, 1.5 million patients have an
I. Many more are hospitalized for UA and for evaluation
nd treatment of stable chest pain syndromes. Beyond the
eed for hospitalization, many patients with chronic chest
ain syndromes are temporarily unable to perform normal
ctivities for hours or days and thus experience a reduced
uality of life. Among patients enrolled in the BARI
Bypass Angioplasty Revascularization Investigation) study
31), about 30% never returned to work after coronary
evascularization, and 15% to 20% of patients rated their
wn health as “fair” or “poor” despite revascularization.
imilarly, observational studies of patients recovering from
n AMI demonstrated that 1 in 5 patients, even after
ntensive treatment at the time of their AMI, still suffered
ngina 1 year later (32). These data confirm the widespread
linical impression that IHD continues to be associated with
onsiderable patient morbidity despite the decline in car-
iovascular mortality rate. Patients who have had ACS,
uch as AMI, remain at risk for recurrent events even if they
ave no, or limited, symptoms and should be considered to
ave SIHD.
In approximately 50% of patients, angina pectoris is the
nitial manifestation of IHD (27). The incidence of angina
ises continuously with age in women, whereas the inci-
ence of angina in men peaks between 55 and 65 years of
ge before declining (27). Despite angina’s clinical impor-
ance and high frequency, modern, population-based data
re quite limited, and these figures likely underestimate the
rue prevalence of angina (33).
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angina for nonblack men are 28.3 for ages 65 to 74 years,
36.3 for ages 75 to 84 years, and 33.0 for age85 years. For
nonblack women in the same age groups, the rates are 14.1,
20.0, and 22.9, respectively. For black men, the rates are
22.4, 33.8, and 39.5, and for black women, the rates are
15.3, 23.6, and 35.9, respectively (30). In a study conducted
in Finland, the age-standardized, annual incidence of an-
gina was 2.03 in men and 1.89 in women per 100 popula-
tions (33).
Further estimates of the prevalence of chronic, symp-
tomatic IHD can be obtained by extrapolating from data
on ACS and, more specifically, AMI. About one half of
patients presenting to the hospital with ACS have
preceding angina (27). One current estimate is that about
50% of patients who suffer an AMI each year in the
United States survive until hospitalization (27). Two
older population-based studies from Olmsted County,
MN, and Framingham, MA, examined the annual rates
of MI in patients with symptoms of angina and reported
similar rates of 3% to 3.5% per year (34,35). On this
basis, it can be estimated that there were 30 patients with
stable angina for every patient with infarction who was
hospitalized, which represents 16.5 million persons with
angina in the United States. However, since the data
reported in these studies were collected, it is likely that
the much greater use of effective medical therapies,
including antianginal medications and revascularization
procedures, has reduced the proportion of patients with
symptomatic angina—although there are still many pa-
tients whose symptoms are poorly controlled (36 –38).
The costs of caring for patients with IHD are enormous,
estimated at $156 billion in the United States for both direct
and indirect costs in 2008. More than one half of direct
costs are related to hospitalization. In 2003, the Medicare
program alone paid $12.2 billion for hospitalizations for
IHD, including $12,321 per discharge for AMI and
$11,783 per discharge for admissions for coronary athero-
sclerosis (39).
Another major expense is for invasive procedures and
related costs. In 2006 in the United States, there were
1,313,000 inpatient PCI procedures, 448,000 inpatient
coronary artery bypass procedures, and 1,115,000 inpa-
tient diagnostic cardiac catheterizations (27,40). In ad-
dition, 13 million outpatient visits for IHD occur in the
United States annually (41). It was estimated that the
costs of outpatient and emergency department visits in
2000 by patients with chronic angina were $922 million
and $286 million, respectively, and prescriptions ac-
counted for $291 million. Long-term care costs—
including skilled nursing, home health, and hospice
care—were $2.6 billion, which represented 30% of the
total cost of care for chronic angina (42).
Although the direct costs associated with SIHD are
substantial, they do not account for the significantindirect costs of lost workdays, reduced productivity,
long-term medication, and associated effects. The indi-
rect costs have been estimated to be almost as great as the
direct costs (27,43) (Table 4). The magnitude of the
problem can be summarized succinctly: SIHD affects
many millions of Americans, with associated annual costs
that are measured in tens of billions of dollars.
1.7. Organization of the Guideline
The overarching framework adopted in constructing this
guideline reflects the complementary goals of treating pa-
tients with known SIHD, alleviating or improving symp-
toms, and prolonging life. This guideline is divided into 4
basic sections summarizing the approaches to diagnosis, risk
assessment, treatment, and follow-up. Five algorithms sum-
marize the management of stable angina: diagnosis (Figure 2),
risk assessment (Figure 3), GDMT (Figure 4), and revascu-
larization (Figures 5 and 6). We readily acknowledge, how-
ever, that in actual clinical practice, the elements comprising
the 4 sections and the steps delineated in the algorithms
often overlap and are not always separable. Some low-risk
patients, for example, might require only clinical assessment
to determine that they do not need any further evaluation or
treatment. Other patients might require only clinical assess-
ment and further adjustment of medical therapy if their
preferences and comorbidities preclude revascularization,
thus obviating the necessity for risk stratification. The stress
testing/angiography algorithm might be applicable for di-
agnostic purposes in patients with symptoms that suggest
SIHD or to perform risk assessment in patients with
established SIHD.
Table 4. Estimated Direct and Indirect Costs (in Billions of
Dollars) of Heart Disease and Coronary Heart Disease:
United States: 2010
Heart Disease
($ in billions)
Coronary Heart
Disease ($ in billions)
Direct costs
Hospital 110.2 56.6
Nursing home 24.7 13.0
Physicians/other professionals 24.7 13.9
Drugs/other
Medical durables 22.5 10.0
Home health care 8.3 2.5
Total expenditures 189.4 96.0
Indirect costs
Lost productivity/morbidity 25.6 11.3
Lost productivity/mortality* 101.4 69.8
Grand totals 316.4 177.1
All estimates prepared by Thomas Thom, National Heart, Lung, and Blood Institute.
*Lost future earnings of persons who will die in 2010, discounted at 3%.
Reproduced from Lloyd-Jones et al. (27).
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*Colors correspond to the class of recommendations in the ACCF/AHA Table 1. The algorithms do not represent a comprehensive list of recommendations (see text for all
recommendations). †See Table 2 for short-term risk of death or nonfatal MI in patients with UA/NSTEMI. ‡CCTA is reasonable only for patients with intermediate probability
of IHD. CCTA indicates computed coronary tomography angiography; CMR, cardiac magnetic resonance; ECG, electrocardiogram; Echo, echocardiography; IHD, ischemic heart dis-
ease; MI, myocardial infarction; MPI, myocardial perfusion imaging; Pharm, pharmacological; UA, unstable angina; and UA/NSTEMI, unstable angina/non–ST-elevation myocardial
infarction.
gical.
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Informed Patient: Recommendation
CLASS I
1. Choices about diagnostic and therapeutic options should be made
through a process of shared decision making involving the patient
and provider, with the provider explaining information about risks,
benefits, and costs to the patient. (Level of Evidence: C)
In accordance with the principle of autonomy, the health-
care provider is obliged to solicit and respect the patient’s
preferences about choice of therapy. Although this princi-
ple, in the setting of cardiovascular disease, has received only
limited study, the concept of shared decision making in-
creasingly is viewed as an approach that ensures that
patients remain involved in key decisions. This approach
leads to higher quality of care (44,45).
To ensure that the patient is able to make the most
informed decisions possible, the provider must give suffi-
cient information about the underlying disease process,
along with all relevant diagnostic and therapeutic options—
including anticipated outcomes, risks, and costs to the
patient (46). This information should be provided in a
manner that is readily comprehensible and permits the
Figure 3. Algorithm for Risk Assessment of Patients With SIHD*
*Colors correspond to the class of recommendations in the ACCF/AHA Table 1. The
recommendations). CCTA indicates coronary computed tomography angiography; CM
left bundle-branch block; MPI, myocardial perfusion imaging; and Pharm, pharmacoloopportunity for dialog and questions.Patients should be encouraged to seek additional infor-
mation from other sources, including those on the Internet,
such as those maintained by the National Institutes of
Health, the Centers for Disease Control and Prevention,
and the ACCF/AHA. Substantial research indicates that
when informed about absolute or marginal benefit, patients
often elect to postpone or forego invasive procedures. Two
patients with similar pretest probabilities of IHD could
prefer different approaches because of variations in personal
beliefs, economic situation, or stage of life. Because of the
variation in symptoms and clinical characteristics among pa-
tients, as well as their unique perceptions, expectations, and
preferences, there is often no single correct approach to any
given set of clinical circumstances. In assisting patients to reach
an informed decision, it is essential to elicit the breadth of their
knowledge, values, preferences, and concerns.
The healthcare provider has a responsibility to ensure that
patients understand and consider both the upside and
downside of available options, in both the near and long
terms. All previous guidelines reviewed by the writing
committee have recognized the crucial role that patient
preferences play in the selection of a treatment strategy
thms do not represent a comprehensive list of recommendations (see text for all
iac magnetic resonance; ECG, electrocardiogram; Echo, echocardiography; LBBB,algori
R, card(9,10,47–49). It is essential that these discussions be con-
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time for discussion and contemplation. Initiating a discus-
sion about the relative merits of PCI or CABG while a
patient is in the midst of a procedure, for example, is not
usually consistent with these principles.
In crafting a diagnostic strategy, the objective is to ascertain,
as accurately as possible, whether the patient has IHD while
minimizing the expense, discomfort, and potential harms of
any tests or procedures. This includes avoiding procedures that
are likely to yield false positive or false negative results or that
are unnecessary or inappropriate. The objective for procedures
intended to assess prognosis is similar.
Treatment options should be emphasized, especially in
cases where there is no substantial advantage of one strategy
over others. For most patients, the goal of treatment should
be to simultaneously maximize survival and to achieve
prompt and complete (or nearly complete) elimination of
anginal chest pain with return to normal activities—in other
Figure 4. Algorithm for Guideline-Directed Medical Therapy for Pat
*Colors correspond to the class of recommendations in the ACCF/AHA Table 1. The
recommendations). †The use of bile acid sequestrant is relatively contraindicated w
mg/dL. ‡Dietary supplement niacin must not be used as a substitute for prescriptio
angiotensin-converting enzyme inhibitor; AHA, American Heart Association; ARB, ang
sure; CCB, calcium channel blocker; CKD, chronic kidney disease; HDL-C, high-dens
Prevention, Detection, Evaluation, and Treatment of High Blood Pressure; LDL-C, low
National Heart, Lung, and Blood Institute; and NTG, nitroglycerin.words, a functional capacity of Canadian CardiovascularSociety (CCS) Class I angina (50). For example, for an
otherwise healthy, active patient, the treatment goal is
usually the complete elimination of chest pain and a return
to vigorous physical activity. Conversely, an elderly patient
with more severe angina and several serious coexisting
medical problems might be satisfied with a reduction in
symptoms that permits limited activities of daily living.
Patients with anatomy that would ordinarily favor the
choice of CABG could have comorbidities that make the
risk of surgery unacceptable, in which case PCI or medical
therapy is a more attractive option.
In counseling patients, the healthcare provider should be
aware of, and help to rectify, common misperceptions.
Many patients assume, for example, that opening a partially
blocked artery will naturally prevent a heart attack and
prolong life irrespective of other anatomic and clinical
factors. When there is little expectation of an improvement
in survival from revascularization, patients should be so
With SIHD*
thms do not represent a comprehensive list of recommendations (see text for all
glycerides are 200 mg/dL and is contraindicated when triglycerides are 500
n. ACCF indicates American College of Cardiology Foundation; ACEI,
in-receptor blocker; ASA, aspirin, ATP III, Adult Treatment Panel 3; BP, blood pres-
protein cholesterol, JNC VII, Seventh Report of the Joint National Committee on
ty lipoprotein cholesterol; LV, left ventricular; MI, myocardial infarction; NHLBI,ients
algori
hen tri
n niaci
iotens
ity lipo
-densiinformed. When evidence points to probable benefit from
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quantified to the extent possible, with explicit acknowledg-
ment of uncertainties, and should be discussed in the
context of what treatment option is best for that particular
patient. When possible, the relative time course of response
to therapy should be described for therapeutic choices.
Some patients might, for example, initially opt for PCI over
medical therapy because relief of symptoms is typically more
rapid. However, when informed of the immediate risk of
complications of PCI, some patients could prefer conserva-
tive therapy. Similarly, many patients choose PCI over
CABG because it is less invasive and provides for quicker
recovery, despite the fact that repeat revascularization pro-
cedures are performed more frequently after PCI. Patients’
preferences in these circumstances often are influenced by
their attitudes toward risk and by the tendency to let
immediate smaller benefits outweigh larger future risks, a
Potential revascularization pr
warranted based on assess
coexisting cardiac and noncard
and patient preference
Perform 
coronary 
angiography
Yes
Heart Team concludes t
anatomy and clinical fac
indicate revascularization
improve survival (Table 
Determine optimal metho
revascularization based u
patient preferences, anatom
clinical factors, and local res
and expertise (Table 1
Yes
Noninvasive testing
suggests high-risk
coronary lesion(s)
from Figure 2
Guideline-Directed Medical
continued in all patien
Figure 5. Algorithm for Revascularization to Improve Survival of Pa
*Colors correspond to the class of recommendations in the ACCF/AHA Table 1. The
recommendations).phenomenon termed “temporal discounting” (51).2. Diagnosis of SIHD
2.1. Clinical Evaluation of Patients With Chest Pain
2.1.1. Clinical Evaluation in the Initial Diagnosis of
SIHD in Patients With Chest Pain: Recommendations
CLASS I
1. Patients with chest pain should receive a thorough history and
physical examination to assess the probability of IHD before addi-
tional testing (52). (Level of Evidence: C)
2. Patients who present with acute angina should be categorized as
stable or unstable; patients with UA should be further categorized as
being at high, moderate, or low risk (4,4a). (Level of Evidence: C)
2.1.2. History
The clinical examination is the key first step in evaluating a
patient with chest pain and should include a detailed
ure 
of 
ctors 
er 
s 
No
No
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e59JACC Vol. 60, No. 24, 2012 Fihn et al.
December 18, 2012:e44–e164 Stable Ischemic Heart Disease: Full Textity, and duration of pain; radiation; associated symptoms;
provocative factors; and alleviating factors. Adjectives often
used to describe anginal pain include “squeezing,” “grip-
like,” “suffocating,” and “heavy,” but it is rarely sharp or
stabbing and typically does not vary with position or
respiration. On occasion the patient might demonstrate the
classic Levine’s sign by placing a clenched fist over the
precordium to describe the pain. Many patients do not,
however, describe angina as frank pain but as tightness,
pressure, or discomfort. Other patients, in particular women
and the elderly, can present with atypical symptoms such as
nausea, vomiting, midepigastric discomfort, or sharp (atyp-
Figure 6. Algorithm for Revascularization to Improve Symptoms of
*Colors correspond to the class of recommendations in the ACCF/AHA Table 1. The
recommendations). CABG indicates coronary artery bypass graft; PCI, percutaneousical) chest pain. In the WISE (Women’s Ischemic Syn-drome Evaluation) study, 65% of women with ischemia
presented with atypical symptoms (54).
Anginal pain caused by cardiac ischemia typically lasts
minutes. The location is usually substernal, and pain can
radiate to the neck, jaw, epigastrium, or arms. Pain above
the mandible, below the epigastrium, or localized to a small
area over the left lateral chest wall is rarely angina. Angina
is often precipitated by exertion or emotional stress and
relieved by rest. Sublingual nitroglycerin also usually relieves
angina, within 30 seconds to several minutes. The history
can be used to classify symptoms as typical, atypical, or
noncardiac chest pain (6) (Table 5). The patient presenting
ents With SIHD*
thms do not represent a comprehensive list of recommendations (see text for all
ry intervention.Pati
algoriwith angina must be categorized as having stable angina or
NI
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frequency, intensity, or duration), or occurring at rest (50)
(Table 6). However, patients presenting with UA are
subdivided by their short-term risk (Table 2). Patients at
high or moderate risk often have experienced rupture of
coronary artery plaque and have a risk of death higher than
that of patients with stable angina but not as great as that of
patients with AMI. These patients should be transferred
promptly to an emergency department for evaluation and
treatment. The short-term prognosis of patients with low-
risk UA, however, is comparable to those with stable angina,
and their evaluation can be conducted safely and expedi-
tiously in an outpatient setting.
After thorough characterization of chest pain, the pres-
ence of risk factors for IHD (55) should be determined.
These include smoking, hyperlipidemia, diabetes mellitus,
hypertension, obesity or metabolic syndrome, physical in-
activity, and a family history of premature IHD (i.e., onset
in a father, brother, or son before age 55 years or a mother,
sister, or daughter before age 65 years). A history of
cerebrovascular or peripheral artery disease (PAD) also
increases the likelihood of IHD.
2.1.3. Physical Examination
The examination is often normal or nonspecific in patients
with stable angina (56) but could reveal related conditions
such as heart failure, valvular heart disease, or hypertrophic
cardiomyopathy. An audible rub suggests pericardial or
pleural disease. Evidence of vascular disease includes carotid
or renal artery bruits, a diminished pedal pulse, or a palpable
abdominal aneurysm. Elevated blood pressure (BP), xan-
thomas, and retinal exudates point to the presence of IHD
risk factors. Pain reproduced by pressure on the chest wall
suggests a musculoskeletal etiology but does not eliminate
the possibility of angina due to IHD.
2.1.4. Electrocardiography
2.1.4.1. RESTING ELECTROCARDIOGRAPHY TO ASSESS RISK:
RECOMMENDATION
CLASS I
1. A resting ECG is recommended in patients without an obvious,
noncardiac cause of chest pain (57–59). (Level of Evidence: B)
Patients with SIHD who have the following abnormalities
on a resting ECG have a worse prognosis than those with
normal ECGs (57–59): evidence of prior MI, especially Q
Table 5. Clinical Classification of Chest Pain
Typical angina
(definite)
1) Substernal chest discomfort with a characteristic quality
and duration that is 2) provoked by exertion or
emotional stress and 3) relieved by rest or nitroglycerin
Atypical angina
(probable)
Meets 2 of the above characteristics
Noncardiac
chest pain
Meets 1 or none of the typical anginal characteristics
Adapted from Braunwald et al. (6).waves in multiple leads or an R wave in V1 indicating aposterior infarction (60); persistent ST-T-wave inversions,
particularly in leads V1 to V3 (61–64); left bundle-branch
block (LBBB), bifascicular block, second- or third-degree
atrioventricular (AV) block, or ventricular tachyarrhythmia
(65); or left ventricular (LV) hypertrophy (62,66).
2.1.5. Differential Diagnosis
Although the symptoms of some patients might be consis-
tent with a very high probability of IHD, in others, the
etiology might be less certain, and alternative diagnoses
should be considered (Table 7). However, even when angina
seems likely to be related to IHD, other coexisting condi-
tions can precipitate symptoms by inducing or exacerbating
myocardial ischemia, by either increased myocardial oxygen
demand or decreased myocardial oxygen supply (Table 8).
When severe, these conditions can cause angina in the
absence of significant anatomic coronary obstruction. Chest
pain in women is less often due to IHD than in men, even
when the pain is typical. Nevertheless, pain in women can
be related to vascular dysfunction in the absence of epicar-
dial CAD. Entities that cause increased oxygen demand
include hyperthermia (particularly if accompanied by vol-
ume contraction) (67), hyperthyroidism, and cocaine or
methamphetamine abuse. Sympathomimetic toxicity, due,
for example, to cocaine intoxication, not only increases
myocardial oxygen demand but also induces coronary vaso-
spasm and can cause infarction in young patients. Long-
term cocaine use can cause premature development of IHD
(68,69). Severe uncontrolled hypertension increases LV wall
tension, leading to increased myocardial oxygen demand
and decreased subendocardial perfusion. Hypertrophic car-
diomyopathy and aortic stenosis can induce even more
severe LV hypertrophy and resultant wall tension. Ventric-
ular or supraventricular tachycardias are another cause of
increased myocardial oxygen demand, but when paroxysmal
these are difficult to diagnose.
Anemia is the prototype for conditions that limit myo-
cardial oxygen supply. Cardiac output rises when the hemo-
globin drops to 9 g/dL, and ST-T-wave changes (depres-
sion or inversion) can occur at levels 7 g/dL.
Hypoxemia resulting from pulmonary disease (e.g., pneu-
monia, asthma, chronic obstructive pulmonary disease, pul-
monary hypertension, interstitial fibrosis, or obstructive
sleep apnea) can also precipitate angina. Polycythemia,
leukemia, thrombocytosis, and hypergammaglobulinemia
Table 6. Three Principal Presentations of UA
Rest angina Angina occurring at rest and usually prolonged 20 min, occurring
within 1 wk of presentation
ew-onset
angina
Angina of at least CCS Class III severity with onset within 2 mo of
initial presentation
ncreasing
angina
Previously diagnosed angina that is distinctly more frequent,
longer in duration, or lower in threshold (i.e., increased by
1 CCS class within 2 mo of initial presentation to at least
CCS Class III severity)CCS indicates Canadian Cardiovascular Society.
Reproduced from Braunwald (50).
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crease coronary artery blood flow and precipitate angina,
even in patients without significant coronary stenoses.
2.1.6. Developing the Probability Estimate
When the clinical evaluation is complete, the practitioner
must determine whether the probability of IHD is sufficient
to recommend further testing, which is often a standard
exercise test. When the probability of disease is 5%,
further testing is usually not warranted because the likeli-
hood of a false-positive test (i.e., positive test in the absence
of obstructive CAD) is actually higher than that of a true
positive. On the other hand, when the exercise test is
negative in a patient who has a very high likelihood of IHD
on the basis of the history, there is a substantial chance that
in reality the result is falsely negative. Thus, further testing
Table 7. Alternative Diagnoses to Angina for Patients With Ch
Nonischemic
Cardiovascular Pulmonary Gastrointestinal
Aortic dissection Pulmonary embolism Esophageal
Esophagitis
Spasm
Reflux
Pericarditis Pneumothorax
Pneumonia
Pleuritis
Biliary
Colic
Cholecystitis Choledocholithi
Cholangitis
Peptic ulcer
Pancreatitis
Reproduced from Gibbons et al. (7).
Table 8. Conditions Provoking or Exacerbating Ischemia
Increased Oxygen Demand Decreased Oxygen Supply
Noncardiac Noncardiac
Hyperthermia
Hyperthyroidism
Sympathomimetic toxicity
(i.e., cocaine use)
Hypertension
Anxiety
Arteriovenous fistulae
Anemia
Hypoxemia
Pneumonia
Asthma
Chronic obstructive pulmonary
disease
Pulmonary hypertension
Interstitial pulmonary fibrosis
Obstructive sleep apnea
Sickle cell disease
Sympathomimetic toxicity (i.e., cocaine
use, pheochromocytoma)
Hyperviscosity
Polycythemia
Leukemia
Thrombocytosis
Hypergammaglobulinemia
Cardiac Cardiac
Hypertrophic cardiomyopathy
Aortic stenosis
Dilated cardiomyopathy
Tachycardia
Ventricular
Supraventricular
Aortic stenosis
Hypertrophic cardiomyopathy
Significant coronary obstruction
Microvascular diseaseaModified from Gibbons et al. (7).is most useful in patients in whom the cause of chest pain is
truly uncertain (i.e., the probability of IHD is between 20%
and 70%). It is necessary to note, however, that these
probabilities relate solely to the presence of obstructive
CAD and do not pertain to ischemia due to microvascular
disease or other causes. They also do not reflect the
likelihood that a nonobstructing plaque could become
unstable and cause ischemia.
A landmark study (52) showed how information about
the type of pain and age and sex of the patient can provide
a reasonable estimate of the likelihood of IHD. For in-
stance, a 64-year-old man with typical angina has a 94%
likelihood of having significant coronary stenosis. A 32-
year-old woman with nonanginal chest pain has a 1%
chance of coronary stenosis (70–72). Other clinical charac-
teristics that improved the accuracy of prediction include
active or recent smoking, Q-wave or ST-T-wave changes on
the ECG, hyperlipidemia (defined at the time of study as a
total cholesterol level 250 mg/dL), and diabetes mellitus
defined at that time as a fasting glucose level 140 mg/dL).
f these characteristics, diabetes mellitus had the greatest
nfluence on increasing the probability of IHD. The pres-
nce of hypertension or a family history of premature IHD
id not provide additional predictive accuracy. The results
f the aforementioned landmark study subsequently were
eplicated with data from CASS (Coronary Artery Surgery
tudy) (73) and were within 5% of the original estimates for
3 of 24 patient groupings. The single major exception was
he category of adults who were 50 years of age with
typical angina, for whom the CASS estimate was 17%
igher. On the basis of this high degree of concordance, the
ata from these studies were merged in the 2002 Chronic
table Angina guideline (7,52,73) (Table 9).
Additional validation studies were conducted with data
rom the Duke Databank for Cardiovascular Disease, which
lso incorporated electrocardiographic findings (Q waves or
T-T changes) and information about risk factors (smok-
ng, diabetes mellitus, hyperlipidemia) (71). Table 10 pres-
nts the Duke data for mid-decade patients (35, 45, 55, and
5 years of age). Two probabilities are given. The first is for
ain
Chest Wall Psychiatric
Costochondritis
Fibrositis
Rib fracture
Sternoclavicular arthritis
Herpes zoster (before the rash)
Anxiety disorders
Hyperventilation
Panic disorder
Primary anxiety
Affective disorders (i.e., depression)
Somatiform disorders
Thought disorders (i.e., fixed delusions)est P
asislow-risk patient with no risk factors and a normal ECG.
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diabetes mellitus and hyperlipidemia but has a normal
ECG. A key contribution of the Duke Databank is the
value of incorporating data about risk factors into the
probability estimate.
A limitation of these predictive models, however, is that
because they were developed with data from patients re-
ferred to university medical centers, they tended to overes-
timate the likelihood of IHD in patients at lower risk. It is
possible to correct this referral (or ascertainment) bias by
using the overall prevalence of IHD in the primary-care
population (72), although these adjustments are themselves
subject to error if the prevalence estimates are flawed.
An additional limitation of these models is that they were
derived from populations of patients 70 years of age. Yet
another drawback is that they perform less well in women,
in part because the prevalence of obstructive CAD is lower
in women than in men. As shown in Table 9, the Diamond-
Forrester model substantially overestimates the likelihood of
CAD compared with the prevalence observed in the WISE
study (52,74).
After integrating data from the clinical evaluation, model
predictions, and other relevant factors to develop a proba-
bility estimate, the clinician must then engage the patient in
a process of shared decision making, as noted in Section 1.8,
to determine whether further testing is warranted.
Table 9. Pretest Likelihood of CAD in Symptomatic Patients
According to Age and Sex* (Combined Diamond/Forrester
and CASS Data)
Nonanginal
Chest Pain Atypical Angina Typical Angina
Age, y Men Women Men Women Men Women
30–39 4 2 34 12 76 26
40–49 13 3 51 22 87 55
50–59 20 7 65 31 93 73
60–69 27 14 72 51 94 86
CAD indicates coronary artery disease; and CASS, Coronary Artery Surgery Study.
*Each value represents the percent with significant CAD on catheterization.
Adapted from Forrester and Diamond (52,73).
Table 10. Comparing Pretest Likelihood of CAD in Low-Risk
Symptomatic Patients With High-Risk Symptomatic Patients
(Duke Database)
Nonanginal
Chest Pain Atypical Angina Typical Angina
Age, y Men Women Men Women Men Women
35 3–35 1–19 8–59 2–39 30–88 10–78
45 9–47 2–22 21–70 5–43 51–92 20–79
55 23–59 4–21 45–79 10–47 80–95 38–82
65 49–69 9–29 71–86 20–51 93–97 56–84
Each value represents the percentage with significant CAD. The first is the percentage for a
low-risk, mid-decade patient without diabetes mellitus, smoking, or hyperlipidemia. The second
is that of a patient of the same age with diabetes mellitus, smoking, and hyperlipidemia. Both
high- and low-risk patients have normal resting ECGs. If ST-T-wave changes or Q waves had been
present, the likelihood of CAD would be higher in each entry of the table.CAD indicates coronary artery disease; and ECG, electrocardiogram.
Reprinted from Pryor et al. (71).2.2. Noninvasive Testing for Diagnosis of IHD
2.2.1. Approach to the Selection of Diagnostic Tests
to Diagnose SIHD
Functional or stress testing to detect inducible ischemia has
been the “gold standard” and is the most common nonin-
vasive test used to diagnose SIHD. All functional tests are
designed to provoke cardiac ischemia by using exercise or
pharmacological stress agents either to increase myocardial
work and oxygen demand or to induce vasodilation-elicited
heterogeneity in induced coronary flow. These techniques
rely on the principles embodied within the ischemic cascade
(Figure 7), in which graded ischemia of increasing severity
and duration produces sequential changes in perfusion,
relaxation and contraction, wall motion, repolarization, and,
ultimately, symptoms, all of which can be detected by an
array of cardiovascular testing modalities (75). The produc-
tion of ischemia, however, depends on the severity of stress
imposed (i.e., submaximal exercise can fail to produce
ischemia) and the severity of the flow disturbance. Coronary
stenoses 70% are often undetected by functional testing.
Because abnormalities of regional or global ventricular
function occur later in the ischemic cascade, they are more
likely to indicate severe stenosis and, thus, demonstrate a
higher diagnostic specificity for SIHD than do perfusion
defects, such as those seen on nuclear MPI. Isolated
perfusion defects, on the other hand, can result from
stenoses of borderline significance, raising the sensitivity of
nuclear MPI for underlying CAD but lowering the speci-
ficity for more severe stenosis.
The recent availability of multislice CCTA allows for the
noninvasive visualization of anatomic CAD with high-
resolution images similar to invasive coronary angiography.
As would be expected, CCTA and invasive angiography
exhibit a high degree of concordance, as they are both
anatomic tests, and CCTA is more sensitive in detecting
obstructive CAD, especially at diameter stenosis 70%,
than is nuclear MPI (76).
The accuracy of a CCTA reader in estimating coronary
Figure 7. The Ischemic Cascade
Reproduced with permission from Shaw et al. (75).stenosis within a vessel is hindered by the presence of dense
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severity of lesions relative to invasive angiography (77). No
direct comparisons of the effectiveness of a functional
approach with inducible ischemia or an anatomic approach
assessing coronary stenosis have been completed in the
noninvasive setting, although several randomized controlled
trials (RCTs) are under way, which will directly or indirectly
compare test modalities: PROMISE (Prospective Multi-
center Imaging Study for Evaluation of Chest Pain; clini-
altrials.gov identifier NCT01174550), RESCUE (Ran-
omized Evaluation of Patients With Stable Angina
omparing Diagnostic Examinations; clinicaltrials.gov
dentifier NCT01262625), and ISCHEMIA (International
tudy of Comparative Health Effectiveness with Medical
nd Invasive Approaches; clinicaltrials.gov identifier
CT01471522).
In 2010, the United Kingdom’s National Institute for
linical Excellence Guidance for “Chest pain of recent
nset: Assessment and diagnosis of recent onset chest pain
r discomfort of suspected cardiac origin” provide, for a
ealthcare system that allocates resources differently from
hat of the United States, recommendations for an initial
ssessment of CAD. This Guidance recommends beginning
n people without confirmed CAD with a detailed clinical
ssessment and performing a 12-lead ECG in those in
hom stable angina cannot be diagnosed or excluded on the
asis of clinical assessment alone. The Guidance suggests
hat there is no need for further testing in those with an
stimated likelihood 10%. In those with an estimated
ikelihood of CAD of 10% to 29%, the National Institute
or Clinical Excellence document recommends beginning
ith CT coronary artery calcium (CAC) scoring as the
rst-line diagnostic investigation, whereas the present
IHD guideline provides a Class IIb recommendation for
everal reasons, as outlined in Section 2.2.4.2.
2.2.1.1. ASSESSING DIAGNOSTIC TEST CHARACTERISTICS
A hierarchy of diagnostic test evidence has been proposed
by Fryback and Thornbury (78) and ranges from evidence
on technical quality (level 1) through test accuracy (sensi-
tivity and specificity associated with test interpretation), to
changes in diagnostic thinking, effect on patient manage-
ment, and patient outcomes, to societal costs and benefits
(level 6). A similar framework has been proposed for
biomarkers by Hlatky et al. (79). In practice, although
knowledge of the effect of diagnostic testing on outcomes
would be highly desirable, the vast majority of available
evidence is on diagnostic or prognostic accuracy. Therefore,
this information most commonly is used to compare test
performance.
Diagnostic accuracy is commonly represented by the
terms sensitivity and specificity, which are calculated by
comparing test results to the “gold standard” of the results of
invasive coronary angiography. The sensitivity of any non-
invasive test to diagnose SIHD expresses the frequency that
a patient with angiographic IHD will have a positive testresult, whereas the specificity measures the frequency that a
patient without IHD will have a negative result. In addition,
predictive accuracy represents the frequency that a patient
with a positive test does have IHD (positive predictive
value) or that a patient with a negative test truly does not
have IHD (negative predictive value). The predictive accu-
racy may be used for both diagnostic and prognostic
accuracy analyses; in the latter case, the comparison is to
subsequent cardiovascular events. It is important to note
that apparent test performance can be altered substantially
by the pretest probability of IHD (52,80,81), making the
accurate assessment of pretest probability and proper patient
selection essential for diagnostic interpretation statements
on IHD prevalence by test results. The positive predictive
value of a test declines as the disease prevalence decreases in
the population under study, whereas the negative predictive
accuracy increases (82). Finally, the performance of nonin-
vasive tests also varies in certain patient populations, such as
obese patients, the elderly, and women (Section 5.12), who
often are underrepresented in clinical studies.
Estimates of all test characteristics are subject to workup
bias, also known as verification or posttest referral bias
(81,83,84). This bias occurs when the results of stress
testing are used to decide which patients undergo the
standard reference procedure (invasive coronary angiogra-
phy) to establish a definitive diagnosis of IHD (i.e., patients
with positive results on stress testing are referred for
coronary angiography, whereas those with negative results
are not). This bias has the effect of raising the measured
sensitivity and lowering the measured specificity in relation
to their true values. Mathematical corrections can be applied
to estimate corrected values (84–86).
Diagnostic testing is most valuable when the pretest
probability of IHD is intermediate—for example, when a
50-year-old man has atypical angina, and the probability of
IHD is approximately 50% (Table 9). The precise definition
of intermediate probability (i.e., between 10% and 90%,
20% and 80%, or 30% and 70%) is somewhat arbitrary. In
addition to these boundaries, other factors are important in
the decision to refer a patient to testing, including the
degree of uncertainty acceptable to the physician and
patient; the likelihood of an alternative diagnosis; the
accuracy of the diagnostic test selected (i.e., sensitivity and
specificity), test reliability, procedural cost, and the potential
risks of further testing; and the benefits and risks of
treatment in the absence of additional testing. A definition
of 10% and 90%, first advocated in 1980 (87), has been
applied in several studies (88,89). Although broad, this
range still excludes several sizable patient groups (e.g., older
men with typical angina and younger women with nonangi-
nal pain). When the probability of IHD is high, a positive
test result is merely confirmatory, whereas a negative test
result might not diminish the probability of disease suffi-
ciently to be clinically useful and could even be misleading
because of the possibility that it is a false negative result.
When the probability of IHD is very low, however, a
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tive test result might not be clinically useful and could be
misleading if falsely positive. The importance of relying on
clinical judgment and refraining from testing in very low-
risk populations is well illustrated by a thought experiment
proposed by Diamond and Kaul in a letter to the editor of
The New England Journal of Medicine:
“As an example, suppose we have a test marker with 80%
sensitivity and 80% specificity (typical of cardiac stress tests).
Given 100 individuals with a10% disease prevalence, there
will be 8 true positives (100  0.1  0.8) and 18 false
positives (100  0.9  0.2). If we refer only these 26
positive responders for angiography, the observed “diagnos-
tic yield” is only 31% (8/26). Moreover, the test’s sensitivity
will appear to be 100% (all diseased subjects having a
positive test), and its specificity will appear to be 0% (all
non-diseased subjects also having a positive test). Hence,
the more we rely on a test, the less well it appears to
perform.” (90, p. 93)
The likelihood of CAD proposed above differs substantially
from that in the populations from which the estimates of
noninvasive test performance were derived; the overall
prevalence of CAD from a meta-analysis was 60% (91).
Instead, contemporary age-, sex-, and symptom-based IHD
probability estimates can be gleaned from a multicenter
cohort of 14,048 patients with suspected IHD undergoing
CCTA (92).
2.2.1.2. SAFETY AND OTHER CONSIDERATIONS POTENTIALLY
AFFECTING TEST SELECTION
All forms of noninvasive stress testing carry some risk.
Maximal exercise testing is associated with a low but finite
incidence of cardiac arrest, AMI, and even death. Pharma-
cological stress agents fall into 2 broad categories: beta-
agonists such as dobutamine, which increase heart rate and
inotropy, and vasodilators such as adenosine, dipyridamole,
or regadenoson, which act to increase blood flow to normal
arteries while decreasing perfusion to stenotic vessels. Each
of these pharmacological stress agents also carries a very
small risk of drug-specific adverse events (dobutamine:
ventricular arrhythmias; dipyridamole/adenosine: broncho-
spasm in chronic obstructive pulmonary disease).
Nuclear perfusion imaging and CCTA use ionizing
radiation techniques for visualizing myocardial perfusion
and anatomic CAD, respectively. Risk projections are based
largely on observations from atomic bomb survivors exposed
to higher levels of ionizing radiation. The Linear-No-
Threshold hypothesis states that any exposure could result
in an increased projected cancer risk and that there is a
dose–response relationship to elevated cancer risk with
higher exposures. Considerable controversy exists surround-
ing the extrapolation of projected cancer risk to low-level
exposure in medical testing, and no reported evidence links
low-level exposure to observed cancer risk. Even when the
Linear-No-Threshold hypothesis is used, the projected
incident cancer is estimated to be very low for nuclear MPI iand CCTA (93–95). Nevertheless, general agreement exists
that the overriding principle of caution and safety should
apply by projecting the Linear-No-Threshold hypothesis.
The principle of As Low as Reasonably Achievable
(ALARA) should be applied in all patient populations. For
CCTA performed with contemporary equipment in accor-
dance with the Society of Cardiovascular Computed To-
mography recommendations, average estimated radiation
dose ranges from 5 to 10 mSv (96). For stress nuclear MPI,
when the American Society of Nuclear Cardiology–
recommended rest-stress Tc-99m SPECT or Rb-82 posi-
tron emission tomography (PET) protocol (97) is used, the
estimated radiation dose is approximately 11 or 3 mSV,
respectively (97,98). On the basis of American Society of
Nuclear Cardiology guidelines, dual-isotope or rest-stress
Tl-201 imaging is discouraged for diagnostic procedures
because of its high radiation exposure. The use of new
high-efficiency nuclear MPI cameras results in a similar or
lower effective dose for both dual-isotope and rest-stress
Tc-99m imaging (99–101). For both CT and nuclear
imaging, the AHA, Society of Cardiovascular Computed
Tomography, and American Society of Nuclear Cardiology
recommend widespread application of dose-reduction tech-
niques whenever possible (96–98). Clinicians should apply
the concept of benefit-to-risk ratio when considering test-
ing. When testing is used appropriately, the clinical benefit
in terms of supportive diagnostic or prognostic accuracy
exceeds the projected risk such that there is an advantage to
testing (13,14). When it is used inappropriately or overused,
the benefit of testing is low, and the risk of exposure is
unacceptably high. Of note, care should be taken when
exposing low-risk patients to ionizing radiation. This is
particularly of concern in younger patients for whom the
projected cancer risk is elevated (102).
Use of contrast agents with CCTA can cause allergic
reactions. Contrast agents also can affect renal function and
therefore should be avoided in patients with chronic kidney
disease. CMR might be contraindicated in patients with
claustrophobia or implanted devices, and use of gadolinium
contrast agents is associated rarely with nephrogenic sys-
temic fibrosis. For this reason, gadolinium is contraindi-
cated in patients with severe renal dysfunction (estimated
glomerular filtration rates 30 mL/min per 1.73 m2), and
he dose should be adjusted for patients with mild to
oderate dysfunction (estimated glomerular filtration rates
0 to 60 mL/min per 1.73 m2). As with all safety consid-
rations, the potential risks need to be considered carefully
n concert with the potential benefits from the added
nformation obtained to guide care.
In addition to pretest likelihood, a variety of clinical
actors influence noninvasive test selection (103–105). Chief
mong these are the patient’s ability to exercise, body
abitus, cardiac medication use, and ECG interpretability.
he decision to add imaging in patients who have an
nterpretable ECG and are capable of vigorous exercise is
mportant because imaging and nonimaging testing have
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Most, but not all, studies evaluating cohorts of patients
undergoing both exercise ECG and stress imaging have
shown that the addition of imaging information provides
incremental benefit in terms of both diagnostic and prog-
nostic information with an acceptable increase in cost
(Section 2.2.1.5) (106–117).
Other factors affecting test choice include local availabil-
ity of specific tests, local expertise in test performance and
interpretation, the presence of multiple diagnostic or prog-
nostic questions better addressed by one form of testing over
another, and the existence of prior test results (especially
when prior images are available for comparison). Finally,
although echocardiographic, radionuclide, and CMR stress
imaging can have complementary roles for estimating pa-
tient prognosis, there is rarely a reason to perform multiple
tests in the same patient, unless the results of the initial
imaging test are unsatisfactory for technical reasons or the
findings are equivocal or require confirmation.
2.2.1.3. EXERCISE VERSUS PHARMACOLOGICAL TESTING
When a patient is able to perform routine activities of
daily living without difficulty, exercise testing to provoke
ischemia is preferred because it often can provide a higher
physiological stress than would be achieved by pharma-
cological testing. This can translate into a superior ability
to detect ischemia as well as providing a correlation to a
patient’s daily symptom burden and physical work capac-
ity not offered by pharmacological stress testing. In
addition, exercise capacity alone is a very strong prognos-
tic indicator (118,119).
The goal of exercise testing for suspected SIHD patients
is 1) to achieve high levels of exercise (i.e., maximal
exertion), which in the setting of a negative ECG generally
and reliably excludes obstructive CAD, or 2) to document
the extent and severity of ECG changes and angina at a
given workload (i.e., demand ischemia) so as to predict the
likelihood of underlying significant or severe CAD. Thus,
candidates for exercise testing must possess sufficient func-
tional capacity to attain maximal, volitional stress levels.
Because there is high variability in age-predicted maximal
heart rate among subjects of identical age (120), achieving
85% of age-predicted maximal heart rate might not indicate
sufficient effort during exercise testing and should not be used
as a criterion to terminate a stress test (121). Failure to reach
eak heart rate (if beta blockers have been held as recom-
ended) or to achieve adequate levels of exercise in the setting
f a negative ECG is consistent with functional disability and
esults in an indeterminate estimation of CAD. Female-
pecific age-predicted maximal heart rate and functional ca-
acity measurements are available (118,122).
Standard treadmill protocols initiate exercise at 3.2 to 4.7
etabolic equivalents (METs) of work and increase by
everal METs every 2 to 3 minutes of exercise (e.g.,
odified or standard Bruce protocol). Most activities ofaily living require approximately 4 to 5 METs of physicalork to perform. Thus, reported limitations in activities of
aily living identify a patient who might be unable to
erform maximal exercise. Gentler treadmill protocols, with
ncremental stages of 1 MET, or bicycle stress can help
ome patients achieve maximal exercise capacity.
Optimal candidates with sufficient physical functioning
ay be identified as those capable of performing at least
oderate physical functioning (i.e., performing at least
oderate household, yard, or recreational work and most
ctivities of daily living) and with no disabling comorbidity
including frailty, advanced age, marked obesity, PAD,
hronic obstructive pulmonary disease, or orthopedic limi-
ations). Patients incapable of at least moderate physical
unctioning or with disabling comorbidity should be re-
erred for pharmacological stress imaging. In the setting of
ubmaximal exercise and a negative stress ECG, consider-
tion should be given to performing additional testing with
harmacological stress imaging to evaluate for inducible
schemia.
2.2.1.4. CONCOMITANT DIAGNOSIS OF SIHD AND ASSESSMENT OF RISK
Although the primary goal of testing among patients with
new onset of symptoms suggesting SIHD is to diagnose or
exclude obstructive CAD, the various modalities also can
provide additional information about long-term risk
(Section 3.3.2), and this prognostic ability may influence
the selection of an initial test. Exercise capacity remains one
of the strongest indicators of long-term risk (including
death) for men and women with suspected and known
CAD (118,123–125). In addition, information derived from
treadmill exercise (e.g., Duke treadmill score (126,127) and
heart rate recovery) provides incremental diagnostic and
prognostic information. For this reason, it is preferable to
perform exercise stress if the patient is able to achieve a
maximal workload. For the exercise-capable patient with a
normal baseline ECG, the decision to perform imaging
with nuclear or echocardiographic techniques along with
stress ECG should be based on many factors, including the
likelihood of garnering substantial incremental prognostic
information that is likely to alter clinical and therapeutic
management.
2.2.1.5. COST-EFFECTIVENESS
Estimates of cost-effectiveness of various testing strate-
gies in symptomatic patients have been used to inform
responses to rising healthcare costs. However, to be of
value, estimates of cost-effectiveness must use contempo-
rary estimates of effectiveness that incorporate consider-
ations of disease prevalence and test accuracy. Further-
more, costs must reflect not only the index test but also
the episode of care and the longer-term induced costs and
outcomes of diagnosed and undiagnosed SIHD. Ideally,
these data would be derived from RCTs or registries
designed to compare the effectiveness of testing strategies
and observed associated costs. However, in the interim
until such evidence is available, mixed methods and
decision analytic models provide general estimates of the
22
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methods use observational evidence of index and down-
stream procedures, hospitalization, and drug costs and
apply cost weights to estimate cumulative costs (128 –
130), whereas decision analytic models simulate clinical and
financial data (131–137). Regardless of the approach, inher-
ent assumptions and uncertainties with regard to the data
and incomplete consideration of risks and benefits require
that such calculations be considered as estimates only (138).
In most studies, stress imaging is estimated to provide a
benefit over exercise ECG at a reasonable cost, commensu-
rate with accepted values for cost effectiveness (i.e., at the
threshold for economic efficiency of $50,000 per added
year of life), a result driven primarily by more frequent
angiography and adverse cardiovascular events for those
with a negative exercise ECG. Results of decision analytic
and mixed modeling approaches comparing stress echocar-
diography with myocardial perfusion SPECT vary, with
some favoring exercise echocardiography and others favor-
ing exercise nuclear MPI (128,133).
The patient’s pretest likelihood of CAD also influences
cost-effectiveness such that exercise echocardiography is
more cost-effective in lower-risk patients (with annual risk
of death or MI 2%) than in higher-risk patients, in whom
nuclear MPI is more cost-effective. Use of invasive coronary
angiography as a first test is not cost-effective in patients
with a pretest probability 75% (139,140). Finally, it is
important to note that as the reimbursement for stress
imaging decreases (it is now less than half the value used in
older studies), the relative cost-effectiveness (dollars/
quality-adjusted life-year saved) of stress imaging is more
favorable than that of exercise ECG, and the comparative
advantage of lower- to higher-cost imaging procedures is
minimized.
The cost-efficiency of CCTA is less well studied but
also depends on disease prevalence (139,140). Data
conflict as to whether patients undergoing CCTA as
initial imaging modality are less or more likely to undergo
invasive coronary angiography or revascularization, al-
though it appears that they have similar or lower rates of
adverse cardiovascular events (128,130,141,142). As a
result, CCTA performed alone or in combination with
functional testing minimizes adverse cardiac events, max-
imizes quality-adjusted life-years (140,143), and is esti-
mated to be cost-effective.
Although data on cost-effectiveness and patient satisfac-
tion for CMR are limited, evidence suggests that CMR can
improve patient management. The German Pilot/European
Cardiovascular Magnetic Resonance (EuroCMR) registry
of 11,040 consecutive patients evaluated for cardiomyopa-
thy, ischemia, and myocardial viability found that CMR
satisfied all requested imaging needs in 86% of patients so
that no further imaging was required (144). In the 3,351
stress CMR cases, invasive angiography was avoided in45%, compared with 18% in patients who underwent
nuclear imaging.
2.2.2. Stress Testing and Advanced Imaging for
Initial Diagnosis in Patients With Suspected SIHD
Who Require Noninvasive Testing: Recommendations
See Table 11 for a summary of recommendations from this
section.
2.2.2.1. ABLE TO EXERCISE
CLASS I
1. Standard exercise ECG testing is recommended for patients with an
intermediate pretest probability of IHD who have an interpretable
ECG and at least moderate physical functioning or no disabling
comorbidity (114,145–147). (Level of Evidence: A)
. Exercise stress with nuclear MPI or echocardiography is recom-
mended for patients with an intermediate to high pretest probability
of IHD who have an uninterpretable ECG and at least moderate
physical functioning or no disabling comorbidity (91,132,148–156).
(Level of Evidence: B)
CLASS IIa
1. For patients with a low pretest probability of obstructive IHD who do
require testing, standard exercise ECG testing can be useful, provided
the patient has an interpretable ECG and at least moderate physical
functioning or no disabling comorbidity. (Level of Evidence: C)
2. Exercise stress with nuclear MPI or echocardiography is reasonable for
patients with an intermediate to high pretest probability of obstructive
IHD who have an interpretable ECG and at least moderate physical
functioning or no disabling comorbidity (91,132,148–156). (Level of
Evidence: B)
3. Pharmacological stress with CMR can be useful for patients with an
intermediate to high pretest probability of obstructive IHD who have
an uninterpretable ECG and at least moderate physical functioning
or no disabling comorbidity (153,157,158). (Level of Evidence: B)
CLASS IIb
1. CCTA might be reasonable for patients with an intermediate pretest
probability of IHD who have at least moderate physical functioning
or no disabling comorbidity (158–166). (Level of Evidence: B)
2. For patients with a low pretest probability of obstructive IHD who do
require testing, standard exercise stress echocardiography might be
reasonable, provided the patient has an interpretable ECG and at
least moderate physical functioning or no disabling comorbidity.
(Level of Evidence: C)
CLASS III: No Benefit
1. Pharmacological stress with nuclear MPI, echocardiography, or
CMR is not recommended for patients who have an interpretable
ECG and at least moderate physical functioning or no disabling
comorbidity (155,167,168). (Level of Evidence: C)
. Exercise stress with nuclear MPI is not recommended as an initial
test in low-risk patients who have an interpretable ECG and at least
moderate physical functioning or no disabling comorbidity. (Level of
Evidence: C)
2.2.2.2. UNABLE TO EXERCISE
CLASS I
1. Pharmacological stress with nuclear MPI or echocardiography is
recommended for patients with an intermediate to high pretest
probability of IHD who are incapable of at least moderate physical
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(Level of Evidence: B)
CLASS IIa
1. Pharmacological stress echocardiography is reasonable for patients
with a low pretest probability of IHD who require testing and are
incapable of at least moderate physical functioning or have dis-
abling comorbidity. (Level of Evidence: C)
. CCTA is reasonable for patients with a low to intermediate pretest
probability of IHD who are incapable of at least moderate physical
functioning or have disabling comorbidity (158–166). (Level of
Evidence: B)
. Pharmacological stress CMR is reasonable for patients with an
intermediate to high pretest probability of IHD who are incapable of
at least moderate physical functioning or have disabling comorbid-
ity (153,157,158,169–172). (Level of Evidence: B)
CLASS III: No Benefit
1. Standard exercise ECG testing is not recommended for patients who
Table 11. Stress Testing and Advanced Imaging for Initial Diag
Who Require Noninvasive Testing
Test
Exercise
Status
ECG
Interpretable
Able Unable Yes No L
Patients able to exercise*
Exercise ECG X X
Exercise with nuclear MPI
or Echo
X X
Exercise ECG X X
Exercise with nuclear MPI
or Echo
X X
Pharmacological stress CMR X X
CCTA X Any
Exercise Echo X X
Pharmacological stress with
nuclear MPI, Echo, or CMR
X X
Exercise stress with nuclear
MPI
X X
Patients unable to exercise
Pharmacological stress with
nuclear MPI or Echo
X Any
Pharmacological stress Echo X Any
CCTA X Any
Pharmacological stress CMR X Any
Exercise ECG X X
Other
CCTA
If patient has any of the
following:
a) Continued symptoms with
prior normal test, or
b) Inconclusive exercise or
pharmacological stress, or
c) Unable to undergo stress
with MPI or Echo
Any Any
CAC score Any Any
CAC indicates coronary artery calcium; CCTA, cardiac computed tomography angiography; CMR,
echocardiography; IHD, ischemic heart disease; LOE, level of evidence; MPI, myocardial perfusi
*Patients are candidates for exercise testing if they are capable of performing at least modera
living) and have no disabling comorbidity. Patients should be able to achieve 85% of age-predichave an uninterpretable ECG or are incapable of at least moderatephysical functioning or have disabling comorbidity (91,132,148–
156,161). (Level of Evidence: C)
2.2.2.3. OTHER
CLASS IIa
1. CCTA is reasonable for patients with an intermediate pretest prob-
ability of IHD who a) have continued symptoms with prior normal
test findings, or b) have inconclusive results from prior exercise or
pharmacological stress testing, or c) are unable to undergo stress
with nuclear MPI or echocardiography (173). (Level of Evidence: C)
CLASS IIb
1. For patients with a low to intermediate pretest probability of ob-
structive IHD, noncontrast cardiac CT to determine the CAC score
may be considered (174). (Level of Evidence: C)
See Online Data Supplement 1 for additional data on diagnos-
tic accuracy of stress testing and advanced imaging for the
s in Patients With Suspected SIHD
st Probability of IHD
COR LOE ReferencesIntermediate High
X I A (114,145–147)
X X I B (91,132,148–156)
IIa C N/A
X X IIa B (91,132,148–156)
X X IIa B (153,157,158)
X IIb B (158–166)
X IIb C N/A
Any III: No Benefit C (155,167,168)
III: No Benefit C N/A
X X I B (148–150,152–156)
IIa C N/A
X IIa B (158–166)
X X IIa B (153,157,158,169–172)
Any III: No Benefit C (91,132,148–156,161)
X IIa C (173)
IIb C (174)
c magnetic resonance imaging; COR, class of recommendation; ECG, electrocardiogram; Echo,
ging; N/A, not available; and SIHD, stable ischemic heart disease.
ical functioning (i.e., moderate household, yard, or recreational work and most activities of daily
ximum heart rate.nosi
Prete
ow
X
X
X
X
X
cardia
on imadiagnosis of suspected SIHD.
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Imaging Stress Testing for the Initial Diagnosis of
Suspected SIHD
2.2.3.1. EXERCISE ECG
The exercise ECG has been the cornerstone of diagnostic
testing of SIHD patients for several decades. The diagnostic
endpoint for an ischemic ECG is 1 mm horizontal or
own-sloping (at 80 ms after the J point) ST-segment
epression at peak exercise. ST-segment elevation (in a
on–Q-wave lead and excluding aortic valve replacement)
uring or after exercise occurs infrequently but represents a
igh-risk ECG finding consistent with an ACS. The
iagnostic accuracy of exertional ST-segment depression
as been studied extensively in several meta-analyses, sys-
ematic reviews, large observational registries, and RCTs
114,145–147,175). The composite diagnostic sensitivity
nd specificity, unadjusted for referral bias, is 61% and
anges from 70% to 77%, but it is lower in women
146,147,175) and lower than that for stress imaging mo-
alities. A similar accuracy has been reported for correlation
f ECG ischemia with anatomic CAD by CCTA (176).
iagnostic accuracy is improved when consideration is
iven to additional non-ECG factors, such as exercise
uration, chronotropic incompetence, angina, ventricular
rrhythmias, heart rate recovery, and hemodynamic re-
ponse to exercise (i.e., drop in systolic BP), or when
ombination scores such as the Duke treadmill or Lauer
cores are applied (118,177–180).
Multiple factors in addition to the patient’s inability to
chieve maximal exercise levels influence the accuracy of the
CG during exercise testing to diagnose obstructive CAD.
esting ECG abnormalities preclude accurate interpreta-
ion of exercise-induced changes and reduce test accuracy;
hese include abnormalities affecting the ST segment, such
s LV hypertrophy, LBBB, ventricular-paced rhythm, or
ny resting ST-segment depression 0.5 mm. Although
ome have proposed calculating the difference from rest to
xercise of changes 1 mm for patients with significant
esting ST-segment changes, the accuracy of this approach
as been less extensively studied and validated. The inter-
retation of ST-segment changes in patients with right
undle-branch block can be limited, especially in the pre-
ordial leads. Certain medications, including digitalis, also
nfluence ST-segment changes and can produce ischemic
CG changes that are frequently false positive findings. In
ddition, anti-ischemic therapies can reduce heart rate and
yocardial workload, and therefore, a lack of ischemic
CG changes can reflect false negative findings when the
est is used to diagnose SIHD. It is routine practice to
ithhold beta-blocker therapy for 24 to 48 hours before
esting. Patients who are candidates for an exercise ECG
ust be able to exercise and must have an interpretable
CG, which is defined as a normal 12-lead ECG or one
ith minimal resting ST-T-wave abnormalities (0.5 mm).2.2.3.2. EXERCISE AND PHARMACOLOGICAL STRESS ECHOCARDIOGRAPHY
The diagnostic endpoint of exercise and pharmacological
stress echocardiography is new or worsening wall motion
abnormalities and changes in global LV function during or
immediately after stress. In addition to the detection of
inducible wall motion abnormalities, most stress echocardi-
ography includes screening images to evaluate resting ven-
tricular function and valvular abnormalities. This informa-
tion can be helpful in a symptomatic patient without a
proven diagnosis.
Pharmacological stress echocardiography in the United
States is performed largely by using dobutamine with an
endpoint of inducible wall motion abnormalities (Table 11).
Vasodilator agents such as adenosine are used rarely in the
United States but are used more commonly in Europe. The
diagnostic accuracy of exercise and pharmacological stress
echocardiography has been studied extensively in multiple
meta-analyses, systematic reviews, and large, multicenter,
observational registries (91,148–152,154,175). In several
contemporary meta-analyses, the diagnostic sensitivity (un-
corrected for referral bias) ranged from 70% to 85% for
exercise and 85% to 90% for pharmacological stress echo-
cardiography (91,150,152,154). The uncorrected diagnostic
specificity ranges from 77% to 89% and 79% to 90% for
exercise and pharmacological stress echocardiography, re-
spectively. The use of intravenous ultrasound contrast
agents can improve endocardial border delineation and can
result in improved diagnostic accuracy (181). Myocardial
contrast echocardiography also has been examined for de-
termination of rest and stress myocardial perfusion, with the
results showing comparability to myocardial perfusion
SPECT findings in small patient series (182). However, the
technique is currently in limited use in the United States.
The diagnostic accuracy of all imaging modalities is
influenced by technical factors that could be inherent in the
technique (i.e., variable correlation between perfusion and
wall motion abnormalities and CAD extent and severity) or
that result from physical characteristics of the patient that
reduce image quality. For echocardiography, reduced image
quality, defined as reduced LV endocardial visualization, has
been reported for obese individuals and those with chronic
lung disease, although the use of intravenous contrast
enhancement results in sizeable improvement in endocardial
border delineation.
2.2.3.3. EXERCISE AND PHARMACOLOGICAL STRESS NUCLEAR
MYOCARDIAL PERFUSION SPECT AND MYOCARDIAL PERFUSION PET
Myocardial perfusion SPECT generally is performed with
rest and (for exercise or pharmacological stress) with stress
Tc-99m agents, with Tl-201 having limited applications
(e.g., viability) because of its higher radiation exposure (97).
Pharmacological stress generally is used with vasodilator
agents administered as a continuous infusion (adenosine,
dipyridamole) or bolus (regadenoson) injection. The diag-
nostic endpoint of nuclear MPI is reduction in myocardial
perfusion after stress. Nonperfusion high-risk markers in-
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wall motion abnormalities, reduced post-stress left ventric-
ular ejection fraction (LVEF) 5% or global LVEF (rest or
post-stress) 45%, transient ischemic LV dilation, in-
creased lung or right ventricular uptake, or abnormal coro-
nary flow reserve with myocardial perfusion PET
(183–186).
The diagnostic accuracy for detection of obstructive
CAD of exercise and pharmacological stress nuclear MPI
has been studied extensively in multiple meta-analyses,
systematic reviews, RCTs, and large, multicenter, observa-
tional registries (91,114,132,147,148,152,155,156,175).
rom these reports, the uncorrected diagnostic sensitivity
anged from 82% to 88% for exercise and 88% to 91% for
harmacological stress nuclear MPI. The uncorrected diag-
ostic specificity ranged from 70% to 88% and 75% to 90%
or exercise and pharmacological stress nuclear MPI,
espectively.
Diagnostic image quality is affected in obese patients, as well
s in women and men with large breasts. Reductions in breast
issue artifact have been reported with the use of the Tc-99m
gents as well as with attenuation-correction algorithms or
rone imaging (187–190). For myocardial perfusion SPECT,
lobal reductions in myocardial perfusion, such as in the setting
f left main or 3-vessel CAD, can result in balanced reduction
nd an underestimation of ischemic burden.
Myocardial perfusion PET is characterized by high spa-
ial resolution of the photon attenuation–corrected images
ith 82Rubidium or 13N-ammonia used as myocardial blood
flow tracers. Although less well studied than myocardial
perfusion SPECT, a meta-analysis of 19 studies suggests
that PET has a slightly higher (uncorrected) sensitivity for
detection of CAD (191,192), including in women and obese
patients (193).
2.2.3.4. PHARMACOLOGICAL STRESS CMR WALL MOTION/PERFUSION
In recent years, more centers have used pharmacological
stress CMR in the diagnostic evaluation of SIHD patients.
The imaging endpoint depends on the stress agent: devel-
opment of a new wall motion abnormality for cine CMR
with dobutamine stress or a new perfusion abnormality with
vasodilator stress. From a contemporary meta-analysis of 37
studies, the uncorrected diagnostic sensitivity and specificity
of dobutamine-induced CMR wall motion imaging were
83% and 86%, whereas the uncorrected diagnostic sensitiv-
ity and specificity of vasodilator stress–induced CMR MPI
were 91% and 81% (153). Several small comparative series
have reported accuracy data in relation to stress echocardi-
ography and nuclear imaging. Importantly, normal CMR
perfusion has a high negative predictive value for obstructive
CAD (194). One multicenter study that enrolled 234
patients demonstrated similar diagnostic accuracy between
CMR perfusion and SPECT MPI in detecting obstructive
CAD (172). More recently, a randomized study of 752
patients directly compared pharmacological stress CMR
with SPECT MPI and reported higher sensitivity bypharmacological stress CMR than SPECT MPI in the
detection of angiographically significant coronary stenosis
(87% versus 67%; p0.0001) (169). With dobutamine
stress, CMR wall motion had high accuracy for detection of
obstructive CAD in patients with suboptimal echocardio-
graphic acoustic window (170). CMR dobutamine wall
motion imaging demonstrated higher accuracy than dobut-
amine echocardiography wall motion (171). Although wall
motion and perfusion imaging are used to assess the
presence and extent of ischemia, most experienced centers
also acquire late gadolinium enhancement (LGE) imaging
in the same session to delineate the extent and severity of
scarred myocardium.
2.2.3.5. HYBRID IMAGING
Current imaging is based largely on the use of a single
modality, but combined or hybrid applications increasingly
are available, which include both PET and CT or SPECT
and CT, thus allowing for combined anatomic and func-
tional testing. In addition, newer scanning techniques have
allowed assessment of perfusion and FFR by CCTA alone,
in addition to coronary anatomy (195–201). Notably, these
combined assessments allow for a fused image in which the
physiological assessment of flow is coupled with the ana-
tomic extent and severity of CAD and also provides infor-
mation on plaque composition and arterial remodeling.
Limited evidence is available on hybrid imaging, although
several reports have reported prognostic accuracy for cardiac
events with both ischemic and anatomic markers (202–206).
Other combinations of imaging modalities also are being
developed, including PET/CMR, which is currently a
research application. The strength of combined imaging is
the added value of anatomy guiding interpretation of
ischemic and scarred myocardium as well as providing
information to guide therapeutic decision making. Hybrid
imaging also can overcome technical limitations of myocar-
dial perfusion SPECT or myocardial perfusion PET by
providing anatomic correlates to guide interpretative accu-
racy (207) and can provide the functional information that
an anatomic technique like CCTA or magnetic resonance
angiography lacks; however, radiation dose is increased.
2.2.4. Diagnostic Accuracy of Anatomic Testing for
the Initial Diagnosis of SIHD
2.2.4.1. CORONARY CT ANGIOGRAPHY
With improvements in temporal and spatial resolution as
well as volume coverage, evaluation of coronary arteries with
CCTA is now possible with a high degree of image quality
(208). The extent and severity of angiographic CAD are 2
of the most important prognostic factors and remain essen-
tial for revascularization decision making (209). Five meta-
analyses and 3 controlled clinical trials have reported the
diagnostic accuracy of CCTA with 64-slice CT, yielding
sensitivity values ranging from 93% to 97% and specificity
values ranging from 80% to 90% (159–166) for detecting
obstructive CAD on invasive coronary angiography, unad-
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diagnostic accuracy of CCTA was similarly high (210).
Prior reports included subsets of patients who already had
been referred for invasive angiography, and as such, test
performance would be altered by the biases inherent in a
preselected population. Factors related to diminished accu-
racy include image quality, the extent of coronary calcifica-
tion, and body mass index (BMI) (208).
A potential advantage of CCTA over standard functional
testing is its very high negative predictive value for obstruc-
tive CAD, which can reassure caregivers that providing
GDMT and deferring consideration of revascularization
constitute a sensible strategy. In addition to documentation
of stenotic lesions, CCTA can qualitatively visualize arterial
remodeling and nonobstructive plaque, including calcified,
noncalcified, or mixed plaque (211–216). The presence of
nonobstructive plaque has been shown to be helpful to
guiding risk assessment and can aid in discerning the
etiology of patient symptoms (211,215,216). CT informa-
tion has been correlated with functional stress testing
(203,204,215). Not every obstructive lesion produces isch-
emia, and ischemia can be present in the absence of a
significant stenosis in epicardial vessels, which results in
discordance between anatomic imaging with CCTA and
functional stress testing. Several series have reported the
positive predictive value of an anatomic lesion detected on
CCTA to range from 29% to 44% when ischemia on a stress
study is used as a reference standard (203,204). The evi-
dence on concordance, however, remains incomplete, with
current research showing the highest degree of concordance
between ischemia and mixed plaque. Because the presence
of significant calcification often can preclude the accurate
assessment of lesion severity or cause a false positive study,
CCTA should not be performed in patients who have
known extensive calcification or a high risk of CAD.
2.2.4.2. CAC SCORING
CT also provides measurement of a CAC score, calculated
as the product of the CAC area by maximal plaque density
(in Hounsfield units) (217). The CAC score frequently has
been applied for risk assessment in asymptomatic individu-
als (5), and it also has been used to predict the presence of
high-grade coronary stenosis as the cause of chest pain in
symptomatic patients. When the data from 2 large multi-
center registries, including a total of 3,615 symptomatic
patients, were combined, the estimated diagnostic sensitiv-
ity for the CAC score to predict obstructive CAD on
invasive angiography was 85%, with a specificity of 75%
(218). In a recent meta-analysis of 18 studies, which
included 10,355 symptomatic patients, the presence of
nonzero CAC score had a pooled sensitivity and specificity
of 98% and 40%, respectively, for detection of significant
CAD on invasive coronary angiography (174).
Although the diagnostic sensitivity of CAC to detect
obstructive CAD is fairly high, the frequency of false
negative exams (i.e., significant CAD in the absence ofCAC) is not well established. In small single-center studies,
perfusion defects on nuclear MPI or high-grade coronary
stenosis on coronary angiography can be present in 0% to 39%
of symptomatic patients with a calcium score of zero (219–
223). In the recent large, multicenter, CONFIRM (Coronary
CT Angiography Evaluation For Clinical Outcomes: An
International Multicenter Registry) registry, CCTA showed
mild, nonobstructive CAD in 13%, stenosis 50% in 3.5%,
nd stenosis 70% in 1.4% of the 10,037 symptomatic
atients without known CAD who had a CAC score of zero
214). Documentation of obstructive CAD without CAC
ccurs more often in younger patients in whom atherosclerotic
laque has not advanced to the stage of calcification.
Previous official documents from the AHA and ACCF
218) concluded that “patients considered to be at low risk of
oronary disease by virtue of atypical cardiac symptoms may
enefit from CAC testing to help in ruling out the presence of
bstructive coronary disease” (218) or that “coronary calcium
ssessment may be reasonable for the assessment of symptom-
tic patients, especially in the setting of equivocal treadmill or
unctional testing (Class IIb, LOE: B).” The present writing
ommittee believed that additional evidence in sufficiently large
ohorts of patients establishing the uncorrected diagnostic
ccuracy of CAC to rule in or rule out high-grade coronary
rtery stenosis in symptomatic patients was needed.
2.2.4.3. CMR ANGIOGRAPHY
Although not widely applied, CMR angiography has been
performed for the detection of the extent and severity of
obstructive CAD. As a result of small coronary artery size,
tortuosity, and motion, the diagnostic accuracy of CMR
angiography is reduced as compared with CCTA (224). A
multicenter, controlled clinical trial of patients referred to
invasive angiography revealed that magnetic resonance an-
giography had an 81% negative predictive value for exclud-
ing CAD (225). Several meta-analyses that included a total
of 59 studies have reported diagnostic sensitivity and spec-
ificity ranging from 87% to 88% and 56% to 70%, respec-
tively (158,226), with reports of a lower accuracy than that
of CCTA (164). Variability in diagnostic accuracy with
CMR angiography has been attributed to a lack of unifor-
mity in pulse sequences and the application of varying
analytic methods (227). Recent improvements applying
32-channel 3.0-T CMR have shown comparable abilities to
detect CAD as compared with CCTA (228). No recom-
mendations for the use of CMR angiography are included in
this guideline.
3. Risk Assessment
3.1. Clinical Assessment
3.1.1. Prognosis of IHD for Death or Nonfatal MI:
General Considerations
IHD is a chronic disorder with a natural history that spans
multiple decades. The disease typically cycles through clin-
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ating angina, and ACS (UA or AMI), although the pro-
gression from one state to another is not necessarily linear.
The specific approach to assessing risk of subsequent ad-
verse outcomes varies according to the patient’s clinical
phase, even though for those with SIHD, there is no
universally accepted approach. This represents a key area for
future research. The approach recommended in the present
guideline is informed by the treatment goals of prolonging
survival and optimizing health status and by the concept
that the benefits of treatment are often proportional to the
patient’s underlying risk. From this perspective, it is essen-
tial to quantify the patient’s prognosis as accurately as
possible. Several approaches to estimating the risk of car-
diovascular mortality or events are provided later in this
guideline. In the absence of an established prognostic
model, the following considerations are highlighted:
1. Sociodemographic characteristics: Age is the single stron-
gest determinant of survival, whereas ethnicity and sex
have conflicting and less important effects on risk. Lower
socioeconomic status also is associated with worse out-
comes (229).
2. Cardiovascular risk factors: Smoking, hypertension, dyslipi-
demia, family history of premature CAD, obesity, and
sedentary lifestyle confer a greater risk of complications.
3. Coexisting medical conditions: Diabetes mellitus (230),
chronic kidney disease (CKD) (231), chronic pulmonary
disease, and malignancy are the most important noncar-
diac conditions to influence prognosis (232–234).
4. Cardiovascular comorbidities: Heart failure, PAD, and
cerebrovascular diseases are strong prognostic risk factors
for mortality.
. Psychosocial characteristics: Depression repeatedly has been
demonstrated to be strongly and independently associated
with worse survival, and anxiety has also been implicated
(235–242). Poor social support, poverty, and stress also are
associated with adverse prognosis (236,243–245).
. Health status: Patients’ symptoms, functional capacity, and
quality of life are associated significantly with survival and
the incidence of subsequent ACS (246,247). In a large,
prospective cohort of patients in the Veterans Affairs
healthcare system, physical limitations due to angina were
second only to age in predicting mortality (246).
. Anginal frequency: Frequency of angina is a very strong
predictor of subsequent ACS hospitalizations (246).
. Cardiac disease severity: The degree and distribution of
stenoses measured by coronary angiography, findings on
exercise testing and stress imaging, and LV function
measured with a variety of technologies all provide
meaningful prognostic information that supplements
more clinical information.
.1.2. Risk Assessment Using Clinical Parameters
lthough there are several models to predict the likelihood
f complications and survival in asymptomatic, generalpopulations and in patients with ACS, there is a relative
paucity of information about models for assessing the risk of
patients with known SIHD that incorporate a broad range
of relevant data. Accurate risk assessment according to
clinical variables is essential to determining optimal treat-
ment strategies. Lauer and colleagues developed a risk index
that incorporates variables from the history and exercise test
on the basis of data from 32,000 individuals (248). They
found that their index, which can be calculated by using a
nomogram (Figure 8), was better able to predict individuals
with a low (3%) risk of death than was the Duke treadmill
score. Daly and colleagues reported an index to estimate risk
of death or nonfatal AMI derived from data on an interna-
tional sample of approximately 3,000 patients who pre-
sented with angina and were followed up for 18 months
(Figures 9 and 10). Obstructive CAD was documented in
one third, whereas another third had negative evaluations.
The c statistic for the model was 0.74, which indicates a
relatively high level of accuracy (57).
Several risk-assessment schemes have been developed to
assist in identifying patients with severe CAD, including
left main disease, although several of these studies are up to
2 decades old. One study (70) identified 8 clinical charac-
teristics that are important in estimating the likelihood of
severe IHD: typical angina, previous MI, age, sex, duration
of chest pain symptoms, risk factors (hypertension, diabetes
mellitus, hyperlipidemia, and smoking), carotid bruit, and
chest pain frequency. A subsequent study (71) provided
detailed equations to predict both severe IHD and survival
on the basis of clinical parameters. One study (249) devel-
oped a simple risk score for predicting severe (left main or
3-vessel) CAD that was based on 5 clinical variables: age,
sex, history of MI, presence of typical angina, and diabetes
mellitus with or without insulin use. This same score was
validated subsequently for prognostic purposes (250,251).
This score can be easily memorized and calculated (Figure 11)
and yields an integer ranging from 0 to 10 (57). The score
can be applied to determine if a patient is more suitable for
stress testing or possibly (in appropriate patients who are at
highest risk) for proceeding directly to coronary angiogra-
phy. Each curve shows the probability of severe IHD as a
function of age for a given cardiac risk score. As shown on
the Figure 11 graph, some patients have a high likelihood
(50%) of having severe disease for which revascularization
might improve survival on the basis of clinical parameters
alone. For example, a 50-year-old male patient who has
diabetes mellitus, is taking insulin, and has typical angina
and a history of previous MI has a likelihood of severe
coronary stenosis 60% and thus might proceed directly to
angiography if warranted by his preferences and other
clinical factors, although in most circumstances stress test-
ing will assist in planning further tests and treatments
(87,252). Creation of valid, quantitative models on the basis
of data from current registries and trials to accurately
identify patients with anatomic distributions of CAD for
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such as left main disease, should be a research priority.
Studies have suggested that addition of levels of novel
biomarkers such as C-reactive protein and brain natriuretic
peptide can improve prediction of mortality and cardiovas-
cular events (5,57). Considerable controversy remains; how-
ever, as to whether these tests truly provide incremental
information beyond more well-accepted risk factors, and
few of the studies have focused on patients with SIHD
(253–255). Inflammatory biomarkers, such as myeloperox-
idase (256), biochemical markers of lipid-related athero-
genic processes [lipoprotein(a), apolipoprotein B, small
Figure 8. Nomogram to Predict Risk of Death Based on Clinical D
To determine risk, draw a vertical line from each risk marker to the top line, labeled
marked on the line labeled “TOTAL POINTS.” Drop vertical lines from there to yield t
no. MET indicates metabolic equivalent. Reproduced from Lauer et al. (248).dense LDL, and lipoprotein-associated phospholipase A2](257,258), and low levels of circulating troponin detected by
high-sensitivity assays (259) also are under investigation as
indices of risk in patients with SIHD.
3.2. Advanced Testing:
Resting and Stress Noninvasive Testing
3.2.1. Resting Imaging to Assess Cardiac Structure
and Function: Recommendations
CLASS I
1. Assessment of resting LV systolic and diastolic ventricular function
and evaluation for abnormalities of myocardium, heart valves, or
pericardium are recommended with the use of Doppler echocardi-
nd Results of Exercise Testing
TS,” to calculate points for each risk marker. The sum of all these points is then
nd 5-year survival probabilities. For binary variables, 1 means yes and 0 meansata a
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ure, complex ventricular arrhythmias, or an undiagnosed heart
murmur (21,57,58,260,261). (Level of Evidence: B)
CLASS IIb
1. Assessment of cardiac structure and function with resting echocar-
diography may be considered in patients with hypertension or
diabetes mellitus and an abnormal ECG. (Level of Evidence: C)
. Measurement of LV function with radionuclide imaging may be
considered in patients with a prior MI or pathological Q waves,
provided there is no need to evaluate symptoms or signs suggestive
Figure 9. Euro Heart Score Sheet to Calculate Risk Score for Pati
ith Newly Diagnosed SIHD)
*1 of previous cerebrovascular event; hepatic disease defined as chronic hepatitis
upper limit of normal; PVD defined as claudication either at rest or on exertion, amp
angioplasty to the extremities, documented aortic aneurysm, or noninvasive evidenc
plantation or serum creatinine 200 mmol/L; chronic respiratory disease defined as
75%, arterial p02 60%, or arterial pCO2 50% predicted in previous studies; chr
upus erythematosus or other connective tissue disease, polymyalgia rheumatica, an
ancy. FEV1 indicates forced expiratory volume; pO2, partial pressure of oxygen; PCO2
rom Daly et al. (57).
Figure 10. Risk of Death or MI Over 1-Year After Diagnosis of
SIHD According to Euro Heart Score
Plot to assign estimated probability of death or nonfatal MI within 1 year of presenta-
tion according to combination of clinical and investigative features in patients with sta-
ble angina. MI indicates myocardial infarction. Reproduced from Daly et al. (57).of heart failure, complex ventricular arrhythmias, or an undiagnosed
heart murmur. (Level of Evidence: C)
CLASS III: No Benefit
1. Echocardiography, radionuclide imaging, CMR, and cardiac CT are not
recommended for routine assessment of LV function in patients with a
normal ECG, no history of MI, no symptoms or signs suggestive of heart
failure, and no complex ventricular arrhythmias. (Level of Evidence: C)
. Routine reassessment (1 year) of LV function with technologies
such as echocardiography radionuclide imaging, CMR, or cardiac CT
is not recommended in patients with no change in clinical status
and for whom no change in therapy is contemplated. (Level of
Evidence: C)
See Online Data Supplement 2 for additional data on using
resting imaging to assess cardiac structure and function.
In the presence of signs or symptoms suggestive of heart
failure, it is imperative to obtain an objective measure of LV
function if a prognosis-altering change in therapy could be
based on the findings. For example, a rest ejection fraction
(EF)35% is associated with an annual mortality rate3%
per year (260). Resting 2-dimensional echocardiography
with Doppler echocardiography is the preferred approach
because it provides a thorough assessment of all aspects of
cardiac structure and function, including identifying the
mechanism of heart failure and differentiating systolic LV
Presenting With Stable Angina (Derived From 3,779 Patients
rhosis, or other hepatic disease causing elevation of transaminases 3 times
for arterial vascular insufficiency, vascular surgery (reconstruction or bypass) or
paired arterial flow; chronic renal failure defined as chronic dialysis or renal trans-
gnosis previously made by physician or patient receiving bronchodilators or FEV1
flammatory conditions defined as a diagnosis of rheumatoid arthritis, systemic
n; malignancy defined as a diagnosis of malignancy within a year of active malig-
l pressure of carbon dioxide; and PVD, peripheral vascular disease. Reproducedents
or cir
utation
e of im
a dia
onic in
d so ofrom diastolic dysfunction.
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ance and prognostic information in patients without symp-
toms or signs of ventricular dysfunction or changing clinical
status, especially in those with evidence of other forms of
heart disease (e.g., hypertensive, valvular). For example,
echocardiography can identify LV or left atrial dilation;
identify aortic stenosis (a potential non-CAD mechanism
for angina-like chest pain); measure pulmonary artery pres-
sure; quantify mitral regurgitation; identify a LV aneurysm;
identify a LV thrombus, which increases the risk of death
(262); and measure LV mass and the ratio of wall thickness
to chamber radius—all of which predict cardiac events and
mortality (20,117,263–267).
Although nuclear imaging accurately measures EF, it
does not provide additional information on valvular or
pericardial disease and requires exposure to ionizing radia-
tion (21,268). Although CMR is applied less widely, it also
accurately measures LV performance and provides insight
into myocardial and valvular structures (269). Use of delayed
hyperenhancement techniques can identify otherwise unde-
tected scarred as well as viable myocardium. Cardiac CT
also provides high-resolution detection of cardiac structures
and EF. Nevertheless, all 3 tests generally are more expen-
sive than a resting echocardiogram. Although the amount of
ionizing radiation required in cardiac CT and nuclear MPI
has been lowered over the years and will continue to reduce,
the use of these tests for risk assessment is discouraged in
patients with low pretest probability of CAD and in young
patients.
3.2.2. Stress Testing and Advanced Imaging in
Patients With Known SIHD Who Require
Noninvasive Testing for Risk Assessment:
Recommendations
See Table 12 for a summary of recommendations from this
Figure 11. Nomogram Showing the Probability of Severe
(3-Vessel or Left Main) Coronary Disease Based on a 5-Point
Score
One point is awarded for each of the following variables: male sex, typical angina,
history and electrocardiographic evidence of MI, and diabetes mellitus and use of
insulin. Each curve shows the probability of severe coronary disease as a function
of age. Reproduced from Hubbard et al. (249).section.3.2.2.1. RISK ASSESSMENT IN PATIENTS ABLE TO EXERCISE
CLASS I
1. Standard exercise ECG testing is recommended for risk assessment
in patients with SIHD who are able to exercise to an adequate
workload and have an interpretable ECG (106–110,112–114,132–
134). (Level of Evidence: B)
2. The addition of either nuclear MPI or echocardiography to standard
exercise ECG testing is recommended for risk assessment in patients
with SIHD who are able to exercise to an adequate workload but have
an uninterpretable ECG not due to LBBB or ventricular pacing
(7,111,264–266,270,299,300). (Level of Evidence: B)
CLASS IIa
1. The addition of either nuclear MPI or echocardiography to standard
exercise ECG testing is reasonable for risk assessment in patients with
SIHD who are able to exercise to an adequate workload and have an
interpretable ECG (271–279). (Level of Evidence: B)
2. CMR with pharmacological stress is reasonable for risk assessment
in patients with SIHD who are able to exercise to an adequate
workload but have an uninterpretable ECG (279–284). (Level of
Evidence: B)
CLASS IIb
1. CCTA may be reasonable for risk assessment in patients with SIHD
who are able to exercise to an adequate workload but have an
uninterpretable ECG (285,286). (Level of Evidence: B)
CLASS III: No Benefit
1. Pharmacological stress imaging (nuclear MPI, echocardiography, or
CMR) or CCTA is not recommended for risk assessment in patients
with SIHD who are able to exercise to an adequate workload and
have an interpretable ECG. (Level of Evidence: C)
3.2.2.2. RISK ASSESSMENT IN PATIENTS UNABLE TO EXERCISE
CLASS I
1. Pharmacological stress with either nuclear MPI or echocardiography is
recommended for risk assessment in patients with SIHD who are
unable to exercise to an adequate workload regardless of interpretabil-
ity of ECG (7,264–266,287–290). (Level of Evidence: B)
CLASS IIa
1. Pharmacological stress CMR is reasonable for risk assessment in
patients with SIHD who are unable to exercise to an adequate
workload regardless of interpretability of ECG (280–284,291).
(Level of Evidence: B)
2. CCTA can be useful as a first-line test for risk assessment in patients
with SIHD who are unable to exercise to an adequate workload
regardless of interpretability of ECG (286). (Level of Evidence: C)
3.2.2.3. RISK ASSESSMENT REGARDLESS OF PATIENTS’ ABILITY TO EXERCISE
CLASS I
1. Pharmacological stress with either nuclear MPI or echocardiogra-
phy is recommended for risk assessment in patients with SIHD who
have LBBB on ECG, regardless of ability to exercise to an adequate
workload (287–290,292). (Level of Evidence: B)
. Either exercise or pharmacological stress with imaging (nuclear
MPI, echocardiography, or CMR) is recommended for risk assess-
ment in patients with SIHD who are being considered for revascu-
larization of known coronary stenosis of unclear physiological sig-
nificance (266,278,293,294). (Level of Evidence: B)
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1. CCTA can be useful for risk assessment in patients with SIHD who
have an indeterminate result from functional testing (286). (Level of
Evidence: C)
CLASS IIb
1. CCTA might be considered for risk assessment in patients with
SIHD unable to undergo stress imaging or as an alternative to
invasive coronary angiography when functional testing indicates a
moderate- to high-risk result and knowledge of angiographic coro-
nary anatomy is unknown. (Level of Evidence: C)
CLASS III: No Benefit
1. A request to perform either a) more than 1 stress imaging study or
b) a stress imaging study and a CCTA at the same time is not
recommended for risk assessment in patients with SIHD. (Level of
Table 12. Using Stress Testing and Advanced Imaging for Pati
for Risk Assessment
Test
Exercise
Status
ECG
Interpretable
COAble Unable Yes No
Patients able to exercise*
Exercise ECG X X I
Exercise with nuclear MPI or
Echo
X X I
Exercise with nuclear MPI or
Echo
X X IIa
Pharmacological stress CMR X X IIa
CCTA X X IIb
Pharmacological stress
imaging (nuclear MPI, Echo,
CMR) or CCTA
X X III: No
Patients unable to exercise
Pharmacological stress with
nuclear MPI or Echo
X Any I
Pharmacological stress CMR X Any IIa
CCTA X Any IIa
Regardless of patient’s ability to exercise
Pharmacological stress with
nuclear MPI or Echo
Any X I
Exercise/pharmacological
stress with nuclear MPI,
Echo, or CMR
Any Any I
CCTA Any Any IIa
CCTA Any Any IIb
Requests to perform multiple
cardiac imaging or stress
studies at the same time
Any Any III: No
*Patients are candidates for exercise testing if they are capable of performing at least moderat
living) and have no disabling comorbidity. Patients should be able to achieve 85% of age-predic
CCTA indicates cardiac computed tomography angiography; CMR, cardiac magnetic resonance
bundle-branch block; LOE, level of evidence; MPI, myocardial perfusion imaging; and N/A, not aEvidence: C)See Online Data Supplement 2 for additional data on risk
assessment.
3.2.2.4. EXERCISE ECG
To assess the risk of cardiovascular events in patients who
are able to exercise to an adequate workload and have an
interpretable resting ECG, exercise is the preferred stressor
because it provides an objective assessment of functional
capacity and correlative information with activities of daily
living. The occurrence of ST-segment depression at a
reduced workload or persisting into recovery coupled with
exertional symptoms is associated with a high risk of
cardiovascular mortality (302). Other risk markers for mor-
tality include low exercise capacity (generally defined as less
With Known SIHD Who Require Noninvasive Testing
LOE References Additional Considerations
B (106–110,112–114,132–134)
B (7,111,264–266,270,299,300) Abnormalities other than LBBB or
ventricular pacing
B (271–279)
B (279–284)
B (285,286)
t C N/A
B (7,264–266,287–290)
B (280–284,291)
C (286) Without prior stress test
B (287–290,292) LBBB present
B (266,278,293,294) Known coronary stenosis of
unclear physiological
significance being considered
for revascularization
C N/A Indeterminate result from
functional testing
C N/A Unable to undergo stress imaging
or as alternative to coronary
catheterization when
functional testing indicates
moderate to high risk and
angiographic coronary
anatomy is unknown
t C N/A
cal functioning (i.e., moderate household, yard, or recreational work and most activities of daily
ximum heart rate.
g; COR, class of recommendation; ECG, electrocardiogram; Echo, echocardiography; LBBB, left
.ents
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120 mm Hg or a sustained 10–mm Hg decrease from
esting values during exercise, complex ventricular ectopy or
rrhythmias during stress or recovery, and delayed heart rate
ecovery (e.g., 10- or 12-beats-per-minute reduction in
he first minute) (303). The Duke treadmill score and the
auer nomogram score are validated predictive instruments
hat incorporate parameters from an exercise ECG test. The
uke treadmill score includes duration of exercise, severity
f ST-depression or elevation, and angina (limiting and
onlimiting); has been demonstrated to be highly predictive
cross an array of patient populations, including women and
en with suspected and known SIHD; and has been shown
o provide independent risk information beyond clinical
ata, coronary anatomy, and LVEF (126,177). It stratifies
atients into risk groups that could prove useful for patient
anagement, as follows: no further testing for low-risk
atients, consideration for invasive testing for high-risk
atients, and stress imaging for the intermediate-risk pa-
ients. By comparison, the Lauer score incorporates clinical
ariables, which results in more effective classification of
ow-risk (1% annual mortality rate) patients (248).
3.2.2.5. EXERCISE ECHOCARDIOGRAPHY AND EXERCISE NUCLEAR MPI
Evidence from thousands of patients evaluated in multiple
large registries and clinical trials and meta-analyses confirm
that a normal exercise echocardiogram or exercise nuclear
MPI is associated with a very low risk of death due to
cardiovascular causes or AMI (111,265,304). The extent
and severity of inducible abnormalities in wall motion or
perfusion are directly correlated with the degree of risk. For
nuclear MPI, reversible perfusion defects encompassing
10% of the myocardium (determined either semiquantita-
tively with summed scores or quantitatively) to assess defect
extent and severity are considered moderately abnormal, and
reversible perfusion defects encompassing 15% of the
yocardium are considered severely abnormal (277,
05,306). Other findings also indicative of elevated risk
nclude a reduction in reduced post-stress LVEF 5% or a
lobal LVEF 45%, transient ischemic LV dilation, in-
reased lung or right ventricular uptake, or abnormal coro-
ary reserve (detected on myocardial perfusion PET). For
chocardiography, a wall motion abnormality extending
eyond 2 to 3 segments as well as the presence of change in
1 coronary territory are suggestive of higher risk. For both
ests, multiple defects in different coronary territories with
ither moderately reduced perfusion (or 10% of the
yocardium) or inducible wall motion abnormalities with
ransient ischemic dilatation are suggestive of severe CAD.
urrently, the National Institutes of Health–National
eart, Lung, and Blood Institute–sponsored ISCHEMIA
rial is under way and is comparing the effectiveness of a
onservative versus catheterization-based initial manage-
ent strategy for patients with moderate–severe ischemia.
Several large single-center and multicenter registries haveemonstrated consistently that both stress nuclear MPI andtress echocardiography provide incremental prognostic
alue beyond that provided by a standard ECG
115,272,299,305,307–315). The addition of imaging is
andatory for patients who have an uninterpretable baseline
CG (including the presence of LBBB or ventricular
acing, LV hypertrophy, use of digitalis or electrolyte
bnormalities, coexisting resting ST-segment abnormality,
r preexcitation syndromes) and might be of value in
atients with equivocal stress-induced (316) ECG ST
hanges (317) or an intermediate Duke treadmill score
316). Poornima et al., demonstrated that nuclear MPI has
ndependent prognostic value even in patients with low-risk
uke treadmill scores, but only if there is increased clinical
isk, such as a history of typical angina, MI, diabetes
ellitus, and advanced age (318,319). Similarly, informa-
ion from exercise echocardiography appears to provide
mproved prediction of mortality among patients with
ow-risk Duke treadmill scores (311,318). From a large
egistry, the extent of ischemic myocardium as quantified by
ummed difference score by nuclear MPI has been shown to
orm an effective prognostic score for the prediction of
ardiac mortality (320). Results from exercise nuclear MPI
nd exercise stress echocardiography appear to provide
ccurate estimates of the likelihood of death among men
nd women with suspected and known SIHD and for
atients from different ethnic groups (314,321,322).
From a review of large single- and multicenter registries
nd meta-analyses (111,115,272), the following conclusions
an be made:
. A normal exercise nuclear MPI study or a normal
exercise stress echocardiogram during which the age-
predicted target heart rate is achieved is associated with
a very low annual risk of cardiac death and AMI
(generally 1%) in both men and women.
. Normal and mildly abnormal nuclear MPI or exercise
stress echocardiography is associated with a low fre-
quency of referral for coronary revascularization or wors-
ening clinical status and UA admission (1.3% and 1%
annually, respectively) (141).
. Rates of cardiac ischemic events increase in proportion to
the degree of abnormalities on stress nuclear MPI or
echocardiography, with moderate to severe abnormalities
associated with an annual risk of cardiovascular death or
MI 5% (115,278,279,284,305,306,310,313,314,323–
330).
. For patients with mild abnormalities, coronary angiog-
raphy might be considered if the patient exhibits other
features that might indicate the likelihood of “high-risk”
CAD, including low EF on gated nuclear MPI or
echocardiographic imaging (331) or transient ischemic
dilatation of the left ventricle (332).
. Moderate to severe abnormalities, such as abnormal wall
motion in 4 segments or multivessel abnormalities,
indicate an increased risk (range: 6- to 10-fold) over that
of patients with a normal stress imaging study (271).
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nuclear MPI or exercise echocardiography should be clari-
fied in several ways. Although a normal exercise nuclear
MPI or exercise echocardiogram usually is associated with a
low annual risk of cardiac death or AMI, the negative
predictive value is reduced among patients with a higher
pretest likelihood of CAD (111,115,279,284,305,306,310,
313,314,323–328,330). Furthermore, although trials have
shown that imaging is useful to detect ischemia and guide
intervention in patients with SIHD and that a reduction in
ischemia by stress nuclear MPI is associated with an
observed (unadjusted) event-free survival (306,333), there is
no trial evidence comparing the effectiveness of a strategy of
imaging testing for risk stratification versus a strategy of
nontesting in patients with SIHD.
3.2.2.6. DOBUTAMINE STRESS ECHOCARDIOGRAPHY AND
PHARMACOLOGICAL STRESS NUCLEAR MPI
In one third to one half of patients who undergo risk
assessment, exercise stress is not recommended because of
an inability to exercise or an abnormal ECG. Similar to
exercise echocardiography, multiple large single-center re-
ports have shown that dobutamine stress echocardiography
accurately classifies patients into high-risk and very-low-risk
groups. A normal dobutamine echocardiogram is associated
with a risk of an adverse cardiac event of 1% to 2%
(312,334). Classification as high risk by dobutamine stress
echocardiography is most reliable when ischemia is detected
in the territory of the LAD and is somewhat less reliable in
patients with diabetes mellitus (335). In specialized centers,
either quantification of strain rate or myocardial contrast
enhancement on dobutamine echocardiography has been
shown to provide information that supplements the wall
motion score alone in predicting cardiac mortality (336).
Dobutamine echocardiography also has been used exten-
sively in risk-stratifying patients with SIHD undergoing
noncardiac vascular surgery. Because the risk of a cardiac
event in the perioperative period is quite low, the positive
predictive value of dobutamine echocardiography is also
low, although the negative predictive value of a normal
result is very high and is associated with a very low
likelihood of a perioperative event (337,338).
Similar to exercise SPECT, vasodilator stress nuclear
MPI has been shown to effectively assess risk of subsequent
events in patients with SIHD, with a low annualized event
rate of 1.6% observed in patients with a normal adenosine
SPECT versus 10.6% in patients with a severely abnormal
study (summed stress score 13) (339). This event rate also
as observed in elderly patients with normal pharmacolog-
cal SPECT (340,341). Because of greater comorbidity in
atients who cannot exercise, the annualized event rate of
atients who had a normal pharmacological stress nuclear
PI increase the event rate nearly 2-fold higher than that
f exercising patients who had a normal nuclear MPI, after
djustment for age and comorbidity (342). Additional
onperfusion risk markers can be derived from pharmaco-logical stress, including an abnormal ECG, high resting
heart rate, and low peak/rest heart rate ratio (276,332). To
facilitate clinical risk assessment, a nomogram based on
robust risk markers, including LV function and extent of
myocardial ischemia by SPECT, has been developed and
validated (Appendix 4) (276).
3.2.2.7. PHARMACOLOGICAL STRESS CMR IMAGING
Although clinical experience with using stress CMR for risk
assessment is substantially less than with stress echocardi-
ography and nuclear MPI, available evidence indicates that
stress CMR can provide highly accurate prognostic infor-
mation. On the basis of 16 single-site studies providing data
from 7,200 patients (283) (8 of these studies used vasodi-
lator stress perfusion imaging, 6 dobutamine stress CMR
cine imaging, and 2 combined stress perfusion and cine
imaging), the following general conclusions can be drawn:
1. A normal stress CMR study with either vasodilator
myocardial perfusion or inotropic stress cine imaging is
associated with a low annual rate of cardiac death or MI,
ranging from 0.01% to 0.6% (280,283), and provides
accurate risk assessment in patients of either sex (281,343).
2. Detection of myocardial ischemia (by either perfusion or
cine imaging) and LGE imaging of infarction appear to
provide complementary information.
3. An abnormal stress CMR with evidence of ischemia is
associated with elevated likelihood of cardiac death or MI,
with hazard ratios ranging from 2.2 to 12 (279,282).
The current evidence related to CMR for risk assessment
of patients is limited by the predominance of data collection
from tertiary care centers with high experience in CMR,
heterogeneity of imaging techniques and equipment, and
evolution of interpretative standards.
3.2.2.8. SPECIAL PATIENT GROUP: RISK ASSESSMENT IN
PATIENTS WHO HAVE AN UNINTERPRETABLE ECG BECAUSE OF
LBBB OR VENTRICULAR PACING
Isolated “false-positive” reversible perfusion defects of the
septum on nuclear MPI due to abnormal septal motion
causing a reduction in diastolic filling time have been
reported in patients with LBBB without significant coro-
nary stenosis. Compared to patients without LBBB, use of
exercise stress in patients with LBBB or ventricular pacing
substantially reduced diagnostic specificity (289,292). Al-
though a normal nuclear perfusion scan in this clinical
setting is highly accurate in indicating the absence of a
significant coronary stenosis and a low risk of subsequent
cardiac events (288), an abnormal study can be nondiagnos-
tic (148,287). In patients with LBBB on a rest ECG,
dobutamine stress echocardiography is less sensitive but
more specific than nuclear MPI in detecting coronary
stenosis and provides prognostic information that is incre-
mental to clinical findings (344). One meta-analysis dem-
onstrated that abnormal stress nuclear MPI and stress
echocardiography each confer an up to 7-fold increased risk
of adverse cardiovascular events (148).
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3.2.3.1. CORONARY CT ANGIOGRAPHY
Given the high accuracy in detecting angiographically sig-
nificant coronary stenosis, estimates of cardiovascular risk
according to the Duke CAD index with data obtained via
CCTA appear to be as accurate as those obtained from
cardiac catheterization. However, the actual event rates in
patients undergoing CCTA have been substantially lower
because of differences in the underlying risk profiles of
patient groups that have been referred for these 2 procedures
(345). Furthermore, data from CONFIRM suggest that the
finding of nonobstructive CAD on CCTA supplements
clinical information in predicting risk of mortality (286).
For example, 20% to 25% of patients with an intermediate
pretest likelihood of risk (1% to 3% annual mortality rate)
based on clinical information (without EF) were reassigned
to a different risk category according to information from
CCTA. Given that failed bypass grafts can result in unpro-
tected CAD, which confers a higher risk, the assessment of
the extent of graft patency by CCTA is also of prognostic
value (346,347). Although exercise stress testing in general
is preferred in risk assessment, for patients unlikely to
achieve conclusive results, consensus opinion suggests that it
is reasonable to proceed with a CCTA for risk-assessment
purposes.
Several ongoing trials are comparing the prognostic
values of CCTA and functional imaging modalities such as
nuclear MPI and stress echocardiography (348). At present,
there are no prospectively gathered trial data demonstrating
that CCTA leads to better patient selection for medical or
invasive intervention or to better clinical outcomes.
3.3. Coronary Angiography
3.3.1. Coronary Angiography as an Initial Testing
Strategy to Assess Risk: Recommendations
CLASS I
1. Patients with SIHD who have survived sudden cardiac death or
potentially life-threatening ventricular arrhythmia should undergo
coronary angiography to assess cardiac risk (349–351). (Level of
Evidence: B)
2. Patients with SIHDwho develop symptoms and signs of heart failure
should be evaluated to determine whether coronary angiography
should be performed for risk assessment (352–355). (Level of
Evidence: B)
3.3.2. Coronary Angiography to Assess Risk After
Initial Workup With Noninvasive Testing:
Recommendations
CLASS I
1. Coronary arteriography is recommended for patients with SIHD
whose clinical characteristics and results of noninvasive testing
indicate a high likelihood of severe IHD and when the benefits are
deemed to exceed risk (59,126,260,310,356–362). (Level of Evi-
dence: C)CLASS IIa
1. Coronary angiography is reasonable to further assess risk in pa-
tients with SIHD who have depressed LV function (EF 50%) and
moderate risk criteria on noninvasive testing with demonstrable
ischemia (363–365). (Level of Evidence: C)
. Coronary angiography is reasonable to further assess risk in pa-
tients with SIHD and inconclusive prognostic information after
noninvasive testing or in patients for whom noninvasive testing is
contraindicated or inadequate. (Level of Evidence: C)
. Coronary angiography for risk assessment is reasonable for patients
with SIHD who have unsatisfactory quality of life due to angina, have
preserved LV function (EF 50%), and have intermediate risk
criteria on noninvasive testing (306,366). (Level of Evidence: C)
CLASS III: No Benefit
1. Coronary angiography for risk assessment is not recommended
in patients with SIHD who elect not to undergo revascularization
or who are not candidates for revascularization because of
comorbidities or individual preferences (306,366). (Level of Evi-
dence: B)
2. Coronary angiography is not recommended to further assess risk in
patients with SIHD who have preserved LV function (EF 50%) and
low-risk criteria on noninvasive testing (306,366). (Level of Evi-
dence: B)
3. Coronary angiography is not recommended to assess risk in pa-
tients who are at low risk according to clinical criteria and who have
not undergone noninvasive risk testing. (Level of Evidence: C)
4. Coronary angiography is not recommended to assess risk in asymp-
tomatic patients with no evidence of ischemia on noninvasive
testing. (Level of Evidence: C)
Coronary angiography defines coronary anatomy, includ-
ing the location, length, diameter, and contour of the
epicardial coronary arteries; the presence and severity of
coronary luminal obstruction(s); the nature of the ob-
struction; the presence and extent of angiographically
visible collateral flow; and coronary blood flow. Despite
the ability of newer noninvasive imaging modalities such
as CT angiography to visualize and characterize the
coronary tree, invasive coronary angiography currently
remains the “gold standard.” Coronary angiography has 2
clinical goals: 1) to assess a patient’s risk of death and
future cardiovascular events through characterization of
the presence and extent of obstructive CAD and 2) to
ascertain the feasibility of percutaneous or surgical revas-
cularization. The likelihood that revascularization might
decrease angina and improve a patient’s quality of life
should be considered when a patient deems his or her
quality of life unsatisfactory despite a conscientious
program of evidence-based medical therapy.
The most commonly used nomenclature for defining
coronary anatomy is that which was developed for CASS
(367) and further modified by the BARI study group
(368). This scheme is based on the assumption that there
are 3 major coronary arteries: the LAD, the circumflex,
and the right coronary artery, with a right-dominant,
left-dominant, or codominant circulation. The extent of
disease is defined as 1-vessel, 2-vessel, 3-vessel, or left
main disease, with a significant stenosis 70% diameter
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defined as a stenosis 50%.
Despite being recognized as the traditional “gold stan-
ard” for clinical assessment of coronary atherosclerosis,
oronary angiography is not without limitations. First, the
echnical quality of angiograms in many settings can make
ccurate interpretation difficult or impossible. In a random
ample of 300 coronary angiograms performed in New
ork State during the 1990s, 4% were of unacceptable
uality, and 48% exhibited technical deficiencies that could
nterfere with accurate interpretation (369). Although more
odern techniques and equipment likely have eliminated
ome of these deficiencies, few studies have addressed this
ssue, particularly in patients who present technical chal-
enges, such as those who are obese. Second, problems also
xist with interobserver reliability. These investigators also
ound only 70% overall agreement among readers with
egard to the severity of stenosis, and this was reduced to
1% when restricted to coronary vessels rated as having
ome stenosis by any reader. Third, angiography in isolation
rovides only anatomic data and is not a reliable indicator of
he functional significance of a given coronary stenosis
nless a technique such as FFR (discussed below) is used to
rovide information about the physiological significance of
n anatomic stenosis. Lastly, coronary angiography does not
istinguish between a vulnerable plaque, with a large lipid
ore, thin fibrous cap, and increased macrophages, and a
table plaque that does not exhibit these features. Serial
ngiographic studies performed before and after acute
vents and early after MI suggest that plaques resulting in
A and MI commonly were found to be 50% obstructive
before the acute event and were therefore angiographically
“silent” (370,371). Diagnostic testing to determine vulner-
able plaque, and therefore the subsequent risk for MI,
remains intensely studied, but no “gold standard” yet has
emerged (372). Despite these limitations of coronary angiog-
raphy, the extent and severity of CAD remain very significant
predictors of long-term patient outcomes (Table 13)
(55,70,71,373,374).
For patients who are found to be at high risk of coronary
events or death on the basis of clinical data and noninvasive
testing, coronary angiography is often warranted to provide
a more complete risk assessment even though cardiac
symptoms might not be severe. Certain clinical character-
istics, though relatively infrequent in patients with IHD,
have been associated with a high likelihood of severe
disease, including the following: chest pain leading to
pulmonary edema, chest pain associated with lightheaded-
ness, syncope or hypotension, exertional syncope, and an
exercise-induced gallop sound on cardiac auscultation. In
addition to clinical signs and symptoms, findings on
noninvasive studies could also suggest that certain pa-
tients are at high risk of serious cardiac events. These
findings include abnormal physiological response to ex-
ercise or imaging studies that suggest extensive myocar-
dial ischemia (Table 14). Some examples from Table 14(high-risk category) which may suggest somewhat less
extensive myocardial ischemia: CCTA 2-vessel disease,
CAC score 400 Agatston units, severe resting LV dys-
function (LVEF 35%) not readily explained by noncoro-
nary causes, stress defects at 10% level, 2 coronary beds wall
motion abnormality on stress echocardiography but only 2
segments.
Coronary angiography helps to quantify risk on the basis
of an anatomic prognostic index; the simplest and most
widely used is the classification of disease into 1-, 2-, or
3-vessel or left main CAD (358,375–377). In the CASS
registry (364) of medically treated patients, the 12-year
survival rate of patients with normal coronary arteries was
91%, compared with 74% for those with 1-vessel disease,
59% for those with 2-vessel disease, and 40% for those with
3-vessel disease. The probability of survival declines progres-
sively with the number of coronary arteries that are occluded.
The presence of severe proximal LAD artery disease signifi-
cantly reduces the survival rate. The 5-year survival rate with
3-vessel disease plus 95% proximal LAD stenosis was re-
ported to be 59%, as compared with a rate of 79% for 3-vessel
disease without LAD stenosis (Table 13).
With the use of data accumulated in the 1980s, a
nomogram was developed to predict 5-year survival rate on
the basis of clinical history, physical examination, coronary
angiography, and LVEF (Figure 12). The importance of
considering clinical factors and especially LV function in
estimating the risk of a given coronary angiographic finding
is illustrated by comparing the predicted 5-year survival rate
of a 65-year-old man with stable angina, 3-vessel disease,
and normal ventricular function with that of a 65-year-old
man with stable angina, 3-vessel disease, heart failure, and
an EF of 30%. The 5-year survival rate for the former was
estimated to be 93%, whereas patients with the same
characteristics but with heart failure and reduced EF had a
predicted survival rate of only 58%. Because of advances in
Table 13. CAD Prognostic Index
Extent of CAD
Prognostic
Weight
(0–100)
5-Year
Survival
Rate (%)*
1-vessel disease, 75% 23 93
1-vessel disease, 50% to 74% 23 93
1-vessel disease, 95% 32 91
2-vessel disease 37 88
2-vessel disease, both 95% 42 86
1-vessel disease, 95% proximal LAD artery 48 83
2-vessel disease, 95% LAD artery 48 83
2-vessel disease, 95% proximal LAD artery 56 79
3-vessel disease 56 79
3-vessel disease, 95% in 1 vessel 63 73
3-vessel disease, 75% proximal LAD artery 67 67
3-vessel disease, 95% proximal LAD artery 74 59
*Assuming medical treatment only. CAD indicates coronary artery disease; LAD, left anterior
descending.
Reproduced from Califf et al. (55).treatment, it is almost certain that the survival rate has
t
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relative differences in survival likely persist.
The development of symptomatic LV failure in a patient
with SIHD is often an indication of severe, obstructive
CAD and demands expeditious evaluation for the presence
of active ischemia. Depending on the acuity and severity of
symptoms, angiography or evaluation for ischemia with
Table 14. Noninvasive Risk Stratification
High risk (3% annual death or MI)
1. Severe resting LV dysfunction (LVEF 35%) not readily explained by
noncoronary causes
2. Resting perfusion abnormalities 10% of the myocardium in patients
without prior history or evidence of MI
3. Stress ECG findings including 2 mm of ST-segment depression at
low workload or persisting into recovery, exercise-induced ST-segment
elevation, or exercise-induced VT/VF
4. Severe stress-induced LV dysfunction (peak exercise LVEF 45% or
drop in LVEF with stress 10%)
5. Stress-induced perfusion abnormalities encumbering 10%
myocardium or stress segmental scores indicating multiple vascular
territories with abnormalities
6. Stress-induced LV dilation
7. Inducible wall motion abnormality (involving 2 segments or
2 coronary beds)
8. Wall motion abnormality developing at low dose of dobutamine
(10 mg/kg/min) or at a low heart rate (120 beats/min)
9. CAC score 400 Agatston units
10. Multivessel obstructive CAD (70% stenosis) or left main stenosis
(50% stenosis) on CCTA
Intermediate risk (1% to 3% annual death or MI)
1. Mild/moderate resting LV dysfunction (LVEF 35% to 49%) not readily
explained by noncoronary causes
2. Resting perfusion abnormalities in 5% to 9.9% of the myocardium in
patients without a history or prior evidence of MI
3. 1 mm of ST-segment depression occurring with exertional symptoms
4. Stress-induced perfusion abnormalities encumbering 5% to 9.9% of
the myocardium or stress segmental scores (in multiple segments)
indicating 1 vascular territory with abnormalities but without LV
dilation
5. Small wall motion abnormality involving 1 to 2 segments and only
1 coronary bed
6. CAC score 100 to 399 Agatston units
7. One vessel CAD with 70% stenosis or moderate CAD stenosis
(50% to 69% stenosis) in 2 arteries on CCTA
Low risk (1% annual death or MI)
1. Low-risk treadmill score (score 5) or no new ST segment changes or
exercise-induced chest pain symptoms; when achieving maximal levels of
exercise
2. Normal or small myocardial perfusion defect at rest or with stress
encumbering 5% of the myocardium*
3. Normal stress or no change of limited resting wall motion abnormalities
during stress
4. CAC score 100 Agaston units
5. No coronary stenosis 50% on CCTA
*Although the published data are limited; patients with these findings will probably not be at low risk in the
presence of either a high-risk treadmill score or severe resting LV dysfunction (LVEF 35%).
CAC indicates coronary artery calcium; CAD, coronary artery disease; CCTA, coronary computed
omography angiography; LV, left ventricular; LVEF, left ventricular ejection fraction; and MI,
yocardial infarction.
Adapted from Gibbons et al. (7).noninvasive testing is warranted.An additional, but less quantifiable, benefit of coronary
angiography and LV function assessment derives from the
ability of experienced angiographers to integrate the find-
ings on coronary angiography and left ventriculography to
estimate the potential benefit of revascularization strategies
discussed below. The characteristics of coronary lesions
(e.g., stenosis severity, length, complexity, and presence of
thrombus), the number of lesions posing jeopardy to regions
of contracting myocardium, the possible role of collaterals,
and the mass of jeopardized viable myocardium also can
afford some insight into the consequences of subsequent
vessel occlusion. For example, a patient with a noncontract-
ing inferior or lateral wall and severe proximal stenosis of a
very large LAD artery is presumably at substantial risk of
developing cardiogenic shock if the LAD artery were to
become occluded.
In view of the importance of proximal versus distal
coronary stenoses, a “jeopardy score” has been developed,
which takes the prognostic significance of a lesion’s location
into consideration (378). Angiographic studies indicate that
a direct correlation also exists between the angiographic
severity of CAD and the amount of angiographically insig-
nificant plaque buildup elsewhere in the coronary tree.
These studies suggest that the higher mortality rate of
patients with multivessel disease could occur because they
have more mildly stenotic or nonstenotic plaques that are
potential sites for acute coronary events than do patients
with 1-vessel disease (379).
For many years, it has been known that patients with
severe stenosis of the left main coronary artery have a poor
prognosis when treated medically. A gradation of worsening
risk also has been found with increasing degrees of stenosis
of the left main in medically managed patients (380–382).
Angiographic determination of the significance of left main
disease can be difficult, with suboptimal intraobserver agree-
ment with regard to the degree of severity of any given
stenosis (381,383,384). However, multiple other modalities
are available to the angiographer to assist in accurately
determining the significance of a left main lesion (i.e., FFR
and intravascular ultrasound). Despite the challenges posed
by angiographic determination of left main disease, it
remains the best option for the diagnosis and reevaluation of
left main disease if concern exists about progression of
previously diagnosed disease because of the inability to
consistently detect and evaluate this condition with nonin-
vasive testing or clinical assessment (385–390).
4. Treatment
4.1. Definition of Successful Treatment
The paramount goals of treating patients with SIHD are to
minimize the likelihood of death while maximizing health
and function. The more specific objectives are to:• Reduce premature cardiovascular death;
ion; an
T
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rectly impair patients’ functional well-being, including
nonfatal AMI and heart failure;
• Maintain or restore a level of activity, functional capacity,
and quality of life that is satisfactory to the patient;
• Completely, or nearly completely, eliminate ischemic
symptoms; and
• Minimize costs of health care, in particular by elimi-
nating avoidable adverse effects of tests and treatments,
Figure 12. Nomogram for Prediction of 5-Year Survival From Cl
Asymp indicates asymptomatic; CAD, coronary artery disease; MI, myocardial infarct
Figure 13. Cumulative Incidence of MACE in Patients With 3-Vessel
reated With Either CABG (Blue) or PCI (Gold)
CABG indicates coronary artery bypass graft; CAD, coronary artery disease; MACE, m
Synergy between Percutaneous Coronary Intervention with TAXUS and Cardiac Surgery. Adaby preventing hospital admissions, and by eliminating
unnecessary tests and treatments.
These goals are pursued with 5 fundamental, comple-
mentary, and overlapping strategies:
1. Educate patients about the etiology, clinical manifesta-
tions, treatment options, and prognosis of IHD, to
support active participation of patients in their treatment
decisions.
l, Physical Examination, and Cardiac Catheterization Findings
d Symp, symptomatic. Reproduced from Califf et al. (55).
Based on SYNTAX Score at 3-Year Follow-Up in the SYNTAX Trial
dverse cardiovascular event; PCI, percutaneous coronary intervention; and SYNTAX,inicaCAD
ajor a
pted from Kappetein (980).
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or complicate IHD.
3. Effectively modify risk factors for IHD by both pharma-
cological and nonpharmacological methods.
4. Use evidence-based pharmacological treatments to im-
prove patients’ health status and survival, with attention
to avoiding drug interactions and side effects.
5. Use revascularization by percutaneous catheter-based
techniques or CABG when there is clear evidence of
the potential to improve patients’ health status and
survival.
4.2. General Approach to Therapy
The writing committee has constructed these guidelines
from the perspective that when making decisions about
diagnostic tests and therapeutic interventions, their poten-
tial effects on improving survival and health status should be
considered independently. Although treatment choices of-
ten are intended to achieve both goals simultaneously,
circumstances exist in which a treatment is administered in
pursuit of only one of these goals. For example, when
pharmacotherapy such as aspirin or angiotensin-converting
enzyme (ACE) inhibitors is prescribed, the goal is to
improve survival but not necessarily quality of life. Similarly,
revascularization can be performed to improve symptoms,
even when there is no expectation of improved survival.
Occasionally, treatment recommendations related to achiev-
ing these goals can be at odds, such as when a patient is
encouraged to take a medication that significantly reduces
the risk of death even though it causes mild or moderate
adverse side effects.
It might also be the case that a patient expresses a
preference for a treatment approach (e.g., PCI) when the
practitioner believes another approach (e.g., GDMT) would
be preferable. Although practitioners always should engage
patients in a detailed discussion about their individual goals
and values in order to tailor therapy, this is particularly
important when therapeutic goals or the patient’s or pro-
vider’s preferences are not aligned. It is essential that these
discussions be conducted in a location and atmosphere that
permits adequate time for discussion and contemplation.
Initiating a discussion about the relative merits of medical
therapy versus revascularization while a patient is in the
midst of procedure, for example, is not usually consistent
with these principles.
Reducing the risk of mortality should be pursued as
intensively as is sensible for all patients with SIHD. It has
been estimated that nearly half of the dramatic decline in
cardiovascular mortality observed during the past 40 years is
attributable to interventions directed at modifying risk
factors. Of this change, 47% can be attributed to treatments,
including risk factor reduction after AMI, other guideline-
based treatments for UA and heart failure, and revascular-
ization for chronic angina (391). An additional 44% reduc-tion in age-adjusted death is attributed to population-based
changes in risk factors (391). Unfortunately, these changes
have been offset somewhat by increases in BMI and type 2
diabetes mellitus, which result in an increased number of
deaths (391).
The 2011 secondary prevention and risk reduction ther-
apy statement (8) summarizes the key interventions known
to improve survival and prevent subsequent cardiac events.
Worldwide, it has been estimated that 90% of the risk of MI
is attributable to 9 measureable risk factors, including
smoking, diabetes mellitus, hypertension, obesity, impaired
psychological well-being, poor diet, lack of exercise, alcohol
consumption, and dyslipidemia (392). The initial approach
to all patients should be focused on eliminating unhealthy
behaviors such as smoking and effectively promoting life-
style changes (e.g., maintaining a healthy weight, engaging
in physical activity, adopting a healthy diet [Figure 4]). In
addition, for most patients, an evidence-based set of phar-
macological interventions is indicated to reduce the risk of
future events. The presumed mechanism by which these
interventions work is stabilization of the coronary plaque to
prevent rupture and thrombosis (8). These include anti-
platelet agents (393), statins (394–401), and beta blockers,
along with other agents if indicated, to control hypertension
(402,403). ACE inhibitors are indicated in many patients
with SIHD, especially those with diabetes mellitus or LV
dysfunction (296,301,404). Similarly, tight glycemic control
not only has not been shown to reduce the risk of macro-
vascular complications in patients with type 2 diabetes
mellitus, it also appears to increase the risk of cardiovascular
death and complications. Nonetheless, weight loss, aerobic
exercise, an AHA Step II diet, and ACE inhibitors in
patients with diabetes mellitus with proteinuria all can
improve patients’ risks of microvascular complications and,
potentially, cardiac events.
For the purposes of this guideline, the writing committee
elected to retain the classification for risk of cardiovascular
events that has been accepted by consensus over the past 2
decades. Patients with a predicted annual cardiac mortality
rate of 1% per year are considered to be at low risk, those
with a predicted rate of 1% to 3% per year are considered to
be at intermediate risk, and those with a predicted average
3% per year are considered to be at high risk.
For patients at high risk of mortality, the prevalence of
severe CAD (e.g., left main coronary occlusion) is higher,
and coronary angiography can define the coronary anatomy
and help to plan further therapy beyond standard GDMT
(Figure 5). If the patient is at low or intermediate risk for
mortality, therapeutic decisions should be directed toward
improving symptoms and function, and catheterization may
be deferred if symptoms can be controlled with medical
therapy alone. For patients in whom angiography is per-
formed and who are determined to be at low or intermediate
risk, evidence reaffirms that it is safe to defer revasculariza-
tion and institute a program of evidence-based medical
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are averted by proceeding immediately to revascularization
(366,397,405–409). If a patient in this category has symp-
toms that are completely or almost completely relieved with
medical therapy, it is usually prudent to continue with
medical therapy without proceeding to revascularization. If
symptoms persist, however, then a discussion with the
patient to elicit his or her preferences and goals is necessary,
along with a frank discussion of the benefits and risks of
PCI and CABG, to ascertain whether the symptoms have
been ameliorated sufficiently to warrant simply continuing
with medical therapy alone (Figures 4 and 5).
Coronary revascularization generally improves survival
mong certain subgroups of patients, particularly those with
evere left main coronary stenosis. When revascularization is
eing considered on an elective basis solely for reducing the
isk of death, the healthcare provider should engage the
atient in an explicit consideration of the estimated im-
rovement in survival relative to the potential risks and costs
f the procedure and related interventions. Because reliable
stimates of benefit, such as absolute risk reduction, are
requently unavailable for many specific subgroups, the risk
or death can be estimated before treatment and the
nticipated absolute risk reduction calculated (obtained by
ultiplying the RR reduction by the pretreatment risk). In
he STICH (Surgical Treatment for Ischemic Heart Fail-
re) trial, in which 1,212 patients with an LVEF35% and
AD amenable to revascularization were randomized to
ABG or medical therapy, there was no significant differ-
nce in overall mortality rate, but during a median follow-up
f 56 months, 28% of those assigned to CABG died of a
ardiovascular cause, compared with 33% of those receiving
edical therapy (410). This information can be converted to
more interpretable framework, such as the average reduc-
ion in risk of events or number needed to treat. In this
xample, the average reduction in cardiovascular events was
9%, and it would be necessary to perform bypass surgery on
bout 5 patients with LV dysfunction to prevent 1 cardio-
ascular death at 5 years (i.e., number needed to treat  5,
calculated as 1  absolute risk reduction, or 1/0.19 [al-
though there would be no effect on overall mortality rate]).
This process complies with the Institute of Medicine’s goals
for transparently sharing evidence with patients so that they
can control (or more actively participate in) their own
decisions (411). In general, a beneficial effect of revascular-
ization on survival has been demonstrated most clearly
among patients with the highest cardiovascular risk (412).
Although traditional methods of risk stratification have
relied on coronary anatomy and LV function, other strate-
gies described in this guideline can be used (Figure 5).
The specific anatomic features of the patient and the
likelihood of procedural success often influence the ap-
proach to a patient for whom revascularization is being
considered. For example, a given patient with 1-vessel
disease might have coronary anatomic features that wouldmake the risk of PCI high enough and the likelihood of
success low enough that CABG or medical therapy would
be preferred. In general, complete revascularization leads to
better outcomes than incomplete revascularization (413–418). In
patients with chronic total occlusion, CABG could be
preferable to PCI (419), but this is still controversial.
Although the technology and techniques for PCI of chronic
total occlusions are improving, there remains no current
evidence that survival is improved after successful PCI of a
chronic total occlusion. Some patients with diabetes melli-
tus can have such diffuse disease that neither CABG nor
PCI is likely to produce sustained benefits. Other patients
can have small-caliber arteries or diffuse disease that is likely
to lead to early graft failure. Still others can have long,
complex lesions that are very likely to undergo restenosis
after PCI, although use of drug-eluting stents (DES) can
reduce this risk.
The majority of patients with SIHD have clinical features
indicating that revascularization is unlikely to improve life
expectancy or the risk of subsequent MI. For such patients,
antianginal therapy and intensive treatment for risk factors
are recommended before consideration of PCI or CABG to
relieve symptoms. A broad range of highly effective drugs is
available, including beta blockers, calcium channel blockers,
long-acting nitrates, and newer agents such as ranolazine.
Comparative trials among these medications are relatively
few and for the most part small (420). On the basis of the
available data, however, all of the classes of agents appear to
be relatively similar in antianginal efficacy, and all have very
acceptable profiles of safety and tolerability. Beta blockers
have been shown to improve survival in patients after AMI
and in patients with hypertension; they provide 24-hour
coverage and have a long history of clinical use. For these
reasons, the writing committee recommends these agents as
first-line drugs for treating angina. In patients who do not
tolerate or adequately respond to beta blockers, calcium
channel blockers and/or long-acting nitrates may be substi-
tuted or added. Ranolazine has been shown to inhibit the
late sodium current in humans and has demonstrated
lusitropic properties (421). Clinical trials have shown that
this agent is comparable to other agents in alleviating
angina. Although this agent has been approved by the U.S.
Food and Drug Administration (FDA) for first-line use in
patients with chronic angina, the writing committee recom-
mends that ranolazine be considered in circumstances in
which beta blockers, calcium channel blockers, and nitrates
are not adequately effective or are not tolerated.
4.2.1. Factors That Should Not Influence
Treatment Decisions
The 2 medical indications for revascularization are to
prevent death and cardiovascular complications and to
improve symptoms and quality of life. Nonetheless, the use
of revascularization has risen dramatically in the past 3
decades. Much of this increase appears to be for indications
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with noninvasive therapies are unlikely (422). National data
suggest that about 12% of PCIs could be inappropriate
because they lack evident potential to improve either sur-
vival or symptoms (423). Several reasons influence patients
and physicians to prefer revascularization when the likeli-
hood of benefit is less than the potential risk of the
procedure. An ingrained preference for action (i.e., revas-
cularization) over perceived inaction (i.e., medical therapy
alone) likely often influences the decision making of both
patients and physicians (252). Moreover, some healthcare
professionals are unduly pessimistic about survival with
conservative medical therapy and inaccurately optimistic
about the survival benefits of revascularization procedures
(424). As indicated earlier, patients often believe mistakenly
that PCI has the potential to prevent AMI and prolong
survival (423,425). In addition, the attendant expense and
risk of combined antiplatelet therapy for an uncertain period
of time might not be fully considered. Physicians are
professionally obligated to provide accurate estimates of the
risks, benefits, and costs of various therapeutic options that
are based on the best available scientific data. Other factors
can induce physicians to recommend revascularization.
These include medicolegal concerns (often exaggerated) and
feeling compelled to satisfy the expectations of patients and
referring physicians (which are sometimes misinformed or
unrealistic) (426). Additionally, there are well-documented
regional variations in the use and appropriateness of cardiac
procedures that appear to reflect local practice styles (427).
This might partly reflect a mistaken belief by some physi-
cians that “more care is better care” (428). Although
successful procedures can be psychologically satisfying to the
physician and the patient, this does not justify the attendant
economic costs and risk of complications of procedures that
offer minimal, if any, genuine benefit (429–431).
Although rarely discussed explicitly, financial incentives
seem to affect the willingness of a minority of physicians and
institutions to recommend certain procedures or drug ther-
apies. Strong incentives created by the payment system
encourage overutilization. Also, a small number of physi-
cians might have financial relationships with the manufac-
turers of devices or drugs that might represent apparent
conflicts that ought to be disclosed to patients. At a higher
level, those responsible for the payment system, the manu-
facturers of devices and drugs, and physicians making
clinical decisions must commit to supporting guideline-
based interventions. Any and all conflicts of interest must be
revealed to patients in the process of informed consent
before any invasive or noninvasive procedure.
4.2.2. Assessing Patients’ Quality of Life
In addition to interventions undertaken to improve survival
and prevent cardiovascular complications, therapy also is
prescribed to improve patients’ health status, a general term
that incorporates many facets, including severity of symp-toms, functional limitations, and quality of life. Assessment
of health status is often unstructured and exclusively quali-
tative, but efforts to standardize this assessment are recom-
mended, beginning with a structured inventory of activity,
symptoms, and quality of life, supplemented by the use of
simple, semiquantitative scales such as the CCS and New
York Heart Association classifications (432,433).
The CCS and New York Heart Association classifica-
tions are limited, however, because they quantify health
status from the physicians’ perspective, rather than directly
reporting patients’ experiences, and they are known to have
limited reproducibility and sensitivity to important clinical
changes. Furthermore, even these simple classifications of
health status are recorded infrequently in health records
(432,434). One approach to directly eliciting perceptions of
health status from patients with IHD is to use the self-
administered Seattle Angina Questionnaire (SAQ), a valid,
sensitive, and prognostically important questionnaire, to
quantify the symptoms, functional limitations, and quality
of life of patients with SIHD (246,247,435). Although such
instruments typically are used in research trials, they are
readily applicable to clinical practice and can be used serially
to assess and monitor the effectiveness of therapy, including
antianginal medications and revascularization (434). The
formal assessment of a patient’s disease-specific health
status, through either the CCS or the SAQ, has been
endorsed as a performance measure of healthcare quality
(436).
4.3. Patient Education: Recommendations
CLASS I
1. Patients with SIHD should have an individualized education plan to
optimize care and promote wellness, including:
a. education on the importance of medication adherence for man-
aging symptoms and retarding disease progression (437–439)
(Level of Evidence: C);
b. an explanation of medication management and cardiovascular
risk reduction strategies in a manner that respects the patient’s
level of understanding, reading comprehension, and ethnicity
(8,440–444) (Level of Evidence: B);
c. a comprehensive review of all therapeutic options (8,441–444)
(Level of Evidence: B);
d. a description of appropriate levels of exercise, with encourage-
ment to maintain recommended levels of daily physical activity
(8,445–448) (Level of Evidence: C);
e. introduction to self-monitoring skills (445,447,448) (Level of
Evidence: C); and
f. information on how to recognize worsening cardiovascular symp-
toms and take appropriate action. (Level of Evidence: C)
2. Patients with SIHD should be educated about the following lifestyle
elements that could influence prognosis: weight control, mainte-
nance of a BMI of 18.5 to 24.9 kg/m2, and maintenance of a waist
circumference less than 102 cm (40 inches) in men and less than
88 cm (35 inches) in women (less for certain racial groups)
(8,440,449–452); lipid management (18); BP control (17,453);
smoking cessation and avoidance of exposure to secondhand
smoke (8,454,455); and individualized medical, nutrition, and life-
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diabetes treatment goals and education (456). (Level of Evidence: C)
CLASS IIa
1. It is reasonable to educate patients with SIHD about:
a. adherence to a diet that is low in saturated fat, cholesterol, and
trans fat; high in fresh fruits, whole grains, and vegetables; and
reduced in sodium intake, with cultural and ethnic preferences
incorporated (8,17,18,457,458) (Level of Evidence: B);
b. common symptoms of stress and depression to minimize stress-
related angina symptoms (459) (Level of Evidence: C);
c. comprehensive behavioral approaches for the management of
stress and depression (237,460–462) (Level of Evidence: C); and
d. evaluation and treatment of major depressive disorder when
indicated (237,238,437,461,463,464,467,468). (Level of Evi-
dence: B)
Multiple risk factors for heart disease, vascular disease,
and stroke are typically present in persons with SIHD,
including hypertension, smoking, dyslipidemia, diabetes
mellitus, overweight, and physical inactivity (27,392). At a
national level, in 2000, only 5% of individuals without IHD
and 7% of those with IHD were fully adherent to recom-
mendations for physical activity, fruit and vegetable con-
sumption, and nonsmoking.
The approach to managing risk factors usually requires
partnerships among the healthcare team, the patient, their
family, and their community. The goal of this partnership is
to assure an effective exchange of information, sharing of
concerns, and an improved understanding of treatments,
with the aim of improving quality of life and health
outcomes. The American Academy of Family Physicians
defines patient education as “the process of influencing
patient behavior through the provision of information and
counseling that is designed to produce changes in knowl-
edge, attitudes, and skills necessary to maintain or improve
health” (469). The Joint Commission mandates patient
education as a principal guiding policy to improve health
outcomes. Effective patient education and counseling are
based on a collaborative approach that acknowledges indi-
vidual patient needs through an understanding of cognitive,
behavioral, and sociodemographic factors. Patients actively
involved in care decisions are more likely to follow a
treatment plan and engage in behaviors that can improve
their health.
When educating patients, it is important to communicate
an understanding of a specific disease process, the need for
laboratory testing, medication management and adherence,
reporting of efficacy and side effects, and behavioral lifestyle
change (8). Unfortunately, the type, intensity, frequency,
and duration of educational programs are not well estab-
lished for individual risk factors. For example, the Ask,
Advise, Assess, Assist, and Arrange algorithm for smoking
cessation often is used, although supporting data from
RCTs are lacking (470). In addition, who should deliver
education programs and how to evaluate efficacy are not well
studied. In smoking cessation, the most effective interven-
tion continues to be a physician’s recommendation for thepatient “to quit.” However, quit rates for smoking are also
dependent on the appropriate use of medical therapies and
group support programs (442,471). In diabetes care, patient
education has the potential to be as effective as or more
effective than medical therapies (472). The management of
hypertension, heart failure, dyslipidemia, type 2 diabetes
mellitus, weight loss, and physical activity is enhanced by
ongoing health education and support in addition to phy-
sician office visits.
Factors that complicate effective patient education in-
clude low literacy, adverse sociodemographic factors (e.g.,
poverty, social isolation, and emotional disorders such as
depression), cultural beliefs and language barriers, environ-
mental factors, advanced age, and the presence of complex
comorbidities. These factors and others play an important
role in the adoption of healthy lifestyles and adherence to
recommended medical therapies. In addition, how to best
provide cost-effective educational strategies remains a chal-
lenge in today’s healthcare environment (473). The lack of
payment for these activities remains an important barrier.
Clinic-based education generally consists of the following:
1. Individual counseling. This educational format commonly
is used in the context of a routine clinic visit. It tends to
be directive and didactic, generally not interactive or
behaviorally oriented, relatively brief, and sometimes
supported with written materials. Follow-up to ascertain
effectiveness is not commonly practiced.
2. Group education. Group care or shared office visits have
been tested in multispecialty group practices. They offer
the benefit of providing education to larger numbers of
patients with similar diagnoses (e.g., type 2 diabetes
mellitus), combined with an individualized physician
visit. They tend to be behaviorally oriented with planned
follow-up for effectiveness and outcomes.
3. Self-monitoring. Self-monitoring skills enhance patient
education and behavior change. Examples such as home
BP and blood glucose monitoring and tracking daily
calories and physical activity minutes can support impor-
tant lifestyle change. Review of self-monitoring logs by
patient and provider at subsequent clinic visits supports
the continued importance of and attention to behavior
change. In some healthcare plans, these data can be
entered via web portals for patients (474).
4. Internet- and computer-based education. A growing num-
ber of health plans provide health information via web-
sites and special programs. This approach is often low in
cost to the patient but requires adequate computer access
and skills, higher reading levels, and self-motivation to
change behavior (e.g., AHA Choose to Move) (475).
5. Hand-held computer devices, smartphones, and other porta-
ble devices. Portable devices have the potential to provide
motivational reminders and prompts for lifestyle change
but have not yet been thoroughly tested.
Present efforts to improve the effectiveness of patient
education and lifestyle interventions integrate key constructs
23
w
t
i
a
b
g
r
i
o
a
w
h
p
t
h
d
t
l
p
d
o
e
t
o
t
w
t
e86 Fihn et al. JACC Vol. 60, No. 24, 2012
Stable Ischemic Heart Disease: Full Text December 18, 2012:e44–e164related to behavior change theory. A summary of the most
common models is provided below:
1. Motivational interviewing, a social learning theory, pro-
motes behavioral change through empathetic and reflec-
tive listening, encouraging patients to determine their
reasons for change, helping healthcare professionals deal
with resistance, and supporting self-efficacy (476).
. Self-efficacy theory posits that the ability to change behav-
ior depends upon one’s self-confidence to perform a
specific action (such as walking 30 minutes daily) and the
belief that one can persist with this action. Low self-
efficacy predicts poor ability to achieve a specified life-
style change. Improving one’s self-efficacy will improve
the ability to change a particular lifestyle (477).
. The Transtheoretical Model of behavior change is based
on “stages of change.” The theory relies on the observa-
tion that many individuals traverse 5 distinct temporal
processes in achieving permanent change. These include
precontemplation, contemplation, preparation, action,
and maintenance. Application of this model of change
entails categorizing an individual’s progress in the pro-
cess of change and recognizing that cycling through
phases is common in the process of achieving permanent
change (478).
The interventions described above should be provided
ithin a medical environment that provides coordinated,
eam-based care. Data accumulating from interventions that
ncorporate principles of the chronic care model (479), such
s the patient-centered medical home, have demonstrated
eneficial effects not only on intermediate outcomes such as
lycemic and BP but also on cost, utilization, and mortality
ate (480,481). This approach depends on the active partic-
pation of an engaged, informed patient, which in turn relies
n the patient’s understanding of his or her condition,
bility to adhere safely to complex medical therapies, and
illingness to communicate on a regular basis with the
ealthcare team. In addition to counseling about the ap-
roach to management of SIHD and risk reduction, pa-
ients often seek information about other aspects of their
ealth, particularly issues that are often not directly ad-
ressed by healthcare providers.
One such topic that commonly arises is possible restric-
ions on sexual activity. Regrettably, there are relatively
imited scientific data on the cardiovascular demands and
otential risks of sexual activity in patients with heart
isease, some of it dating back 3 or 4 decades and nearly all
f it dealing with men. In general, sexual activity is
quivalent to mild to moderate physical activity requiring 3
o 5 METs (i.e., the equivalent of climbing 2 flights of stairs
r walking briskly) (482). The few available studies suggest
hat AMI within 1 to 2 hours of sexual activity is associated
ith an average RR of 2.7 among middle-aged men, with
he greatest risk among those who are sedentary (483–486).
Because the overall incidence of AMI is low in the popu-
lation and periods of exposure relatively infrequent, it hasbeen postulated that the absolute risk is exceedingly low for
any individual (487). However, ECG monitoring during
sexual activity in 1 study of men with IHD revealed that
nearly a third developed ST depression and nearly half
developed arrhythmias. It appeared, however, that these
findings also were found during similarly stressful activities
that did not involve sex, and the arrhythmias were largely
benign. Moreover, these patients were not initially on
anti-ischemic medications, and it was reported that the
ischemic changes on ECG resolved when subjects took beta
blockers. Thus, it seems that sexual activity should not
necessarily be regarded as appreciably different from other
types of physical activity that impose equivalent metabolic
demands. Needless to say, patients should be treated to
maximize their capacity for physical activity, as described
subsequently in this guideline.
Patients often express concerns that medications given to
treat symptoms or reduce cardiovascular risk could cause
erectile dysfunction. Although these perceptions are often
firmly and widely held, studies and reviews have not
delineated a clear association between these drugs, including
beta blockers, and sexual dysfunction (488–492).
A related issue that could arise is use of phosphodiesterase
5 inhibitors, such as sildenafil, vardenafil, or tadalafil, to
improve erectile function. Although, as discussed in the
section on treatment of SIHD, current evidence has shown
that these drugs do not raise the risk of adverse cardiovas-
cular events in men with SIHD (493,494), there is a clear
risk of serious hypotension when they are taken in conjunc-
tion with nitrates, and the combination is absolutely con-
traindicated. There are also potential drug–drug interac-
tions with alpha-blockers that are sometimes used to treat
hypertension (495).
4.4. Guideline-Directed Medical Therapy
4.4.1. Risk Factor Modification: Recommendations
4.4.1.1. LIPID MANAGEMENT
CLASS I
1. Lifestyle modifications, including daily physical activity and weight
management, are strongly recommended for all patients with SIHD
(18,496). (Level of Evidence: B)
2. Dietary therapy for all patients should include reduced intake of
saturated fats (to 7% of total calories), trans fatty acids (to 1%
of total calories), and cholesterol (to 200 mg/d) (18,497–500).
(Level of Evidence: B)
3. In addition to therapeutic lifestyle changes, a moderate or high dose
of a statin therapy should be prescribed, in the absence of contra-
indications or documented adverse effects. (18,398,400,458,501).
(Level of Evidence: A)
CLASS IIa
1. For patients who do not tolerate statins, LDL cholesterol–lowering
therapy with bile acid sequestrants,* niacin,† or both is reasonable
(502,504,505). (Level of Evidence: B)
*The use of bile acid sequestrant is relatively contraindicated when triglycerides are
200 mg/dL and is contraindicated when triglycerides are 500 mg/dL.
†Dietary supplement niacin must not be used as a substitute for prescription niacin.
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as an important coronary heart disease risk factor. The
Framingham Heart Study, Multiple Risk Factor Interven-
tion trial, and the Lipid Research Clinics trials all found a
continuous, graded increase in coronary events with increas-
ing LDL cholesterol in men and women who were initially
free of IHD (502,506–508). A similar relationship has been
observed among patients with SIHD (509–511). The asso-
ciation between LDL cholesterol and cardiovascular risk is
curvilinear, or log-linear, meaning that the decrease in RR
for a given 1-mg/dL decrease in LDL cholesterol seems to
be the same at any level of baseline LDL cholesterol. The
principal lipid modification strategy recommended by the
NCEP ATP-III (National Cholesterol Education Program
Adult Treatment Panel III) in patients with SIHD is the
reduction of LDL cholesterol (18,24). This should start
with therapeutic lifestyle changes, including dietary therapy,
daily physical activity, and weight management. Most pa-
tients also will benefit from cholesterol-lowering drug ther-
apy, preferably with a statin.
Effective dietary approaches to lowering LDL cholesterol
include replacing saturated and trans fatty acids with dietary
carbohydrates or unsaturated fatty acids and reducing di-
etary cholesterol. Although the response to dietary inter-
ventions is variable, a diet low in saturated fat and choles-
terol typically lowers LDL cholesterol by 10% to 15%
(497–500). Other beneficial dietary interventions can in-
clude addition of plant stanols/sterols (2 g/d), which trials
suggest lower LDL cholesterol by 5% to 15%, and addition
of viscous fiber (10 g/d), which reduces LDL cholesterol
by 3% to 5% (512–515). A 10-lb weight loss reduces LDL
cholesterol by 5% to 8% (496). Regular physical activity is
also a key component of therapeutic lifestyle modification.
Although exercise does not reliably lower LDL cholesterol,
it facilitates weight loss and has other beneficial effects on
the lipid profile (516–518).
Controlled clinical trials of lipid-lowering drug therapy
have demonstrated that lowering of LDL cholesterol is
associated with a reduced risk of adverse cardiovascular
events. Earlier trials used bile acid sequestrants (cholesty-
ramine), fibric acid derivatives (gemfibrozil and clofibrate),
or niacin. More contemporary studies have convincingly
established the efficacy of statins in the primary and sec-
ondary prevention of coronary events (394–396,398,400,
501,519–522). In a prospective meta-analysis published by
the Cholesterol Treatment Trialist Collaborators in 2010
that examined data from 26 randomized trials of statin
therapy (comparing higher- to lower-dose statin therapy or
statin therapy to a control regimen), the mean difference in
LDL cholesterol was 31 mg/dL, ranging from 12 to 68
mg/dL. Each 40-mg/dL reduction in LDL cholesterol was
associated with a 10% reduction in all-cause mortality and a
20% reduction in coronary mortality, with corresponding
reductions in nonfatal MI, need for coronary revasculariza-
tion, and first nonfatal ischemic stroke (458). The absolute
benefit of therapy was a function of an individual’s absoluterisk of fatal MI (458). In trials comparing higher- to
lower-dose statin therapy, the average, weighted reduction
in LDL cholesterol at 1 year was 20 mg/dL among those
receiving higher-dose regimens. Among patients assigned
to more intensive regimens, there was a 15% lower inci-
dence of major vascular events (95% CI: 11 to 18;
p0.0001), which reflected a 13% lower risk of coronary
death or nonfatal MI (95% CI: 7 to 19; p0.0001), a 19%
lower risk of undergoing coronary revascularization (95%
CI: 15 to 24; p0.0001), and a 16% lower risk of ischemic
stroke (95% CI: 5 to 26; p0.005). The reductions in serum
LDL cholesterol and in cardiovascular risk were similar in
magnitude to those observed in trials comparing statin
therapy to a control regimen. The absolute benefit of
therapy was defined chiefly by an individual’s absolute risk
of death due to coronary occlusion (458). Appropriate
treatment goals for patients with SIHD have been informed
by several trials of intensive lipid-lowering therapy. The
HPS (Heart Protection Study) compared simvastatin 40 mg
daily to placebo in patients with IHD, other occlusive
vascular disease, or diabetes mellitus. On-treatment LDL
cholesterol levels averaged 88 mg/dL in those allocated to
simvastatin and 127 mg/dL in those randomized to placebo.
A consistent and early benefit of therapy was demonstrated,
with a 13% reduction in mortality rate and an 18% reduction
in coronary death rate (398). Similar reductions in RR were
observed regardless of baseline levels of LDL cholesterol,
including in those with initial levels 116 mg/dL or 97
mg/dL. (Of note, LDL cholesterol levels in the HPS were
not drawn with patients in the fasting state and were
measured values rather than the calculated values used in
clinical practice and in most trials; measured LDL choles-
terol is generally about 15% higher than calculated LDL
cholesterol) (398). In the TNT (Treating to New Targets)
trial, patients with clinically apparent IHD and LDL
cholesterol 130 mg/dL were randomly assigned to either
10 mg or 80 mg of atorvastatin per day. The mean LDL
cholesterols were 77 mg/dL during treatment with 80 mg of
atorvastatin and 101 mg/dL during treatment with 10 mg of
atorvastatin. There was a 22% reduction in a composite
cardiovascular endpoint and a 20% reduction in cardiac
deaths with more intensive therapy but no reduction in
all-cause mortality (400). In the IDEAL (Incremental
Decrease in End Points Through Aggressive Lipid Lower-
ing) study patients with a past history of MI were randomly
assigned to intensive lipid-lowering therapy with atorvasta-
tin 80 mg daily or simvastatin 20 mg daily. During treat-
ment, mean LDL cholesterol levels were 104 mg/dL in the
simvastatin group and 80 mg/dL in the atorvastatin group.
The results showed a nonsignificant trend toward reduction
of the primary composite endpoint of coronary death,
nonfatal MI, or cardiac arrest (hazard ratio: 0.89; 95% CI:
0.78 to 1.01); significant reductions in some secondary
endpoints such as nonfatal MI and coronary revascular-
ization; and no effect on all-cause mortality (501). It
should be noted that both these trials compared 2 drug
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a given level of LDL cholesterol and that, to date, there
is no clear evidence that treating to a specific target, as
opposed to treating with a higher dose of a higher-
potency statin, is beneficial. The mean achieved LDL
cholesterol levels among patients treated in the high-dose
atorvastatin arms of the TNT and IDEAL studies were
77 and 81 mg/dL, respectively.
These data support intensive LDL cholesterol lowering
with statins in patients with SIHD. An update of the
ATP-III report (18,24) recommends treatment to an LDL
cholesterol level 100 mg/dL in patients with established
CAD or other high-risk features, with an LDL cholesterol
goal of 70 mg/dL as a therapeutic option in patients at
very high risk. However, as discussed above, although the
presence of data confirming the use of a specific, numeric
target LDL cholesterol level for all patients with SIHD has
been challenged, the benefit of therapy with moderate- to
high-dose statin therapy is well established (458). For this
reason, the recommendations in this guideline stress the
importance of prescribing a statin in at least a moderate
dose. The ATP-IV report is anticipated later in 2012 and is
expected to provide guidance for the treatment of LDL
cholesterol levels on the basis of the results of an extensive
systematic review. Factors that identify patients at very high
risk in the ATP-III update include the presence of estab-
lished coronary vascular disease, plus 1) multiple major risk
factors, especially diabetes mellitus; 2) severe and poorly
controlled risk factors, especially continued tobacco use; and
3) multiple risk factors for the metabolic syndrome. Again,
it should be acknowledged that no studies have assessed the
benefits of titrating lipid-lowering drugs to achieve a specific
LDL cholesterol target. In addition, trials of intensive lipid
lowering for secondary prevention have used statins alone.
Although the addition of other agents could lower LDL
cholesterol in patients in whom a target level cannot be
achieved with a statin, the utility of this approach in
reducing risk of cardiovascular morbidity and mortality has
not been firmly established.
A secondary target of therapy introduced by ATP-III is
non–HDL cholesterol in patients with elevated triglycerides
(18,24). Non–HDL cholesterol is defined as the difference
between total cholesterol and HDL cholesterol. It includes
all cholesterol and lipoprotein particles that are considered
atherogenic, including LDL cholesterol, lipoprotein,
intermediate-density lipoprotein, and very-low-density li-
poprotein, and is a predictor of cardiovascular death (523).
Because statins lower LDL cholesterol and non–HDL
cholesterol to a similar extent, the relative benefits of
lowering these 2 lipid measures cannot be distinguished
from recent clinical trials. Fibrates could reduce the risk of
coronary events in patients with high triglycerides and low
HDL cholesterol levels and could have an adjunctive role in
these patients in combination with statins (503,524). Nic-
otinic acid raises HDL cholesterol, and several trials supportthe efficacy of niacin when used alone or in combination
with statins (504,505,525).
Observational studies and treatment trials suggest that
consumption of omega-3 fatty acids reduces cardiovascular
risk. Cohort and case–control studies have found an RR
reduction of about 15% for fish consumption versus little or
no fish consumption (526). In the GISSI (Gruppo Italiano
per lo Studio della Sopravvivenza nell’Infarto Miocardico)
Prevention study in patients with prior MI, 1 g daily of fish
oil supplement resulted in a 20% reduction in mortality at
42 months (527). Pharmacological treatment with fish oil at
higher doses (2 to 4 g daily) is effective in reducing
triglyceride levels (528).
4.4.1.2. BLOOD PRESSURE MANAGEMENT
CLASS I
1. All patients should be counseled about the need for lifestyle modi-
fication: weight control; increased physical activity; alcohol moder-
ation; sodium reduction; and emphasis on increased consumption
of fresh fruits, vegetables, and low-fat dairy products (17,529–537).
(Level of Evidence: B)
2. In patients with SIHD with BP 140/90 mm Hg or higher, antihyper-
tensive drug therapy should be instituted in addition to or after a
trial of lifestyle modifications (538–543). (Level of Evidence: A)
3. The specific medications used for treatment of high BP should be
based on specific patient characteristics and may include ACE
inhibitors and/or beta blockers, with addition of other drugs, such as
thiazide diuretics or calcium channel blockers, if needed to achieve
a goal BP of less than 140/90 mm Hg (544,545). (Level of Evi-
dence: B)
Hypertension is an important independent risk factor for
ischemic cardiovascular events. Observational studies have
demonstrated a continuous and graded relationship between
BP and cardiovascular risk. In a collaborative meta-analysis
of prospective studies of nearly 1 million adults without
preexisting vascular disease, the risk of a vascular death
increased linearly over the BP range of 115/75 mm Hg to
185/115 mm Hg, without a threshold effect. Each incre-
ment of 20 mm Hg in systolic BP or 10 mm Hg in diastolic
BP was associated with a doubling of risk (546). RCTs
indicate that treatment results in a reduction of cardiovas-
cular risk consistent with predictions from epidemiological
studies (538–543,547).
Treatment of high BP should begin with lifestyle mea-
sures. Maintenance of an appropriate body weight (BMI
25 kg/m2) is a key element of the nonpharmacological
strategies recommended to improve BP control; weight loss
of 10 kg typically results in a decrease in BP of 5 to 20 mm Hg
(529–531,548,549). Consumption of a diet rich in fruits,
vegetables, and low-fat dairy products (532,533); reduction
of dietary sodium intake (529,531,533,534,550); regular
physical activity (535); and moderation of alcohol consump-
tion (536) also result in significant lowering of BP.
In many patients with SIHD, therapy with medications
will be required to lower BP to the desired level. Treatment
trials have definitively demonstrated a beneficial effect of
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An overview of 17 placebo-controlled trials, most of which
focused on lowering diastolic BP, showed that reducing
diastolic BP 5 to 6 mm Hg (or an estimated 10 to 20 mm Hg
in systolic BP) within a population was associated with a
significant reduction in vascular mortality, with approxi-
mately 40% reduction in stroke and 20% reduction in
coronary events (547). This benefit of treatment also has
been observed in studies of older adult patients with isolated
systolic hypertension (539,551,552).
Despite the plethora of clinical studies, the appropriate
BP threshold for initiating medical therapy and specific
treatment goals for patients with chronic IHD remain
controversial. RCTs have demonstrated a benefit from
antihypertensive therapy in patients with a diastolic BP90
mm Hg (547) and also in patients with isolated systolic
hypertension and a systolic BP 160 mm Hg (539,551,
552). The Seventh Report of the Joint National Committee
on Prevention, Detection, Evaluation, and Treatment of
High Blood Pressure recommends a target BP of 140/90
mm Hg in patients with uncomplicated hypertension and of
130/80 mm Hg in patients with diabetes mellitus or CKD
(17). Observations from epidemiological studies and the
relatively high absolute risk of cardiovascular events in
patients with vascular disease have led some to suggest that
a lower BP target might also be appropriate in individuals
with SIHD (553).
On the other hand, excessive reduction in diastolic BP
could compromise coronary perfusion in SIHD patients,
and some studies have demonstrated a J-shaped relationship
between diastolic BP and coronary events (554). The
ACCORD (Action to Control Cardiovascular Risk in
Diabetes) BP trial (555), which enrolled patients with type
2 diabetes mellitus at high risk of cardiovascular events,
found no benefit of targeting a systolic BP of 120 mm Hg
compared with a systolic BP of 140 mm Hg in reducing a
composite endpoint of MI, stroke, or death from cardiovas-
cular causes. In a related vein, in AASK (African-American
Study of Kidney Diseases and Hypertension) (556), 1,094
black patients with hypertensive kidney disease (diastolic
pressure95 mm Hg and glomerular filtration rate of 20 to
60 mL/min) and no diabetes mellitus were randomly
Table 15. Indications for Individual Drug Classes in the Treatm
Indication Diuretic Beta Blocker
Heart failure ● ●
LV dysfunction
After myocardial infarction ●
Angina ●
Diabetes mellitus ●
Chronic kidney disease
*Table indicates drugs that should be considered and does not indicate that all drugs should ne
together).
ACE indicates angiotensin-converting enzyme; ARB, angiotensin-receptor blocker; and LV, left ventricassigned to achieve a mean arterial pressure target92 mm Hg
(corresponding to 130/80 mm Hg) or to a target of 102 to
107 mm Hg (corresponding to 140/90 mm Hg). Overall,
there was no advantage to more intensive BP control with
regard to progression to end-stage kidney disease or death
(556).
Although in patients with uncomplicated hypertension
there are a variety of considerations in selecting a medica-
tion, effective BP lowering is the most important factor in
preventing stroke and MI. Clinical trials have failed to
convincingly demonstrate superiority of any single antihy-
pertensive drug class in preventing cardiovascular events
(544,545). In many patients with SIHD, the choice of
medications is guided by compelling indications for specific
classes of drugs, as discussed elsewhere in this guideline
(Table 15) (557). ACE inhibitors improve outcomes in
most patients with CAD, especially those with a history of
MI, LV dysfunction and heart failure, or CKD or diabetes
mellitus (295,296,301,558 –562). Angiotensin-receptor
blockers (ARBs) are beneficial in the same spectrum of
patients (563–566). Beta blockers are recommended in
patients with angina pectoris, a history of MI, or LV
dysfunction (567–571). Aldosterone antagonists improve
prognosis in patients with LV dysfunction and heart failure
(572,573). Calcium antagonists are useful in the treatment
of angina. Many patients with SIHD will require a combi-
nation of drugs, including a diuretic, to achieve optimal BP
control.
The role of emotional stress in relationship to hyperten-
sion has yet to be fully elucidated. It might be important to
acknowledge the potential relationship of stress to many of
the cardiovascular risk factors, particularly hypertension,
when counseling patients.
4.4.1.3. DIABETES MANAGEMENT
CLASS IIa
1. For selected individual patients, such as those with a short duration
of diabetes mellitus and a long life expectancy, a goal hemoglobin
A1c (HbA1c) of 7% or less is reasonable (574–576). (Level of
Evidence: B)
2. A goal HbA1c between 7% and 9% is reasonable for certain patients
according to age, history of hypoglycemia, presence of microvascu-
f Hypertension in Patients With SIHD*
Recommended Drugs
Inhibitor ARB
Calcium-Channel
Blocker
Aldosterone
Antagonist
● ● ●
● ●
● ● ●
●
● ●
● ●
ly be prescribed in an individual patient (e.g., ACE inhibitors and ARB typically are not prescribedent o
ACE
cessariular.
8
g
p
e
f
i
d
a
o
a
o
p
a
t
i
H
p
m
e90 Fihn et al. JACC Vol. 60, No. 24, 2012
Stable Ischemic Heart Disease: Full Text December 18, 2012:e44–e164lar or macrovascular complications, or presence of coexisting med-
ical conditions (577,578). (Level of Evidence: C)
CLASS IIb
1. Initiation of pharmacotherapy interventions to achieve target HbA1c
might be reasonable (456,579–588). (Level of Evidence: A)
CLASS III: Harm
1. Therapy with rosiglitazone should not be initiated in patients with
SIHD (589,590). (Level of Evidence: C)
Diabetes mellitus is an important independent risk factor
for cardiovascular disease. Type 1 diabetes mellitus is
associated with at least a 10-fold increase in cardiovascular
events (591,592), and patients with type 2 diabetes mellitus
have a risk of death from cardiovascular causes that is 2 to
6 times that of persons without diabetes mellitus (593–595).
The complications of atherosclerosis account for 80% of
deaths among patients with diabetes mellitus, and IHD is
responsible for the majority of deaths (574,596). Diabetes
mellitus is associated with a poor outcome in patients with
SIHD, even after the extent of disease and other clinical
characteristics are taken into account. In the CASS registry,
for example, patients with diabetes mellitus had a 57% greater
risk of death after adjustment for other risk factors (597).
Clinical trials have demonstrated a salutary effect of
intensive glycemic control on the development of microvas-
cular complications of diabetes mellitus, such as retinopa-
thy, nephropathy, and peripheral and autonomic neuropa-
thy (574,575,598), with secondary analyses suggesting a
benefit extending into the normal range of HbA1c. How-
ever, the efficacy of intensive diabetes therapy in reducing
cardiovascular disease is less well established. In the DCCT
(Diabetes Control and Complications Trial), patients with
type 1 diabetes mellitus were randomized to intensive (mean
achieved HbA1c 7.4%) or conventional (mean achieved
HbA1c 9.1%) therapy. During the mean 6.5 years of
observation, fewer cardiovascular events occurred in the
intensive-treatment group, but the number of events was
small, and the difference between groups did not reach
statistical significance (574). In a long-term follow-up study
of this population, however, intensive therapy reduced the
risk of cardiovascular events by 42% (579). Intensive glyce-
mic controlled to a reduction in microvascular complications
(primarily the need for retinal laser photocoagulation) but
not cardiovascular events in the patients with type 2 diabetes
mellitus who participated in the UKPDS (UK Prospective
Diabetes Study) (575). In a secondary analysis, treatment
with metformin seemed to confer most of the benefit,
whereas treatment with a sulfonylurea was not associated
with a significant improvement in any endpoint (599).
Patients in UKPDS treated with metformin had a lower
median HbA1c (7.4% versus 8.0%) and a 37% reduction in
1 diabetes endpoints compared with those in the conven-
tional therapy (diet alone) group (580). In the PROactive
(Prospective Pioglitazone Clinical Trial in Macrovascular
Events) study, patients with type 2 diabetes mellitus and
evidence of vascular disease were randomized to pioglita- fzone or placebo. HbA1c averaged 7.8% at baseline and
decreased by 0.3% in the placebo group and by 0.8% in
those on active therapy. There was no significant difference
between treatment groups in the primary study endpoint,
although pioglitazone resulted in a statistically significant
16% relative reduction in a secondary endpoint of mortality,
nonfatal MI, and stroke (581).
Three studies in patients with type 2 diabetes mellitus
suggest that even more intensive glucose lowering fails to
reduce the incidence of cardiovascular events and could
cause harm (576,578,600). The ADVANCE (Action in
Diabetes and Vascular Disease: Preterax and Diamicron
Modified Release Controlled Evaluation) trial tested a
strategy of intensive glucose control with a target HbA1c of
6.5%, with the sulfonylurea gliclazide (modified release) and
other drugs used as required (576). After a median 5 years
of follow-up, HbA1c averaged 6.5% in the intensive-control
group and 7.3% in the standard-control group. Intensive
control reduced the incidence of microvascular events but
had no effect on a composite of macrovascular events that
included nonfatal MI, nonfatal stroke, or death from car-
diovascular causes (576). In the ACCORD study, patients
were assigned to receive intensive therapy with a goal of
normalizing the HbA1c (to 6%) or standard therapy
targeting a level of 7.0% to 7.9% (600). Median achieved
HbA1c levels at 1 year were 6.4% and 7.5% in the 2 groups,
respectively. Over 3.5 years, the use of intensive therapy did
not significantly reduce major cardiovascular events (nonfa-
tal MI, nonfatal stroke, and death from cardiovascular
causes) but was associated with a 22% greater all-cause
mortality (578,600). The VADT (Veterans Affairs Diabetes
Trial) examined macrovascular complications in patients
randomized to standard glycemic control or to intensive
therapy (goal HbA1c of 6%), with a planned HbA1c
separation of 1.5% (578). Median HbA1c levels were
.4% and 6.9% in the standard- and intensive-therapy
roups, respectively. There were no differences in the
rimary endpoint of time to occurrence of a cardiovascular
vent or all-cause mortality in the 2 groups over a median
ollow-up of 5.6 years.
In summary, the most appropriate goal level for HbA1c
n patients with diabetes mellitus has not been established
efinitively by clinical trials. A goal HbA1c 7%—a level
pproximating that achieved in the intensive-therapy arms
f the DCCT, UKPDS, and PROactive studies—is reason-
ble for many younger patients, depending on their duration
f diabetes mellitus, comorbidities, adherence, and personal
references. Secondary analyses of the DCCT and UKPDS
nd microvascular data from the ADVANCE trial suggest
hat even lower HbA1c levels could be beneficial in selected
ndividuals. On the other hand, treatment to achieve a
bA1c 7% might not be safe or practical for some
atients, and factors such as life expectancy, advanced
icrovascular or macrovascular complications, cognitiveunction, comorbidities, and risk of hypoglycemia should be
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tic regimen.
Regardless of the degree of glycemic control, treatment of
other modifiable risk factors that often accompany diabetes
mellitus, such as hypertension and dyslipidemia, results in a
substantial reduction in cardiovascular risk. The benefits of
a target-driven, multifactorial intervention in patients with
type 2 diabetes mellitus were demonstrated in the Steno-2
study (601). Behavioral modification and pharmacological
therapy targeting hyperglycemia, hypertension, dyslipide-
mia, and microalbuminuria lowered the risk of cardiovascu-
lar disease by 50% (601).
When the patient and provider elect to use pharmaco-
ogical therapy to improve glycemic control, several factors
hould be considered in selecting an agent, including ac-
eptability and safety. Although head-to-head comparisons
f different pharmacological regimens are largely lacking,
imited evidence suggests that all agents are not equivalent.
or example, long-term follow-up from the UKPDS indi-
ates that patients receiving metformin, particularly those
ho were overweight, had a lower incidence of diabetic
omplications, MI, and death than those who received
nsulin plus a sulfonylurea (588). In addition, available
nformation suggests that certain agents lack an acceptable
afety profile. The FDA, for example, has imposed restric-
ions on use of rosiglitazone, a thiazolidinedione, because of
ata that suggest an increased risk of cardiovascular com-
lications. Prescriptions for rosiglitazone should not be
nitiated for patients with SIHD. Patients who are already
eceiving this agent and whose blood glucose is well con-
rolled should be counseled about the potential hazards, and
witching to a different agent should be strongly considered.
n this light, when deciding whether to prescribe newer
ypoglycemic agents, providers should bear in mind the
otential for safety concerns that could emerge when these
rugs are adopted into wider use.
4.4.1.4. PHYSICAL ACTIVITY
CLASS I
1. For all patients, the clinician should encourage 30 to 60 minutes of
moderate-intensity aerobic activity, such as brisk walking, at least 5
days and preferably 7 days per week, supplemented by an increase
in daily lifestyle activities (e.g., walking breaks at work, gardening,
household work) to improve cardiorespiratory fitness and move
patients out of the least-fit, least-active, high-risk cohort (bottom
20%) (602–604). (Level of Evidence: B)
. For all patients, risk assessment with a physical activity history
and/or an exercise test is recommended to guide prognosis and
prescription (605–608). (Level of Evidence: B)
. Medically supervised programs (cardiac rehabilitation) and
physician-directed, home-based programs are recommended for at-
risk patients at first diagnosis (602,609,610). (Level of Evidence: A)
CLASS IIa
1. It is reasonable for the clinician to recommend complementary
resistance training at least 2 days per week (611,612). (Level of
Evidence: C)Physical activity counseling is an integral component of a
comprehensive coronary risk factor modification strategy in
patients with SIHD. Consistent with the American College
of Sports Medicine and AHA recommendations for healthy
adults (603), most patients with CAD should be encouraged
to engage in 30 to 60 minutes of moderate-intensity aerobic
activity, such as brisk walking, on most, and preferably all,
days of the week. Similar recommendations (2 hours and 30
minutes of moderate-intensity aerobic activity and muscle-
strengthening activities on 2 days a week) have been
advanced by the Centers for Disease Control and Preven-
tion (18,613). Many patients benefit from participation in a
cardiac rehabilitation program that incorporates supervised
exercise into a comprehensive secondary prevention pro-
gram (614).
Multiple controlled clinical trials have examined the
benefits of exercise training and cardiac rehabilitation in
patients with IHD. Most of these studies have been
relatively small, but in aggregate they demonstrate that
regular exercise reduces mortality in patients with IHD. A
systematic review and meta-analysis published in 2004
examined 48 RCTs of exercise interventions in a total of
8,940 patients with IHD (602). The median intervention
duration was 3 months (range, 0.25 to 30 months), and the
median duration of follow-up was 15 months (range, 6 to 72
months). Exercise training resulted in a 20% reduction in
all-cause mortality and a 26% reduction in total cardiac
mortality; favorable but nonsignificant trends were noted in
nonfatal MI, CABG, and percutaneous coronary revascu-
larization procedures. There was no difference between the
mortality rate effects of exercise-only and more comprehen-
sive cardiac rehabilitation interventions, and the benefits
were independent of actual amount and intensity of exercise.
Many of the studies demonstrating the efficacy of
exercise-based cardiac rehabilitation enrolled patients after
an AMI or coronary revascularization procedure. Clear
benefits of exercise training also have been shown in patients
with stable angina. Controlled trials consistently have dem-
onstrated an improvement in functional capacity and a delay
in the onset of ischemia in anginal patients who complete an
exercise training program (444,615–620). Exercise-based car-
diac rehabilitation could also reduce subjective evidence of
ischemia and could ameliorate symptoms (615,619,621,622).
The reduction in mortality rate associated with exercise
interventions might be explained partially by modification
of traditional cardiovascular risk factors. Controlled trials
have demonstrated reductions in total cholesterol, triglyc-
erides, and BP, although these findings have not been
uniform. Exercise also can enhance smoking quit rates.
Other potential mechanisms include decreased fibrinogen
and coagulability (623), moderation of inflammation (624),
improved endothelial function (625–627), and improved
autonomic regulation (628,629).
Several studies have documented the safety of exercise-
based cardiac rehabilitation in patients with documented
SIHD (630–633). The 2007 AHA Scientific Statement on
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of a major adverse cardiac event (MACE) at 1 in 80,000
patient-hours (447). This low event rate applies to medically
supervised programs that evaluate patients before participa-
tion, provide serial surveillance, and are equipped to handle
emergencies. Specific strategies for reducing exercise-related
cardiovascular events have not been evaluated. It seems
prudent, however, that patients at high risk of cardiac
complications (i.e., those with a history of multiple MIs or
cardiac arrest, New York Heart Association functional class
III or IV or exercise capacity 6 METs, or significant
exercise-induced ischemia on treadmill testing) participate
in a medically supervised program for at least 8 to 12 weeks
to establish the safety of the prescribed exercise regimen.
The value of resistance exercise increasingly is recognized
for improving functional capacity, independence, and qual-
ity of life in patients with and without cardiovascular
disease. Although the risks and benefits of resistance ther-
apy have not been evaluated extensively in patients with
SIHD, several small studies have indicated that resistance
therapy is well tolerated and is associated with improve-
ments in quality of life, strength, and endurance when
added to a program of regular aerobic exercise (611,612).
Although previous guidelines have recommended that all
patients undergo an exercise test before participating in a
cardiac rehabilitation program, according to the World
Health Organization (634), an exercise test is not consid-
ered necessary for medical and economic reasons if the
patient enters a low- or moderate-intensity-level training
program.
4.4.1.5. WEIGHT MANAGEMENT
CLASS I
1. BMI and/or waist circumference should be assessed at every visit,
and the clinician should consistently encourage weight mainte-
nance or reduction through an appropriate balance of lifestyle
physical activity, structured exercise, caloric intake, and formal
behavioral programs when indicated to maintain or achieve a BMI
between 18.5 and 24.9 kg/m2 and a waist circumference less than
102 cm (40 inches) in men and less than 88 cm (35 inches) in
women (less for certain racial groups) (257,449,635–642). (Level of
Evidence: B)
2. The initial goal of weight loss therapy should be to reduce body weight
by approximately 5% to 10% from baseline. With success, further
weight loss can be attempted if indicated. (Level of Evidence: C)
Population studies consistently have demonstrated an asso-
ciation of increased BMI with ischemic cardiac events. In a
meta-analysis of 21 cohort studies including 300,000
persons, the risks for cardiovascular events in patients who
were overweight (BMI 25.0 to 29.9 kg/m2) and obese (BMI
30 kg/m2) compared with those of normal weight were
2% and 81% higher, respectively, after adjustment for age,
ex, physical activity, and smoking (635). Cardiovascular risk
s increased particularly in patients with central obesity, which
an be identified by a waist circumference102 cm (40 inches)
n men or 88 cm (35 inches) in women (643,644), and inhose with extreme obesity, defined as a BMI 40 kg/m2
(645).
Obesity likely contributes to increased cardiovascular risk
through multiple pathophysiological pathways. Obesity is
associated with traditional cardiovascular risk factors, such
as diabetes mellitus, dyslipidemia, and hypertension, but in
and of itself obesity increases sympathetic tone, induces a
hypercoagulable state, and is associated with markers of
inflammation (646). Curiously, despite the strong associa-
tion of BMI with cardiovascular risk in population studies,
a similar relationship between BMI and death is not
observed consistently in cohorts with established IHD
(647). This could be due to weaknesses of BMI as a measure
of adiposity; confounding factors such as age, smoking, or
medications; or weight loss in association with advanced
chronic illness.
No clinical trials have examined specifically the effects of
weight loss on cardiovascular event rates in patients with
SIHD. In the SOS (Swedish Obese Subjects) study, how-
ever, weight losses of 20% to 32% at 1 year achieved with
bariatric surgery were associated with a 24% reduction in
mortality rate (648). The association of adiposity with other
cardiovascular risk factors suggests that weight reduction is
indicated in all overweight or obese patients. Reducing
caloric intake is a cornerstone of weight management
therapy. Referral to an experienced dietitian or to a reputa-
ble weight loss program for nutritional counseling and
behavioral modification therapy can be helpful. The effects
of caloric restriction are potentiated by regular aerobic
physical activity. Therapy with medications or bariatric
surgery may be considered in selected patients who are
unable to achieve adequate weight loss by conventional
lifestyle modifications (649).
4.4.1.6. SMOKING CESSATION COUNSELING
CLASS I
1. Smoking cessation and avoidance of exposure to environmental
tobacco smoke at work and home should be encouraged for all
patients with SIHD. Follow-up, referral to special programs, and
pharmacotherapy are recommended, as is a stepwise strategy for
smoking cessation (Ask, Advise, Assess, Assist, Arrange, Avoid)
(650–652). (Level of Evidence: B)
Observational studies over the past 4 decades have furnished
incontrovertible evidence that smoking increases the risk of
cardiovascular disease events (653,654). A dose–response
relationship exists between cigarettes smoked and cardio-
vascular risk, with an RR approaching 5.5 for cardiovascular
events among heavy smokers compared with nonsmokers
(654). Potential mechanisms by which smoking predisposes
to cardiovascular events include adverse effects on fibrinogen
levels (655), platelet adhesion (656), and endothelial func-
tion (657); reduced HDL cholesterol levels (658); and
coronary artery vasoconstriction (659).
Although RCTs have not been performed in patients
with SIHD, results of observational studies strongly suggest
that smoking cessation is an effective strategy for secondary
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spective cohort studies found a 30% reduction in RR of
mortality for those who quit compared with those who
continued smoking, and a similar reduction was noted in
nonfatal MIs (650). Some studies suggest that most of the
reduction in risk occurs within 2 or 3 years of quitting
(660,661).
The most effective smoking-cessation therapies include
both nonpharmacological and medical interventions. Phy-
sician advice has a significant effect on quit rates (662).
Self-help programs, telephone counseling, behavioral ther-
apy, and perhaps exercise programs also have modest effi-
cacy in increasing cessation rates (663–667). Nicotine-
replacement therapy (gum, patch, tablet, lozenge, or nasal
spray) approximately doubles the chances of success of a quit
attempt (668). Similar efficacy has been demonstrated with
bupropion sustained-release (669). Varenicline, a partial
agonist of the 42 nicotinic receptor, is the most recent
DA-approved agent for smoking cessation and compares
avorably with placebo and with bupropion in clinical trials
670,671). There have, however, been concerns about pos-
ible worsening of preexisting depression and the risk of
uicide due to varenicline, and the FDA has issued an alert
arning that serious neuropsychiatric symptoms can occur
n patients taking this drug (672,673).
Physicians should approach smoking cessation by using
he 6 A’s framework:
• Ask each patient about tobacco use at every visit;
• Advise each smoker to quit;
• Assess each smoker’s willingness to make a quit
attempt;
• Assist each smoker in making a quit attempt by offering
medication and referral for counseling;
• Arrange for follow-up; and
• Avoid exposure to environmental tobacco smoke.
4.4.1.7. MANAGEMENT OF PSYCHOLOGICAL FACTORS
CLASS IIa
1. It is reasonable to consider screening SIHD patients for depression
and to refer or treat when indicated (237,239,323,457,463,674,
675). (Level of Evidence: B)
CLASS IIb
1. Treatment of depression has not been shown to improve cardiovas-
cular disease outcomes but might be reasonable for its other
clinical benefits (237,238,676). (Level of Evidence: C)
Depression is a major cause of disability in developed
countries and often coexists with SIHD (677,678). About
20% of patients with angiographic evidence of CAD and a
similar percentage of those recovering from AMI have
comorbid depression (679–682).
Multiple observational studies have demonstrated an
association between depression and cardiovascular events. In
several studies involving 1,000 outpatients with SIHD,
those with symptoms of depression had more physical
limitation, more frequent angina, and lower perceived qual-ity of life than patients without depressive symptoms
(239,683). One meta-analysis examined 21 prospective
studies in healthy populations and 34 studies in patients
with existing IHD (684). The studies in healthy cohorts
demonstrated an 81% greater incidence of ischemic events
(MI or fatal IHD) among patients with symptoms of
depression over an average follow-up period of 10.8 years. A
similarly increased risk was observed in patients with estab-
lished IHD who had symptoms of depression. Relatively
few studies, however, have reported estimates of risk that
have been adjusted for traditional risk factors or severity of
CAD. Although in aggregate the observational cohort
studies suggest that depression confers a significant risk for
adverse cardiovascular outcomes, confounding by other risk
factors or by disease severity is difficult to exclude. More-
over, most studies in patients with CAD have enrolled
patients after recent MI or CABG, and the relevance to
patients with SIHD is uncertain.
Putative mechanisms for a contribution of depression to
atherogenesis and adverse cardiovascular events include
both behavioral and biological effects. Depression is associ-
ated with poor compliance with risk factor–modification
strategies and with poor adherence to prescribed medication
regimens (460,462). Patients diagnosed with this disorder
are 2- to 4-fold less likely to adhere to medications and
lifestyle recommendations, engage in self-management
practices, or comply with recommendations for testing and
follow-up (462,675,685–691). Alternatively, some studies
suggest the possibility of more direct pathophysiological
links, including platelet activation (692–695), endothelial
dysfunction (696), reduced heart rate variability (697–699),
and inflammation (700).
Despite the association of depression with adverse car-
diovascular outcomes, no clinical trials have established a
reduction in cardiovascular risk with either counseling or
antidepressant therapy. In the ENRICHD (Enhancing
Recovery in Coronary Heart Disease) trial, 2,481 patients
with depression or low social support after MI were ran-
domized to usual care or cognitive behavioral therapy,
supplemented by a selective serotonin reuptake inhibitor
when indicated. Active therapy was associated with im-
provements in depression and low social support but with
no improvement in event-free survival after a mean 24
months of follow-up (237). A secondary analysis, however,
demonstrated a significantly lower risk of death or MI in
patients treated with a selective serotonin reuptake inhibitor
(676). The safety and efficacy of sertraline in patients with a
recent ACS were demonstrated in SADHART (Sertraline
Antidepressant Heart Attack Randomized Trial). Patients
were randomized to sertraline or placebo for 24 weeks.
Sertraline resulted in improved depressive symptoms and no
change in LVEF, ventricular ectopy, or QT interval. The
study was not powered to detect a difference in cardiovas-
cular outcomes (238). Similarly, citalopram, a selective
serotonin reuptake inhibitor, and mirtazapine, a dual-acting
antidepressant, improved depression in postinfarction pa-
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with SIHD by cognitive therapy or medication is safe and
contributes to relief of depressive symptoms but does not
have proven efficacy in reducing cardiovascular morbidity
and mortality rates.
Either the 2-item Patient Health Questionnaire
(PHQ)-2 or the 9-item PHQ-9 can be used as a screening
tool for depression (701,702) (Tables 16 and 17). Patients
ho respond affirmatively to either item on the PHQ-2 or
o item 9 on the PHQ-9 or who have a score 10 on the
HQ-9 should be referred for a more comprehensive
linical evaluation (701,702) (Table 17).
Patients with SIHD report high levels of psychosocial
tress, and indices of stress are associated with an increased
isk of cardiovascular events (245). Counseling to reduce
sychological stress is recommended as a core component of
omprehensive cardiac rehabilitation programs. Stress-
anagement interventions use relaxation techniques and
rovide instruction in specific skills to reduce cognitive,
ehavioral, and psychological stress levels. Although stress-
anagement programs are not of proven value in reducing
he risk of cardiovascular events, they are effective in
elieving anxiety and reducing depressive symptoms (461).
4.4.1.8. ALCOHOL CONSUMPTION
CLASS IIb
1. In patients with SIHD who use alcohol, it might be reasonable for
nonpregnant women to have 1 drink (4 ounces of wine, 12 ounces
of beer, or 1 ounce of spirits) a day and for men to have 1 or 2 drinks
a day, unless alcohol is contraindicated (such as in patients with a
history of alcohol abuse or dependence or with liver disease)
(703–705). (Level of Evidence: C)
Observational studies suggest that light to moderate alcohol
consumption is associated with a lower risk of IHD and
all-cause mortality. Most studies report a J-shaped relation-
ship between alcohol consumed and cardiovascular event
rate or mortality; light to moderate drinkers have less risk
than abstainers, but heavy drinkers are at greatest risk. A
meta-analysis of 34 prospective studies found mortality rate
reductions of 17% in men and 18% in women with low
levels of alcohol intake, with the lowest mortality rate at 6 g
of alcohol (approximately one half drink) per day (703).
Most of these studies were performed in healthy cohorts,
and data in patients with IHD are limited. One study (704)
examined survival rate among early survivors of MI and
found that moderate alcohol consumption in the year before
presentation was predictive of lower all-cause mortality.
Table 16. Patient Health Questionnaire-2
Over the past 2 weeks, how often have you been bothered by any of the
following problems?
1) Little interest or pleasure in doing things
2) Feeling down, depressed, or hopeless
Reproduced from Kroenke et al. (702).Similarly, among participants in the Physician’s HealthStudy who experienced a self-reported MI, moderate drink-
ers had a 30% lower risk of death than abstainers (705).
Light to moderate alcohol consumption might confer
protection against cardiovascular disease through beneficial
effects on the lipid profile and on insulin sensitivity. Alcohol
intake modestly increases HDL cholesterol in a dose-
dependent fashion (706,707). Consumption of 2 drinks per
day lowers fasting and postprandial insulin levels and
increases insulin sensitivity in healthy subjects (708). Light
to moderate alcohol consumption might also have antiin-
flammatory effects, as reflected by a reduction in C-reactive
protein (709,710). Alternatively, the apparent cardioprotec-
tive effects of modest alcohol consumption reported in
observational studies could represent uncontrolled con-
founding, as many coronary risk factors are more prevalent
in nondrinkers than in light to moderate drinkers (711).
There are no RCTs in either healthy individuals or in
patients with SIHD demonstrating improved clinical out-
comes with alcohol consumption. Because of the many
health and societal consequences of alcohol abuse, patients
who do not already drink alcohol should not be encouraged
to start. Patients who do consume alcoholic beverages
should be counseled to do so in moderation: no more than
1 drink (4 ounces of wine or 1 ounce of spirits) per day for
women and no more than 2 drinks per day for men.
4.4.1.9. AVOIDING EXPOSURE TO AIR POLLUTION
CLASS IIa
1. It is reasonable for patients with SIHD to avoid exposure to in-
creased air pollution to reduce the risk of cardiovascular events
(712–715). (Level of Evidence: C)
Although they are seldom an explicit focus in provision of
care to individual patients, environmental influences such as
exposure to air pollution can increase the risk of cardiovas-
cular events, possibly because of progression of atheroscle-
rosis due to oxidative stress and inflammation (715). In
particular, fine particulate matter, defined as particulate
Table 17. Patient Health Questionaire-9:
Depression Screening Scales
Over the past 2 weeks, how often have you been bothered by any of the
following problems?
1) Little interest or pleasure in doing things
2) Feeling down, depressed, or hopeless
3) Trouble falling asleep, staying asleep, or sleeping too much
4) Feeling tired or having little energy
5) Poor appetite or overeating
6) Feeling bad about yourself, feeling that you are a failure, or feeling that
you have let yourself or your family down
7) Trouble concentrating on things such as reading the newspaper or
watching television
8) Moving or speaking so slowly that other people could have noticed. Or
being so fidgety or restless that you have been moving around a lot more
than usual
9) Thinking that you would be better off dead or that you want to hurt
yourself in some wayReproduced from Kroenke et al. (702).
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ith a heightened risk of death due to cardiovascular causes
714). In nonsmokers, the relative odds of AMI death rise
2% for each 10 mcg increase in PM2.5 (712). Short-term
xposure to higher concentrations of pollution, for example
fter a forest fire, also is associated with the risk for ACS
nd death (713). Thus, patients with SIHD may be advised
o avoid exposure to increased air pollution (i.e., by remain-
ng indoors during transient elevations of air pollution).
ublic policy efforts to minimize small particulate matter
i.e., through tighter regulations on the emissions from
oal-fired power plants) have the potential to reduce cardiac
omplications among patients with SIHD.
.4.2. Additional Medical Therapy to Prevent MI
nd Death: Recommendations
4.4.2.1. ANTIPLATELET THERAPY
CLASS I
1. Treatment with aspirin 75 to 162 mg daily should be continued
indefinitely in the absence of contraindications in patients with SIHD
(716,717). (Level of Evidence: A)
2. Treatment with clopidogrel is reasonable when aspirin is contrain-
dicated in patients with SIHD (718). (Level of Evidence: B)
CLASS IIb
1. Treatment with aspirin 75 to 162 mg daily and clopidogrel 75 mg
daily might be reasonable in certain high-risk patients with SIHD
(719). (Level of Evidence: B)
CLASS III: No Benefit
1. Dipyridamole is not recommended as antiplatelet therapy for pa-
tients with SIHD (720–722). (Level of Evidence: B)
4.4.2.1.1. ANTIPLATELET AGENTS. Because platelet aggrega-
ion is a key element of the thrombotic response to plaque
isruption, platelet inhibition is recommended in patients
ith SIHD unless contraindicated. Aspirin is a cyclooxy-
enase inhibitor that produces irreversible blockade of
rostaglandin endoperoxide formation. Among 2,920 pa-
ients with SIHD, a comprehensive meta-analysis of source
ata revealed an association of aspirin use with a 37%
eduction in the risk of serious vascular events, including a
6% decrease in the risk for UA and a 53% decrease in the
isk of requiring coronary angioplasty (716). Almost two
hirds of the patients included in this meta-analysis were
articipants in SAPAT (Swedish Angina Pectoris Aspirin
rial), in which patients with SIHD were assigned ran-
omly to aspirin 75 mg per day or placebo for a median of
5 months (717). Aspirin in a dose of 75 to 162 mg daily is
qually as effective as 325 mg in secondary prevention and is
ssociated with a lower risk of bleeding. Doses75 mg have
ess proven benefit (716,723). Aspirin is relatively contrain-
icated in patients with known allergies to nonsteroidal
ntiinflammatory drugs and in patients with the syndrome
f asthma, rhinitis, and nasal polyps.
Clopidogrel, a thienopyridine derivative, inhibits platelet
ggregation via selective and irreversible inhibition of the
denosine diphosphate P2Y12 receptor. Clopidogrel 75 mg Oas been compared with aspirin 325 mg in patients with
revious MI, stroke, or symptomatic PAD in the prospec-
ive, randomized CAPRIE (Clopidogrel versus Aspirin in
atients at Risk of Ischaemic Events) study (718). Although
lopidogrel demonstrated superiority over aspirin in the
econdary prevention of MI and death in this group of
atients, the magnitude of difference was small. Because no
dditional trials comparing aspirin and clopidogrel in pa-
ients with SIHD have been conducted, clopidogrel remains
n acceptable alternative agent to aspirin.
In certain high-risk patients, combined treatment with
spirin and clopidogrel has been shown to be beneficial. In
he CURE (Clopidogrel in Unstable Angina to Prevent
ecurrent Events) study, patients with a recent NSTEMI
ere randomized to clopidogrel plus aspirin (300 mg/d and
5 mg/d) for an average of 9 months. These patients
xperienced fewer deaths from cardiovascular causes, non-
atal MIs, and strokes than did patients receiving placebo
lus aspirin (75 to 325 mg/d) (724). Similar results were
ound in the CREDO (Clopidogrel for Reduction of Events
uring Observation) study. Combined therapy for an aver-
ge of 1 year significantly reduced the risk of death, MI, or
troke (725). In contradistinction to these positive results
mong high-risk patients, a comparison of aspirin alone versus
spirin combined with clopidogrel in 15,603 patients with
ultiple cardiovascular risk factors (most of whom were
ithout a prior cardiovascular event) in the CHARISMA
Clopidogrel for High Atherothrombotic Risk Ischemic
tabilization, Management, and Avoidance) trial demon-
trated no differences in the rates of MI, stroke, or death
393). A post hoc analysis of this study suggested that a
ubgroup of patients with documented prior MI, ischemic
troke, or symptomatic PAD might have had better out-
omes from dual antiplatelet therapy (DAPT) with clopi-
ogrel plus aspirin (719). In a meta-analysis of 5 RCTs
omparing clopidogrel plus aspirin to aspirin alone in
atients with IHD, the incidence of all-cause mortality, MI,
nd stroke was found to be reduced in the clopidogrel-plus-
spirin group, whereas the risk of major bleeding increased
ignificantly (726). Overall, it appears that the addition of
lopidogrel to aspirin could be beneficial in certain high-risk
roups of patients with SIHD, but data on specific sub-
roups are lacking (727), and further research will be
equired to identify the ideal target population.
The effectiveness of clopidogrel depends on generation of
he active metabolite in 2 steps that are catalyzed by
nzymes of the cytochrome P450 system, principally
YP2C19. Variants of the CYP2C19 gene have been iden-
ified that are associated with impaired antiplatelet effects,
s measured by ex vivo platelet aggregation assays, and with
igher cardiovascular event rates after ACS and percutane-
us revascularization procedures (728–731). Poor metabo-
izers of clopidogrel can be identified by clinically available
ests, but optimal dosing strategies for these individuals have
ot been established in clinical outcome trials (732,733).
ther drugs that are metabolized by CYP2C19 could
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clopidogrel. Several studies have demonstrated a pharmaco-
dynamic interaction between proton pump inhibitors and
clopidogrel (734,735). Observational studies have suggested
that use of a proton pump inhibitor in combination with
clopidogrel is associated with an approximately 25% in-
creased RR of adverse cardiovascular events (736,737),
although post hoc analyses of several clinical trials and a
recent observational study have failed to demonstrate a
clinically significant interaction (738,739). Pantoprazole is
less likely than other proton pump inhibitors to inhibit
CYP2C19 and does not impair the pharmacodynamic re-
sponse to clopidogrel (740–742); alternatively, treatment
with an H2 antagonist or antacid could be sufficient in some
patients. The combination of clopidogrel with a statin can
be prescribed safely on the basis of a secondary analysis of
the CHARISMA trial in 10,078 patients with cardiovascu-
lar disease or multiple high-risk coronary risk factors (743).
There was no difference in the composite endpoint of MI,
stroke, or cardiovascular death between the agents, inde-
pendent of the metabolism pathway of the statin. Clopi-
dogrel requires a loading dose to accelerate the onset,
intensity, and consistency of inhibition (744,745).
Prasugrel is a third-generation thienopyridine that has
more potent antiplatelet effects and is associated with less
interpatient variability in response than clopidogrel. In
TRITON-TIMI (Trial to Assess Improvement in Thera-
peutic Outcomes by Optimizing Platelet Inhibition with
Prasugrel–Thrombolysis In Myocardial Infarction) 38,
there was a 19% reduction in RR of the primary efficacy
endpoint (cardiovascular death, nonfatal MI, or nonfatal
stroke) but an increased risk of bleeding with prasugrel
compared with clopidogrel in ACS patients scheduled for
percutaneous revascularization (746). Clinical trials evaluat-
ing prasugrel in patients with SIHD have not been con-
ducted. It has not been tested or approved for use in patients
with SIHD. Ticagrelor is a newly approved agent that has
been shown to be beneficial in patients with ACS but has
not been tested in patients with SIHD (747).
Ticlopidine is a thienopyridine derivative that also inhib-
its platelet aggregation but compares less favorably to
clopidogrel as an alternative to aspirin, because it has limited
evidence for cardiovascular event reduction among patients
with SIHD and an associated risk of blood dyscrasias
(720,721). For these reasons, its use is quite limited for
secondary prevention among patients with SIHD.
The pyrimido-pyrimidine derivative, dipyridamole, pos-
sesses antiplatelet effects but does not have a proven role in
patients with SIHD. The combination of aspirin and
dipyridamole was not clearly superior to aspirin alone in
preventing reinfarction in the PARIS (Persantine-Aspirin
Reinfarction Study) (722). Because dipyridamole vasodilates
coronary resistance vessels and can provoke exercise-induced
myocardial ischemia, it is not recommended for secondary
prevention in patients with SIHD (748,749).4.4.2.1.2. ORAL ANTICOAGULANT THERAPY. Fibrinolytic
unction can be disturbed in patients with IHD, particularly
elated to activation of the extrinsic coagulation pathway
eading to formation of thrombin. Thrombin, in turn,
enerates fibrin and promotes platelet activation and aggre-
ation, thereby amplifying the activity of both the coagula-
ion and platelet pathways (750–752). These observations
ave provided a potential rationale for antithrombotic ther-
py in patients with SIHD. A systematic review of random-
zed trials of oral anticoagulants with and without antiplate-
et therapy among 20,000 patients with IHD, however,
ailed to provide evidence of benefit from anticoagulation,
nd it is not recommended (753). Similarly, there is no
vidence that individuals with defects in the coagulation
ystem, such as G1691A factor V Leiden, G20201A pro-
hrombin, G455A fibrinogen chain, G10976A factor VII,
r the plasminogen activator inhibitor-1 4G/5G polymor-
hisms, are at higher risk of cardiac events, and they should
ot receive anticoagulation therapy solely to prevent such
vents (754–756).
4.4.2.2. BETA-BLOCKER THERAPY
CLASS I
1. Beta-blocker therapy should be started and continued for 3 years in
all patients with normal LV function after MI or ACS (757–759).
(Level of Evidence: B)
2. Beta-blocker therapy should be used in all patients with LV systolic
dysfunction (EF 40%) with heart failure or prior MI, unless contra-
indicated. (Use should be limited to carvedilol, metoprolol succi-
nate, or bisoprolol, which have been shown to reduce risk of death.)
(571,760–763) (Level of Evidence: A)
CLASS IIb
1. Beta blockers may be considered as chronic therapy for all other
patients with coronary or other vascular disease. (Level of Evidence: C)
Beta-receptor activation is associated with increases in heart
rate, accelerated AV nodal conduction, and increased con-
tractility, which contribute to increased myocardial oxygen
demand. Decreases in the rate–BP product, AV nodal
conduction, and myocardial contractility from beta blockers
reduce myocardial oxygen demand, counteracting beta-
receptor activity and contributing to a reduction in angina
onset, with improvement in the ischemic threshold during
exercise and in symptoms (764–769). These agents signif-
icantly reduce deaths and recurrent MIs in patients who
have suffered a MI and are especially effective when a
STEMI is complicated by persistent or recurrent ischemia
or tachyarrhythmias early after the onset of infarction (757).
However, no large trials have assessed effects of beta
blockers on survival or coronary event rates in patients with
SIHD.
Many clinically important differences exist between beta
blockers. These differences relate to cardioselectivity, pres-
ence of intrinsic sympathomimetic activity or vasodilating
properties, and relative lipid solubility in the presence of
renal or hepatic impairment. Despite these differences, all
2e97JACC Vol. 60, No. 24, 2012 Fihn et al.
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(765–767,770,771).
Two large long-term follow-up studies investigating the
prognostic importance of heart rate showed that all-cause
mortality rate progressively increases with higher resting
heart rate after adjustment for exercise capacity, age, diabe-
tes mellitus, systolic arterial pressure, BMI, and level of
physical activity (772,773). Therefore, it is recommended
that beta-blocker dosing be adjusted to limit the heart rate
to 55 to 60 beats per minute at rest.
In large prospective studies, bisoprolol, carvedilol, and
metoprolol, when administered on a background of ACE
inhibitors and diuretics with or without digoxin, have been
shown to reduce the risk of death and to improve symptoms,
clinical status, and quality of life in patients with chronic
systolic heart failure. Importantly, these benefits were seen
in patients with and without IHD (571,760,761).
Studies on multiple polymorphisms in the gene encoding
for the beta-adrenergic receptor have variously shown asso-
ciations with physiological responses to exercise (774–781).
Clinical studies with a variety of beta blockers in different
patient populations with hypertension have, however,
yielded divergent results in terms of associations with BP
and heart rate (782–785), but it remains to be studied
whether this variation is mainly a function of beta-
adrenergic receptor genotype and whether genotype influ-
ences the clinical outcome of beta-blocker use in patients
with SIHD.
Beta blockers have been compared with and combined
with dihydropyridine calcium channel blockers in controlled
clinical trials. The results of the APSIS (Angina Prognosis
Study in Stockholm), TIBBS (Total Ischemic Burden
Bisoprolol Study), and IMAGE (International Multicenter
Angina Exercise) studies showed that a beta blocker was
more effective than a calcium channel blocker in control of
angina, reduction of cardiovascular events, and need for
revascularization (786–788). A rationale for combining
these agents is a reduction of dihydropyridine-induced
tachycardia by beta-blockade. When combined, beta block-
ers and dihydropyridine calcium channel blockers have
increased exercise time and shown a trend toward a lower
rate of cardiovascular outcomes (788,789). Caution is war-
ranted when a beta blocker is combined with verapamil or
diltiazem because of the potential for development of
bradycardia, AV block, or excessive fatigue.
The combination of a beta blocker with a nitrate could be an
additive combination in patients with SIHD. Nitrates increase
sympathetic tone, which can lead to reflex tachycardia, which
is attenuated by the beta blocker. Beta blockers can increase LV
wall tension associated with decreased heart rate, which is
counteracted by the concomitant use of nitroglycerin. Clinical
trials have validated this rationale, showing that the combina-
tion is more effective in controlling angina than is either
monotherapy alone (790,791).
Absolute contraindications to beta blockers are severe
bradycardia, preexisting high-degree AV block, sick sinussyndrome (without a pacemaker in place), and refractory
heart failure. Relative contraindications include bronchos-
pastic disease or active PAD (beta blockers without vasodi-
lating properties or selective agents at low doses may be
used). Because they can mask symptoms of hypoglycemia,
beta blockers should be used with caution in patients with
insulin-dependent diabetes mellitus. Abrupt beta-blocker
withdrawal should be avoided because heightened beta-
receptor density and sensitivity can result in a rebound
phenomenon associated with an increased risk for AMI and
sudden death. If withdrawal is necessary, beta blockers
should be tapered over a 1- to 3-week period, with consid-
eration given to use of sublingual nitroglycerin or substitu-
tion with a nondihydropyridine calcium channel blocker
during the withdrawal period.
The principle adverse effects of beta blockers are fatigue,
exercise intolerance, lethargy, insomnia, nightmares, and
impotence.
4.4.2.3. RENIN-ANGIOTENSIN-ALDOSTERONE BLOCKER THERAPY
CLASS I
1. ACE inhibitors should be prescribed in all patients with SIHD who
also have hypertension, diabetesmellitus, LVEF 40% or less, or CKD,
unless contraindicated (295–298,301). (Level of Evidence: A)
2. ARBs are recommended for patients with SIHD who have hyperten-
sion, diabetes mellitus, LV systolic dysfunction, or CKD and have
indications for, but are intolerant of, ACE inhibitors (792–794).
(Level of Evidence: A)
CLASS IIa
1. Treatment with an ACE inhibitor is reasonable in patients with both
SIHD and other vascular disease (795,796). (Level of Evidence: B)
. It is reasonable to use ARBs in other patients who are ACE inhibitor
intolerant (797). (Level of Evidence: C) (Table 15)
A substantial body of evidence supports the concept that
ACE inhibitors have cardiovascular protective effects, re-
ducing the risks of future ischemic events. ACE inhibitors
result in a reduction in angiotensin II with an increase in
bradykinin. These changes in the physiological balance
between angiotensin II and bradykinin could contribute to
the reductions in LV and vascular hypertrophy, atheroscle-
rosis progression, plaque rupture, and thrombosis; the fa-
vorable changes in cardiac hemodynamics; and the im-
proved myocardial oxygen supply/demand that result from
treatment with ACE inhibitors and ARBs (798–801).
Clinical studies have demonstrated significant reductions in
the incidence of AMI, UA, and the need for coronary
revascularization in patients after MI with LV dysfunction,
independent of etiology (559,561,801).
The benefits of ACE inhibitors extend to patients with
IHD in the absence of LV dysfunction. In patients with
atherosclerotic vascular disease or diabetes mellitus and at
least 1 other IHD risk factor, the HOPE (Heart Outcomes
Prevention Evaluation) study (301) showed that compared
with placebo, ramipril significantly decreased the primary
composite endpoint of cardiovascular death, AMI, and
stroke by 22% (301). MICRO-HOPE (Microalbuminuria,
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HOPE, additionally showed, in middle-aged patients with
diabetes mellitus who were at high risk for cardiovascular
events, significant reductions in MI by 22%, stroke by 33%,
cardiovascular death by 37%, and the combined primary
event outcome by 25% (802). Furthermore, the need for
revascularization and incidence of worsening angina also
were significantly reduced. The EUROPA (European trial
on Reduction Of cardiac events with Perindopril in stable
coronary Artery disease) trial provided added support to the
HOPE trial results in patients with SIHD without clinical
evidence of heart failure (296). In 12,218 patients followed
up for a mean of 4.2 years, there was a 20% relative increase
in the time to the primary composite endpoint of cardio-
vascular death, nonfatal MI, or cardiac arrest with perindo-
pril compared with placebo (296). Perindopril was further
tested in the PEACE (Prevention of Events with
Angiotensin-Converting Enzyme Inhibitor) trial, which
enrolled 4,158 patients with SIHD and normal or slightly
reduced LV function (i.e., absence of LV wall-motion
abnormalities) (295). The incidence of the primary endpoint
of death from cardiovascular causes, MI, or coronary revas-
cularization was equivalent between perindopril and pla-
cebo, but the overall rate of cardiovascular events was lower
than in the HOPE and EUROPA trials. Equivalent results
were seen in HOPE and EUROPA when examined by age,
sex, known IHD, LV function, previous MI, hypertension,
or diabetes mellitus. In QUIET (Quinapril Ischemic Event
Trial), there was also no significant reduction with quinapril
in ischemic events and progression of CAD in coronary
angioplasty patients without systolic LV dysfunction (RR:
13%; p0.49), although this finding has been attributed to
study design limitations (797). Similarly, the IMAGINE
(Ischemia Management With Accupril Post-Bypass Graft
via Inhibition of the Converting Enzyme) study demon-
strated no reduction in clinical outcomes in low-risk pa-
tients (LVEF 40%) with quinapril after surgical revascu-
larization (803). In a meta-analysis of ACE-inhibitor
therapy versus placebo in 31,555 patients from HOPE,
EUROPA, PEACE, and QUIET, ACE-inhibitor therapy
produced 14% reductions in all-cause mortality and MI
(both p0.0004), a 23% reduction in stroke (p0.0004),
and a 7% reduction in revascularization procedures
(p0.025) compared with placebo (796).
Although the cited studies involved a variety of ACE
inhibitors that differ with regard to structure, bioavailability,
potency, receptor-binding characteristics, tissue distribu-
tion, metabolism, and excretion properties, there is little
evidence that these differences are associated with therapeu-
tic advantages. Because the benefits of ACE inhibitors seem
to reflect a class effect, the selection of a particular agent can
be based on such factors as availability in local formularies,
cost, and tolerability.
ACE inhibitors are recommended for all patients with
SIHD and hypertension, diabetes mellitus, LV dysfunction
(EF 40%), or CKD. Also included in the HOPE (301) orEUROPA (296) trials were participants who did not have
one of these conditions but did have multiple cardiac risk
factors, and it seems that they also benefited from use of
ACE inhibitors (797).
ARBs also play an important role in vascular protection.
They bind in a competitive or insurmountable manner to
the type 1 angiotensin II receptor, increasing plasma renin
activity, plasma renin, and angiotensin I and II concentra-
tions. In patients with hypertension or cardiovascular dis-
ease, ARBs produce reductions in BP equivalent to those
achieved with ACE inhibitors (804). These agents signifi-
cantly reduce LV mass and stroke incidences compared with
beta blockers and improve outcomes in diabetic nephropa-
thy and heart failure (563,565,792,805). A meta-regression
analysis of 26 trials compared the effects of ACE inhibitors
and ARBs on major vascular events by BP effects (804).
reatment with ACE inhibitor–based regimens was asso-
iated with a reduction in the risk for stroke (by 19%), IHD
by 16%), and heart failure (by 27%) for each 5–mm Hg
eduction in BP; corresponding figures for the reduction in
isk for ARBs were 26%, 17%, and 12%, respectively. There
ere no significant differences between ARB- and ACE
nhibitor–based regimens in the risk of stroke, IHD, and
eart failure for each 5–mm Hg reduction in BP. When
hese outcomes were assessed at zero BP reduction, the risk
eduction for IHD was significantly greater for ACE
nhibitors than for ARBs (p0.002). Furthermore, unlike
RBs, ACE inhibitors were associated with a significant
dditional risk reduction for IHD of 9% (p0.004), without
ifferences seen for stroke or heart failure versus ARBs. It is
herefore recommended that ARBs be substituted for ACE
nhibitors in patients with SIHD and hypertension who are
ntolerant of ACE inhibitors (563,565,792,804,805).
4.4.2.4. INFLUENZA VACCINATION
CLASS I
1. An annual influenza vaccine is recommended for patients with SIHD
(806–810). (Level of Evidence: B)
In patients with chronic medical conditions such as cardio-
vascular disease, influenza contributes to a higher risk for
mortality and hospitalization and exacerbates underlying
medical conditions. The World Health Organization and
the AHA/ACCF recommend annual vaccination with in-
activated vaccine (administered intramuscularly) against
seasonal influenza to prevent all-cause mortality and mor-
bidity in patients with underlying cardiovascular conditions
(806,807). A cohort study in 1,340 elderly (i.e.,65 years of
age) patients with heart failure or IHD showed that annual
influenza vaccinations reduced the risk of mortality by 37%
during the winter period (January through April), but not
the summer period (June through September), resulting in a
number needed to treat to prevent 1 death during 1
influenza period of 122 annual vaccinations (808). Further
mechanistic and confirmatory studies in heart failure and
other cardiovascular disease are needed to confirm these
findings. Evidence from 2 prospective randomized clinical
34
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stable supports increasing influenza vaccine doses to achieve
higher serum antibody titers and potentially improved
protection from influenza infection (809,810). This dosing
scheme was associated with higher injection site reactions,
including pain and myalgias. Currently, it is recommended
that patients with SIHD receive an annual influenza vacci-
nation in the standard dose.
4.4.2.5. ADDITIONAL THERAPY TO REDUCE RISK OF MI AND DEATH
CLASS III: No Benefit
1. Estrogen therapy is not recommended in postmenopausal women
with SIHD with the intent of reducing cardiovascular risk or improv-
ing clinical outcomes (811–814). (Level of Evidence: A)
2. Vitamin C, vitamin E, and beta-carotene supplementation are not
recommended with the intent of reducing cardiovascular risk or
improving clinical outcomes in patients with SIHD (398,527,815–
818,818). (Level of Evidence: A)
. Treatment of elevated homocysteine with folate or vitamins B6 and
B12 is not recommended with the intent of reducing cardiovascular
risk or improving clinical outcomes in patients with SIHD (819–
822). (Level of Evidence: A)
. Chelation therapy is not recommended with the intent of improving
symptoms or reducing cardiovascular risk in patients with SIHD
(823–826). (Level of Evidence: C)
. Treatment with garlic, coenzyme Q10, selenium, or chromium is not
recommended with the intent of reducing cardiovascular risk or
improving clinical outcomes in patients with SIHD. (Level of Evi-
dence: C)
4.4.2.5.1. HORMONE REPLACEMENT THERAPY. Numerous
bservational studies have suggested that estrogen therapy
ight provide protection against the development of IHD
n postmenopausal women (827–829). Beneficial effects of
xogenous estrogen include an increase in HDL cholesterol,
decrease in LDL cholesterol, and enhanced endothelial
unction (830–833). In light of the epidemiological data
nd evidence of salutary physiological effects, postmeno-
ausal estrogen replacement previously was advocated for
he primary and secondary prevention of CAD in women.
linical trials in women with and without established
AD, however, have failed to confirm a decrease in cardio-
ascular events with hormone therapy. In HERS (Heart and
strogen/progesterone Replacement Study), 2,763 post-
enopausal women with CAD were randomized to therapy
ith 0.625 mg of conjugated estrogen plus 2.5 mg of
edroxy progesterone acetate or placebo and were followed
p for an average of 4.4 years. Despite an 11% lower level of
DL cholesterol and a 10% higher level of HDL cholesterol
n the hormone therapy group, there was no difference in
he composite primary endpoint of MI or IHD death, and
n early increase in cardiovascular events was observed
811). In HERS-II, an unblinded follow-up study of
ERS, the lack of benefit with estrogen/progestin therapy
ersisted at an average of 6.8 years (834). A subsequent
ngiographic study demonstrated a nonsignificant worsen-
ng of coronary stenoses in patients prescribed estrogen
herapy (835). The Women’s Health Initiative, a random- tzed controlled primary prevention trial, also found no
vidence that estrogen protects against IHD (812–814).
hus, the weight of current scientific evidence suggests that
strogen/progestin therapy in postmenopausal women does
ot reduce the risk of vascular events or coronary deaths in
econdary prevention. Women who are taking estrogen
herapy and who have vascular disease can continue this
herapy if it is prescribed for other well-established indica-
ions and if no better alternative therapies are appropriate,
lthough the FDA recommends use in the lowest dose and
hortest duration acceptable. There is, however, no basis for
dding or continuing estrogens in postmenopausal women
ith clinically evident SIHD in an effort to prevent or retard
rogression of their atherosclerotic disease.
4.4.2.5.2. VITAMIN C, VITAMIN E, AND BETA-CAROTENE.
Epidemiological and population studies have suggested that
antioxidant vitamins, such as vitamin E, vitamin C, and
beta-carotene, could lower cardiovascular risk (836,837).
Controlled clinical trials, however, have failed to demon-
strate a beneficial effect of antioxidant supplements on risk
of cardiovascular morbidity and mortality (398,527,815–
817). A meta-analysis of antioxidant vitamin studies exam-
ined 7 trials of vitamin E treatment and 8 trials of
beta-carotene treatment with1,000 subjects in each. Most
of these studies were performed in patients with CAD or at
risk of CAD. Vitamin E had no effect on all-cause mortality
or cardiovascular death (838). Beta-carotene led to a small
but statistically significant increase in all-cause mortality
and cardiovascular death. Thus, existing scientific evidence
does not justify routine use of antioxidant supplements for
the prevention or treatment of cardiovascular disease.
4.4.2.5.3. FOLATE AND VITAMINS B6 AND B12. Prospective ob-
ervational studies have demonstrated that the serum ho-
ocysteine level is a strong, independent risk factor for
schemic events (839–841). Homocysteine levels can be
owered with folic acid or B-vitamins. Trials of folate and
itamin B supplementation, however, consistently have
ailed to demonstrate a decrease in cardiovascular morbidity
r mortality rates. The VISP (Vitamin Intervention for
troke Prevention) trial randomized patients with prior
ondisabling stroke to varying doses of folic acid, B6, and
12. Despite a reduction in homocysteine that was 2
mol/L greater in the group allocated to the high dose of
upplementation, there were no differences in the incidence
f recurrent stroke, IHD, or death (822). Similarly, the
OPE 2 (Heart Outcome in Prevention) trial found no
enefit of folate and vitamins B6 and B12 in patients with
ascular disease or diabetes mellitus (821). The NORVIT
Norwegian Vitamin Trial) examined 3 combinations of
olate and B vitamins in patients who had an AMI and
bserved no decrease in the risk of cardiovascular events
820). A meta-analysis of these and 9 other smaller trials
lso found no reduction in cardiovascular events or mortality
ith folate supplementation (819). These studies indicatehat routine use of folate and B vitamins for the prevention
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recommended.
4.4.2.5.4. CHELATION THERAPY. Chelation therapy, which
onsists of a series of intravenous infusions of disodium
thylene diamine tetraacetic acid (EDTA) in combina-
ion with other substances, has been promoted as a
oninvasive means of improving blood flow in athero-
clerotic vessels. EDTA combines with polyvalent cat-
ons, such as calcium ions, to form soluble complexes that
an be excreted. Advocates maintain that this process can
esult in regression of atherosclerotic plaques and relief of
ngina and that EDTA reduces oxidative stress in the
ascular wall.
Anecdotal reports have suggested that EDTA chelation
herapy can result in relief of angina in patients with SIHD.
n general, however, the efficacy of chelation therapy in
therosclerotic disease is not supported by clinical trials.
tudies in patients with intermittent claudication have failed
o demonstrate improvements in exercise measures
823,824), ankle-brachial index (823,824), or digital sub-
raction angiograms with chelation (825). The only RCT
xamining the effectiveness of chelation therapy on SIHD
826) studied 84 patients with stable angina and a positive
readmill test for ischemia. Those randomized to active
herapy received weight-adjusted disodium EDTA chela-
ion therapy for 3 hours per treatment, twice weekly for 15
eeks and then once monthly for an additional 3 months.
here were no differences between groups in changes in
xercise time to ischemia, exercise capacity, or quality-of-
ife scores. The National Center of Complementary and
lternative Medicine and the National Heart, Lung, and
lood Institute have sponsored TACT (Trial to Assess
helation Therapy) (842), an RCT comparing chelation to
lacebo in patients who had experienced an MI. There is
nsufficient evidence to support chelation therapy for im-
roving symptoms or preventing adverse outcomes in pa-
ients with SIHD. Moreover, this therapy is costly and time
onsuming, can result in harm, and could result in patients
ailing to pursue proven treatment strategies.
4.4.2.5.5. GARLIC, COENZYME Q10, SELENIUM, AND CHROMIUM.
Nutritional supplements for the prevention and treatment of
cardiovascular disease have grown increasingly popular in
the United States. These alternative therapies often are
promoted with anecdotal claims of efficacy but have not
been studied rigorously. When data are available, they often
conflict and consist of results of small, open-label trials. At
present, there is no definitive evidence to recommend
treatment with garlic, coenzyme Q10, selenium, or chro-
mium for improving cardiovascular outcomes in patients
with SIHD.
4.4.3. Medical Therapy for Relief of Symptoms
4.4.3.1. USE OF ANTI-ISCHEMIC MEDICATIONS: RECOMMENDATIONS
CLASS I
1. Beta blockers should be prescribed as initial therapy for relief ofsymptoms in patients with SIHD (757,765,766). (Level of Evidence: B). Calcium channel blockers or long-acting nitrates should be pre-
scribed for relief of symptoms when beta blockers are contraindi-
cated or cause unacceptable side effects in patients with SIHD
(420,768,769). (Level of Evidence: B)
. Calcium channel blockers or long-acting nitrates, in combination
with beta blockers, should be prescribed for relief of symptoms
when initial treatment with beta blockers is unsuccessful in patients
with SIHD (420). (Level of Evidence: B)
. Sublingual nitroglycerin or nitroglycerin spray is recommended for
immediate relief of angina in patients with SIHD (843–845). (Level
of Evidence: B)
CLASS IIa
1. Treatment with a long-acting nondihydropyridine calcium channel
blocker (verapamil or diltiazem) instead of a beta blocker as initial
therapy for relief of symptoms is reasonable in patients with SIHD
(420). (Level of Evidence: B)
2. Ranolazine can be useful when prescribed as a substitute for beta
blockers for relief of symptoms in patients with SIHD if initial
treatment with beta blockers leads to unacceptable side effects or
is ineffective or if initial treatment with beta blockers is contraindi-
cated (846). (Level of Evidence: B)
. Ranolazine in combination with beta blockers can be useful when
prescribed for relief of symptoms when initial treatment with beta
blockers is not successful in patients with SIHD (847,848). (Level of
Evidence: A)
4.4.3.1.1. BETA BLOCKERS. Beta blockers are recommended
as the initial agents to relieve symptoms in most patients
with SIHD. Beta blockers reduce myocardial oxygen con-
sumption by reducing heart rate, myocardial contractility,
and afterload, with attenuation of cardiovascular remodeling
by decreasing LV wall tension with long-term use. The
reduction in myocardial oxygen demand is directly propor-
tional to the level of adrenergic tonic stimulation. Further-
more, the reduction in heart rate also shifts the cardiac cycle,
permitting more diastolic time and greater coronary perfu-
sion, thereby improving myocardial oxygen supply.
Long-term beta-blocker treatment is well tolerated, has
proven benefit in SIHD by reducing ischemic burden and
threshold, and improves survival in patients with LV dysfunc-
tion or history of MI (757,765,766). When prescribed in
combination with agents that block the renin-angiotensin-
aldosterone system, beta blockers are the preferred agents
for the treatment of angina in patients with LV dysfunction
after MI and in patients with heart failure, on the basis of
documented improvements in survival and ventricular per-
formance (402,571,760,792,801).
A meta-analysis of comparison trials between beta block-
ers and calcium channel blockers (dihydropyridine and
nondihydropyridine agents) showed negligible differences in
the rate of death or MI over relatively brief durations of
administration (i.e., 6 wk to 6 mo), although patients with
heart failure, heart block, or significant pulmonary disease
were excluded from the meta-analysis (420). Beta blockers
were found to exhibit an advantage with regard to control of
angina and withdrawals from therapy due to adverse events,
a problem that was most pronounced with nifedipine (420).
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improve survival after MI, as beta blockers have, but have
been shown to offer protection against severe angina and to
reduce the risk of reinfarction after MI (849–851).
Adherence to beta-blocker therapy can be influenced by
the occurrence of adverse effects such as fatigue, lethargy,
sexual dysfunction, or sleep disturbances. Although beta
blockers have the potential to worsen symptoms in patients
with significant depressive illness or PAD, these effects are
observed rarely in clinical practice. For patients with severe
PAD or those with vasospastic (Prinzmetal’s) angina, wors-
ening symptoms due to vasoconstriction from unopposed
alpha-adrenergic activity can be avoided by using beta
blockers with alpha-adrenergic blocking (e.g., labetalol or
carvedilol) or direct vasodilator (e.g., nebivolol) properties.
4.4.3.1.2. CALCIUM CHANNEL BLOCKERS. If adverse effects or
ontraindications limit the use of beta blockers, calcium
hannel blockers are recommended for relief of anginal
ymptoms. These agents noncompetitively limit calcium ion
nflux through voltage-dependent L-type calcium channels,
esulting in negative inotropic effects, cardiac pacemaker
epression, slowing conduction, and smooth muscle relax-
tion. There are 3 classes of calcium channel blockers: the
ihydropyridines (e.g., nifedipine) and 2 types of nondihy-
ropyridines, the phenylalkylamines (e.g., verapamil) and
he benzothiazepines (e.g., diltiazem). All classes improve
yocardial oxygen supply by decreasing coronary vascular
esistance and augmenting epicardial conduit vessel and
ystemic arterial blood flow. Myocardial demand is de-
reased by a reduction in myocardial contractility, systemic
ascular resistance, and arterial pressure. However, the
henylalkylamines and, to a lesser extent, the benzothiaz-
pines also depress cardiac pacemaker rate and slow con-
uction. This depressant effect can cause sinus bradycardia
r can worsen preexisting conduction defects, leading to
eart block. Myocardial contractile depression also is a
ommon feature, although the degree is variable according
o drug class. As a result of these pharmacological proper-
ies, the calcium channel blockers are effective anti-ischemic
rugs, but their use must be individualized (852,853).
All classes of calcium channel blockers reduce anginal
pisodes, increase exercise duration, and reduce use of
ublingual nitroglycerin in patients with effort-induced an-
ina (854–856). Because all 3 classes also reduce the
requency of Prinzmetal’s variant angina, they are the drugs
f choice, along with nitrates, used alone or in combination
857–859).
Because the 3 classes seem to be equally efficacious in
reating angina, the choice of a particular agent should be
ased on potential drug interactions and adverse events. The
ihydropyridine class is preferred over other calcium chan-
el blockers in patients with cardiac conduction defects such
s sick sinus syndrome, sinus bradycardia, or significant AV
onduction disturbances. Dihydropyridines should be used
ith caution in patients with severe aortic valve stenosis.
hort-acting dihydropyridines in patients with fixed lesionsan exacerbate angina, possibly by excessive lowering of
rterial pressure with reflex tachycardia, and therefore
hould be avoided. Short-acting nifedipine seems to in-
rease mortality in patients with hypertension (860), but
here is currently no evidence that these concerns apply to
xtended-release preparations (861,862). Because of their
ffects on contractility, none of the calcium channel blockers
re recommended for routine treatment of patients with
urrent or prior symptoms of heart failure and a reduced
VEF (21).
Many drug interactions associated with calcium channel
lockers occur because of rapid absorption or low bioavail-
bility due to high first-pass metabolism by the cytochrome
450 (i.e., CYP3A4) system. These pharmacokinetic prop-
rties result in high intraindividual and interindividual
ariability, necessitating dosage adjustment. These drugs
hould be used with caution when combined with cyclo-
porine, carbamazepine, lithium carbonate, amiodarone, or
igoxin (i.e., 50% to 70% increase in digoxin concentrations
n first week of therapy). Combining verapamil or diltiazem
ith beta blockers generally should be avoided because of
otentially profound adverse effects on AV nodal conduc-
ion, heart rate, or cardiac contractility.
Overall, calcium channel blockers, particularly diltiazem,
re well tolerated. The major adverse effects of dihydropyri-
ines are related to vasodilation and systemic hypotension,
ncluding headache, dizziness, palpitations, and flushing.
any patients experience peripheral edema because of
xcessive arterial vasodilation unmatched to venous dilation.
erapamil can cause constipation that can be severe, par-
icularly in the elderly.
4.4.3.1.3. NITRATES. Nitrates are effective in the treatment of
all forms of angina. They relax vascular smooth muscle in
the systemic arteries, inclusive of the coronary arteries, and
veins (predominant effect at lower doses) in patients with
SIHD. Short-term continuous nitroglycerin delivery by the
intravenous or transdermal route for only 2 to 4 hours
protects the endothelium from experimental ischemia in
healthy volunteers and reduces ischemia during coronary
angioplasty and physical exercise in IHD patients (863–
865). Oxygen free radical release seems to be associated with
these protective outcomes. Nitroglycerin causes dilation of
the artery wall not affected by plaque, but independent of an
intact endothelium, leading to reduced resistance across the
obstructed lumen (866). Furthermore, nitroglycerin con-
tributes to coronary blood flow redistribution, by augment-
ing collateral flow and lowering ventricular diastolic pres-
sure, from areas of normal perfusion to ischemic zones
(867). Preload is reduced, leading to reductions in myocar-
dial wall tension and myocardial oxygen demand, although
this effect is offset by increased heart rate and myocardial
contractile state due to reflex sympathetic activity. Nitro-
glycerin also has demonstrated antithrombotic and anti-
platelet effects (868,869).
Long-term nitrate therapy, however, could offset the
beneficial short-term ischemic preconditioning effects.
e102 Fihn et al. JACC Vol. 60, No. 24, 2012
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thelial dysfunction via accumulation of the same oxygen free
radicals that seem to be beneficial in short-term administration
(870,871). The oxygen free radical accumulation increases
arterial sensitivity to vasoconstrictors such as angiotensin II,
which can be counteracted by concomitant treatment with
an ACE inhibitor or hydralazine (872–875). Importantly,
these physiological changes are independent of dose or the
presence or absence of a nitrate-free interval and can result
in a decrease in the anginal threshold during the nitrate-free
interval (876). Further research to better understand the
balance between the long-term benefits and safety concerns
of these compounds is warranted in patients with SIHD.
Despite these physiological observations, nitrates improve
exercise tolerance, time to ST-segment depression, and time
to onset of angina in patients with SIHD, albeit in small
patient studies conducted for relatively short periods (876–
878). Comparisons of nitrates to beta blockers or calcium
channel blockers have not shown significant differences with
regard to weekly anginal episodes, time to ST-segment
depression, total exercise time, or sublingual nitroglycerin
use (420). Withdrawal for adverse effects was also not
statistically different between the drug classes.
All patients with SIHD should be prescribed sublingual
nitroglycerin tablets or nitroglycerin spray for immediate
relief of angina. Most patients respond within 5 minutes of
taking 1 to 2 sublingual dose(s) of 0.3 to 0.6 mg. Nitro-
glycerin spray is available in a 0.4-mg metered-dose canister
that dispenses 200 doses. The tablets should be placed under
the tongue and not swallowed. If the spray is used, it should
be applied to the tongue and not swallowed or inhaled. If
additional doses are necessary, they should be taken at
5-minute intervals, for a maximum dose of 1.2 mg within
15 minutes. During this timeframe, if relief does not occur,
the patient should seek immediate medical attention. These
products are also effective for prevention of effort-induced
angina when administered 5 to 10 minutes before activity,
with relief lasting approximately 30 to 40 minutes. The
tablets must be kept in the manufacturer’s bottle (loss of
potency can occur in a few hours if out of the bottle) and
should be stored in a cool, dry place but should not be
refrigerated. The tablets should not be used 6 to 12 months
after opening the bottle. Patients usually are able to detect
when tablets have lost potency by the absence of a burning
sensation beneath the tongue. Nitroglycerin ointment also
may be used for short-term relief of angina. Applied to the
chest in doses of 0.5 to 2.0 inches, with a delay in relief of
30 minutes, this preparation can be effective for 4 to 6 hours.
Absorption can be increased by rotating the application
sites, covering the paste with plastic, or not applying the
ointment continuously (i.e., maintenance of a nitrate-free
interval) (879–881). All short-acting nitrate preparations
can cause hypotension, sometimes severe, and headaches
that limit adherence to these agents. Patients should be
counseled about these adverse effects and advised to seek
medical treatment if syncope or resistant chest pain occurs.The ointment can cause permanent discoloration of
clothing.
Long-acting nitrate preparations (e.g., nitroglycerin,
isosorbide dinitrate, isosorbide-5-mononitrate) are recom-
mended for treatment of angina when initial therapy with a
beta blocker or nondihydropyridine calcium channel blocker
is contraindicated or poorly tolerated or when additional
therapy to control angina is necessary. Isosorbide dinitrate
undergoes rapid high first-pass metabolism, resulting in low
bioavailability. However, substantial interpatient variability
exists in the metabolic enzyme systems responsible for
isosorbide dinitrate conversion. Isosorbide mononitrate, the
active metabolite of the dinitrate formulation, is 100%
bioavailable. Nitroglycerin also can be delivered through
silicone gel or polymer matrix release patch systems. The
rate of release varies between these systems, necessitating
individualization of dosing. With all formulations, titration
of dose is important to gain adequate anginal control with
the lowest possible dose to limit the occurrence of head-
aches, avoid nitrate tolerance, and facilitate long-term
adherence. The effectiveness of all of these formulations
seems to be roughly equivalent despite differences in the
preparation and dosing schedules (843,882). With all of
them, it is necessary to maintain a daily nitrate-free interval
of 10 to 14 hours to avoid development of nitrate tolerance
(843). Nitrate tolerance does not develop with the sublin-
gual route of administration. Use of long-acting nitrates also
does not result in tolerance to the use of sublingual products.
Nitrates are relatively well tolerated if a titration schedule
is used at initiation and with discontinuation. The most
common side effects are headache, flushing, and hypoten-
sion. Patients should be instructed to remain seated when
taking rapid-acting nitrate products as a safety precaution to
avoid syncope from vasodilation. Tolerance to the head-
aches could develop after a few weeks of continuing the
medication. Prophylactic analgesics can be helpful until
headache tolerance develops. Methemoglobinemia is a rare
adverse effect, usually seen only with large doses. Nitrates
are relatively contraindicated in hypertrophic obstructive
cardiomyopathy because of the potential to increase the
outflow tract obstruction and mitral regurgitant flow. They
should be avoided in patients with severe aortic valvular
stenosis. Coadministration of the phosphodiesterase inhib-
itors sildenafil, tadalafil, or vardenafil with long-acting
nitrates should be strictly avoided within 24 hours of nitrate
administration because of the risk of profound hypotension
(e.g., 25–mm Hg drop in systolic BP). Patients should be
advised not to take phosphodiesterase inhibitors within 24
hours of long-acting nitrates, and nitrates should not be
taken for 24 hours after use of sildenafil or 48 hours after
tadalafil; a suitable time interval after vardenafil has not
been determined. Patients should be made aware of the
possibility of intensification of their angina if nitrates are
discontinued abruptly. This effect could be reduced by
concomitant administration of other antianginals or by
tapering of the long-acting nitrate dosage.
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odium current, indirectly reducing the sodium-dependent
alcium current during ischemic conditions and leading to
mprovement in ventricular diastolic tension and oxygen
onsumption. Minimal changes in mean heart rate (2
eats per minute) and systolic BP (3 mm Hg) occur in
ontrolled studies. At maximal exercise, the rate–pressure
roduct is not increased, independent of age, or in the
resence of diabetes mellitus, reactive airway disease, or
eart failure (883). Ranolazine is currently indicated for the
reatment of chronic angina and may be used in combina-
ion with beta blockers, nitrates, dihydropyridine calcium
hannel blockers, ACE inhibitors, ARBs, and antiplatelet
nd lipid-lowering therapy. It should be prescribed only in
ow doses in combination with verapamil or diltiazem, as
escribed later. The lack of an effect on BP and heart rate
akes ranolazine an attractive alternative in patients with
radycardia or low BP. Although ranolazine has been well
tudied in SIHD, the agent was not administered in the
OURAGE (Clinical Outcomes Utilizing Revasculariza-
ion and Aggressive Drug Evaluation) study (366), and
urther clinical evaluation is needed, especially of ranolazine
s an element of intensive interventions for multiple risk
actors.
The ranolazine extended-release preparation reduces the
requency of angina, improves exercise performance, and
elays the development of exercise-induced angina and
T-segment depression (847,884). In one study, ranolazine
educed weekly anginal frequency by 36% and nitroglycerin
se by 43% in comparison with placebo (848). Other studies
ndicated that among patients with ACS, ranolazine did not
educe the incidence of MI or death (885) but did reduce
ecurrent ischemia in the postinfarction period (886). In
atients with preexisting angina, it was superior to placebo in
mproving patients’ angina and quality of life (887). Ranolazine
ould exert a beneficial effect on glycemic control and has
emonstrated consistent reductions in HbA1c in patients with
iabetes mellitus in 2 studies (883,888,889).
Ranolazine blocks the delayed rectifier potassium current
nd prolongs the QTc interval in a dose-related manner,
esulting in a mean increase in QTc of approximately 6 msec
t maximal recommended dosing. Currently, there is limited
xperience with concomitant administration of ranolazine and
ther drugs that prolong the QT interval, including Class IA
nd III antiarrhythmics and certain antipsychotics (thiorid-
zine and ziprasidone). In 3,162 patients with ACS, there
as no increased risk of proarrhythmia or sudden death. In
his study, there was a significantly lower incidence of
rrhythmias, including ventricular tachycardia, bradycardia,
upraventricular tachycardia, and new atrial fibrillation, in
atients treated with ranolazine (80%) versus placebo (87%)
883,885,890,891).
Ranolazine does not require dose adjustment for age, sex,
ew York Heart Association class I–IV heart failure, or
iabetes mellitus. Plasma concentrations of ranolazine are
ncreased by up to 50% in patients with Stage 4 CKDcreatinine clearance 30 mL/min) (892). The drug is
ontraindicated in patients with clinically significant hepatic
mpairment because of increased plasma concentrations and
T prolongation. In general, dosing in the elderly should
tart at the low end of the dosing range (883).
Ranolazine is contraindicated in combination with potent
nhibitors of the CYP3A4 pathway, including ketoconazole
3.2-fold increase in ranolazine plasma levels) and other
zole antifungals, macrolide antibiotics, HIV (human im-
unodeficiency virus) protease inhibitors, grapefruit prod-
cts or juice, diltiazem (1.8- to 2.3-fold increase in ranola-
ine plasma levels), itraconazole, clarithromycin, and certain
IV protease inhibitors. When administered with moder-
te inhibitors of CYP3A such as diltiazem, verapamil,
prepitant, erythromycin, fluconazole, or grapefruit juice,
he dose of ranolazine should be limited to 500 mg twice
aily because of an approximately 2-fold increase in rano-
azine plasma levels. No dose adjustment is required in
atients treated with cimetidine or paroxetine. Coadminis-
ration of ranolazine (1,000 mg twice daily) with simvastatin
ncreases the plasma concentration of simvastatin and its
ctive metabolite 2-fold. Digoxin plasma concentrations are
ncreased 1.5-fold, but this interaction might not be
linically relevant with lower digoxin dosing (0.125 mg
aily). Coadministration of ranolazine with drugs that
nhibit CYP2D6, with the exceptions of tricyclic antide-
ressants and some antipsychotics, does not require
osage adjustment.
Ranolazine is well tolerated; the major adverse effects are
onstipation, nausea, dizziness, and headache. The inci-
ence of syncope is 1%.
4.4.3.1.5. ANTIANGINAL AGENTS NOT CURRENTLY AVAILABLE
N THE UNITED STATES
4.4.3.1.5.1. Nicorandil. Nicorandil is a nicotinamide ester
with a dual mechanism of action. It activates adenosine
triphosphate–sensitive potassium channels and promotes
systemic venous and coronary vasodilation through a nitrate
moiety (893). This dual action increases coronary blood
flow, with reductions in afterload, preload, and oxidative
injury (893). The agent does not exhibit effects on contrac-
tility or conduction (894,895). The antianginal efficacy and
safety of nicorandil are similar to those of oral nitrates, beta
blockers, and calcium channel blockers (893,896,897). In a
prospective, randomized, study of 5,126 patients with
chronic stable angina, the addition of nicorandil to standard
therapy was found to produce a 17% RR reduction in the
composite endpoint of IHD death, nonfatal MI, or un-
planned hospital admission for cardiac chest pain (898).
There was, however, no difference between nicorandil and
placebo with regard to death from IHD or nonfatal MI
(894). Tolerance can develop with long-term dosing (899).
Common side effects include flushing; palpitation; weak-
ness; headache; ulceration of the mouth, perianal, ileal, and
peristomal areas; nausea; and vomiting. The agent is not
currently available in the United States.
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the If current of pacemaker cells in the sinoatrial node at
concentrations that do not inhibit other cardiac currents
(900). This action results in heart rate reduction, pro-
longing diastole and thereby improving myocardial oxy-
gen balance. Ivabradine has no effect on BP, myocardial
contractility, or intracardiac conduction parameters (901–
903). Ivabradine improves exercise capacity and reduces
anginal frequency in comparison to atenolol among
patients with chronic stable angina (904,905). In 5,479
patients with IHD and LV systolic dysfunction, however,
ivabradine added to standard treatment had no effect,
when compared with placebo, on the composite endpoint
of cardiovascular death, admission to the hospital for
AMI, and admission to the hospital for new-onset or
worsening heart failure (906). The most common adverse
event, reported in 14.5% of patients, is phosphenes,
described as a transient enhanced brightness in a limited
area of the visual field that typically occurs within the first
2 months of treatment. Most of these luminous visual-
field disturbances (77%) resolve without discontinuing
treatment. The drug is approved in Europe (not currently
available in the United States) for the symptomatic
treatment of chronic stable angina in patients with
normal sinus rhythm with a contraindication or intoler-
ance to beta blockers.
4.4.3.1.5.3. Trimetazidine. Trimetazidine seems to improve
cellular tolerance to ischemia by inhibiting fatty acid me-
tabolism and secondarily by stimulating glucose metabo-
lism, although the exact anti-ischemic mechanisms are
unknown (907). In patients with chronic stable angina, this
agent increases coronary flow reserve, delaying the onset of
ischemia associated with exercise and reducing the number
of weekly angina episodes and weekly nitroglycerin con-
sumption (908,909). The anti-ischemic effects are not
associated with changes in heart rate or systolic BP. Few
data exist on the effect of trimetazidine on cardiovascular
endpoints, mortality, or quality of life. The most frequently
reported adverse events are gastrointestinal disorders, but
the incidence is low. The agent is not available in the United
States but is available in Europe and reportedly in 80
ountries worldwide.
.4.4. Alternative Therapies for Relief of Symptoms in
atients With Refractory Angina: Recommendations
CLASS IIb
1. Enhanced external counterpulsation (EECP) may be considered for
relief of refractory angina in patients with SIHD (910). (Level of
Evidence: B)
. Spinal cord stimulation may be considered for relief of refractory
angina in patients with SIHD (911,912). (Level of Evidence: C)
. Transmyocardial revascularization (TMR) may be considered for
relief of refractory angina in patients with SIHD (913–915). (Level ofEvidence: B)CLASS III: No Benefit
1. Acupuncture should not be used for the purpose of improving
symptoms or reducing cardiovascular risk in patients with SIHD
(916,917). (Level of Evidence: C)
TMR has been used as either a percutaneous or a surgical
procedure concomitant with CABG or as sole therapy in patients
with angina refractory to medical therapy (913–915,918), al-
though the mechanism by which it might be efficacious is
unknown (919,920). Early studies of the percutaneous
approach demonstrated no therapeutic benefit, and it was
promptly abandoned (921). When used as sole therapy by a
surgical approach, TMR is reserved for the patient with
incapacitating, medically refractory angina and no other
feasible therapeutic options. Proposed mechanisms of action
include stimulation of microcirculation, creation of myocar-
dial scarring, and denervation of ischemic myocardium
(922). Various energy sources have been used, including
carbon dioxide XeCl excimer and holmium:YAG lasers
(923–925). There is no convincing evidence that one energy
source is superior to the others. TMR also has been
combined with cardiac denervation by thoracic sympathec-
tomy (926).
Numerous single-center and a few multicenter random-
ized trials have been published that compare TMR with
medical therapy for relief of refractory angina (927–930).
Most have shown better angina relief with TMR but no
survival benefit. The exception is a single multicenter trial
that shows a survival benefit as well as better relief of angina
at 5 years (931). A 5-year follow-up of a multicenter,
prospectively randomized trial reported not only sustained
angina relief but also improved survival in CCS Class IV
angina, and patients with no additional options for therapy
who were randomized to sole-therapy TMR (931). A
meta-analysis of 7 RCTs involving 1,053 patients evaluated
the effect of TMR on survival and angina relief (932). The
conclusion was that at 1 year, TMR improved angina class
but not survival when used as the sole procedural interven-
tion compared with medical therapy alone. A number of
other series also have reported sustained angina relief and
improved quality of life in randomized patients receiving
TMR at 3 to 5 years after treatment (Section 5.10 for
additional information on TMR in revascularization).
A growing number of patients with SIHD have refractory
angina, defined as multivessel CAD with ischemia and
symptoms that cannot be controlled with medical therapy or
surgical or percutaneous revascularization. The prevalence
of this syndrome is not well established, but data from
registries suggest that about 10% of patients referred for
angiography for symptomatic SIHD have coronary anatomy
that is not amenable to revascularization (933–935). Other
nonpharmacological therapies may be considered in these
patients in an effort to improve quality of life.
4.4.4.1. ENHANCED EXTERNAL COUNTERPULSATION
EECP is a technique that uses inflatable cuffs wrapped
around the lower extremities to increase venous return and
d
a
a
p
a
a
r
9
c
8
r
t
1
p
m
i
E
8
i
r
d
t
e105JACC Vol. 60, No. 24, 2012 Fihn et al.
December 18, 2012:e44–e164 Stable Ischemic Heart Disease: Full Textaugment diastolic BP. The cuffs are inflated sequentially
from the calves to the thigh muscles during diastole and are
deflated instantaneously during systole. The resultant dia-
stolic augmentation increases coronary perfusion pressure,
and the systolic cuff depression decreases peripheral resis-
tance. Treatment is associated with improved LV diastolic
filling and improved endothelial function (936–938); other
putative mechanisms for improvement in symptoms include
recruitment of collaterals, release of proangiogenic cyto-
kines, and a peripheral training effect. A treatment course
typically consists of 35 hour-long treatment sessions, given
5 days a week. Contraindications include decompensated
heart failure, severe PAD, and severe aortic regurgitation.
The efficacy of EECP in treating stable angina pectoris
has been evaluated in a single RCT and several observa-
tional registry studies. In MUST-EECP (Multicenter
Study of Enhanced External Counterpulsation), 139 pa-
tients with angina, documented CAD, and evidence of
ischemia on exercise testing were randomized to 35 hours of
active counterpulsation or to inactive counterpulsation
(910). Time to 1-mm ST-segment depression increased
significantly in patients treated with active counterpulsation
(from 33718 s to 37918 s) compared with placebo (from
32621 s to 33020 s; p0.01), although there was no
ifference between the groups in exercise duration. More
ctive counterpulsation patients experienced a decrease in
nginal episodes. Of patients receiving EECP, 55% re-
orted adverse events, including leg and back pain and skin
brasions, compared with 26% in the control group, with
pproximately half of these events categorized as device
elated.
In a meta-analysis of 13 observational studies that tracked
49 patients, anginal class as categorized by the CCS
lassification was improved by 1 class in 86% (95% CI:
2% to 90%) (939). The EECP Consortium reported
esults in 2,289 consecutive patients undergoing EECP
herapy at 84 participating centers, including a subgroup of
75 patients from 7 centers who underwent radionuclide
erfusion stress tests before and after therapy (940). Treat-
ent was associated with improved perfusion images and
ncreased exercise duration. Similarly, the International
ECP Registry reported improvement of1 angina class in
1% of patients immediately after the last treatment (941).
In general, existing data, largely from uncontrolled stud-
es, suggest a benefit from EECP in patients with angina
efractory to other therapy. Additional data from well-
esigned RCTs are needed to better define the role of this
herapeutic strategy in patients with SIHD (942).
4.4.4.2. SPINAL CORD STIMULATION
Spinal cord stimulation at the T1 to T2 level has been
advocated as a therapeutic option for patients with angina
pectoris that is refractory to medical therapy and coronary
revascularization. The stimulation lead is inserted into the
epidural space and is connected to a pulse generator im-
planted subcutaneously. A paresthetic stimulus is deliveredin a continuous, cyclic, or intermittent manner. The mech-
anisms by which spinal cord stimulation leads to reduced
angina are not well established. Although inhibition of pain
transmission plays a role, some studies suggest that spinal
cord stimulation also might reduce myocardial ischemia
(943–945).
The efficacy of spinal cord stimulation has been evaluated
in several observational and cohort studies. The Prospective
Italian Registry described outcomes in 104 patients with
severe angina refractory to medical therapy over an average
of 13 months after initiation of spinal cord stimulation
(946). A 50% reduction in anginal symptoms was ob-
served in 73% of patients. CCS class improved by 1 class
in 80% and by 2 classes in 42% of patients. Similarly, in a
cohort of 51 patients with refractory CCS Class III or IV
angina, spinal cord stimulation was associated with a sig-
nificant reduction in anginal episodes in 88% of subjects at
24 months of follow-up (947). There were no significant
complications of therapy in either series.
The published RCTs of spinal cord stimulation were
small. One study tested the efficacy of spinal cord stimula-
tion in 13 patients with chronic, intractable angina com-
pared with 12 controls over 6 weeks (912). Patients with
spinal cord stimulation demonstrated greater exercise dura-
tion and time to angina during treadmill testing and fewer
bouts of angina and fewer episodes of ST depression on
ambulatory echocardiographic monitoring. A subsequent
trial compared spinal cord stimulation to CABG (911).
Subjects included 104 patients with severe angina who
would not be expected to derive survival benefit from
revascularization, were at increased risk of surgical compli-
cations, and were unsuitable for PCI. Patients in both
groups had significant symptom relief. Those assigned to
bypass surgery had greater increases in exercise capacity and
less ST depression on treadmill testing than did those
treated with spinal cord stimulation. Mortality and cardio-
vascular morbidity rates were lower in the spinal cord
stimulation group.
In summary, studies of spinal cord stimulation suggest
that this technique might have some use as a method to
relieve angina in patients with symptoms that are refractory
to standard medical therapy and revascularization. There is
a paucity of data on the mechanisms and long-term risks
and benefits of this therapeutic approach, however.
4.4.4.3. ACUPUNCTURE
Acupuncture is used by some practitioners for the relief of
acute and chronic pain. The efficacy of acupuncture in the
treatment of angina pectoris has not been studied rigorously,
however. In part this is due to the difficulty of blinding both
patients and healthcare providers. Twenty-six patients with
severe angina resistant to standard medical therapy were
studied in one of the first randomized trials comparing
acupuncture and sham acupuncture (917). There was no
difference between groups in the frequency of angina or use
of nitroglycerin, although patients treated with acupuncture
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A subsequent study by the same investigators in patients
with less severe ischemia failed to show a difference in either
exercise variables or subjective measures between acupunc-
ture and placebo patients (916). In contrast, a decrease in
anginal episodes and an increase in the workload required to
induce ischemia were observed with acupuncture in a
crossover study of 21 patients with stable angina. The
control condition in this trial was a pill placebo, however, so
neither subjects nor investigators were blinded (948).
In summary, acupuncture has not been studied suffi-
ciently to warrant recommendation as a treatment option
for relief of symptoms in patients with SIHD.
5. CAD Revascularization
Recommendations and text in this section are the result of
extensive collaborative discussions between the PCI and
CABG writing committees, as well as key members of the
SIHD and UA/NSTEMI writing committees. Certain
issues, such as older versus more contemporary studies,
primary analyses versus subgroup analyses, and prospective
versus post hoc analyses, have been carefully weighed in
designating COR and LOE; they are addressed in the
appropriate corresponding text. The goals of revasculariza-
tion for patients with CAD are to 1) improve survival and
2) relieve symptoms.
Revascularization recommendations in this section are
based predominantly on studies of patients with symptom-
atic SIHD and should be interpreted in this context. As
discussed later in this section, recommendations on the type
of revascularization are, in general, applicable to patients
with UA/NSTEMI. In some cases (e.g., unprotected left
main CAD), specific recommendations are made for pa-
tients with UA/NSTEMI or STEMI.
Historically, most studies of revascularization have been
based on and reported according to angiographic criteria.
Most studies have defined a “significant” stenosis as 70%
diameter narrowing; therefore, for revascularization deci-
sions and recommendations in this section, a “significant”
stenosis has been defined as 70% diameter narrowing
50% for left main CAD). Physiological criteria, such as
n assessment of FFR, have been used in deciding when
evascularization is indicated. Thus, for recommendations
bout revascularization in this section, coronary stenoses
ith FFR 0.80 can also be considered to be “significant.”
As noted, the revascularization recommendations have
een formulated to address issues related to 1) improved
urvival and/or 2) improved symptoms. When one method
f revascularization is preferred over the other for improved
urvival, this consideration, in general, takes precedence
ver improved symptoms. When options for revasculariza-
ion are discussed with the patient, he or she should
nderstand when the procedure is being performed in an
ttempt to improve symptoms, survival, or both.Although some results from the SYNTAX (Synergy
between Percutaneous Coronary Intervention with TAXUS
and Cardiac Surgery) study are best characterized as sub-
group analyses and “hypothesis generating,” SYNTAX
nonetheless represents the latest and most comprehensive
comparison of PCI and CABG (949,950). Therefore, the
results of SYNTAX have been considered appropriately
when formulating our revascularization recommendations.
Although the limitations of using the SYNTAX score for
certain revascularization recommendations are recognized,
the SYNTAX score is a reasonable surrogate for the extent
of CAD and its complexity and serves as important infor-
mation that should be considered when making revascular-
ization decisions. Recommendations that refer to SYNTAX
scores use them as surrogates for the extent and complexity
of CAD.
Revascularization recommendations to improve survival
and symptoms are provided in the following text and are
summarized in Tables 18 and 19. References to studies
omparing revascularization with medical therapy are pre-
ented when available for each anatomic subgroup. When
uch studies have been completed only for CABG, RCTs or
ohort studies comparing CABG with PCI are presented,
ut the LOE for PCI is downgraded.
ee Online Data Supplements 3 and 4 for additional data
egarding the survival and symptomatic benefits with CABG or
CI for different anatomic subsets.
5.1. Heart Team Approach to Revascularization
Decisions: Recommendations
CLASS I
1. A Heart Team approach to revascularization is recommended in
patients with unprotected left main or complex CAD (950–952).
(Level of Evidence: C)
CLASS IIa
1. Calculation of the STS and SYNTAX scores is reasonable in patients
with unprotected left main and complex CAD (949,950,953–957).
(Level of Evidence: B)
One protocol used in RCTs (950–952,958) often involves a
multidisciplinary approach referred to as the Heart Team.
Composed of an interventional cardiologist and a cardiac
surgeon, the Heart Team 1) reviews the patient’s medical
condition and coronary anatomy, 2) determines that PCI
and/or CABG are technically feasible and reasonable, and
3) discusses revascularization options with the patient before
a treatment strategy is selected. Support for using a Heart
Team approach comes from reports that patients with
complex CAD referred specifically for PCI or CABG in
concurrent trial registries have lower mortality rates than
those randomly assigned to PCI or CABG in controlled
trials (951,952).
The SIHD, PCI, and CABG guideline writing commit-
tees endorse a Heart Team approach in patients with
unprotected left main CAD and/or complex CAD in whom
the optimal revascularization strategy is not straightforward.
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Anatomic Setting COR LOE References
UPLM or complex CAD
CABG and PCI I—Heart Team approach recommended C (950–952)
CABG and PCI IIa—Calculation of STS and SYNTAX scores B (949,950,953–957)
UPLM*
CABG I B (73,381,412,959–962)
PCI IIa—For SIHD when both of the following are present:
● Anatomic conditions associated with a low risk of PCI procedural complications
and a high likelihood of good long-term outcome (e.g., a low SYNTAX score of
22, ostial or trunk left main CAD)
● Clinical characteristics that predict a significantly increased risk of adverse
surgical outcomes (e.g., STS-predicted risk of operative mortality 5%)
B (949,953,955,958,963–980)
IIa—For UA/NSTEMI if not a CABG candidate B (949,968–971,976–979,981)
IIa—For STEMI when distal coronary flow is TIMI flow grade 3 and PCI can be
performed more rapidly and safely than CABG
C (965,982,983)
IIb—For SIHD when both of the following are present:
● Anatomic conditions associated with a low to intermediate risk of PCI procedural
complications and an intermediate to high likelihood of good long-term outcome
(e.g., low-intermediate SYNTAX score of 33, bifurcation left main CAD)
● Clinical characteristics that predict an increased risk of adverse surgical
outcomes (e.g., moderate—severe COPD, disability from prior stroke, or prior
cardiac surgery; STS-predicted operative mortality 2%)
B (949,953,955,958,963–980,984)
III: Harm—For SIHD in patients (versus performing CABG) with unfavorable anatomy
for PCI and who are good candidates for CABG
B (73,381,412,949,953,955,959–964)
3-vessel disease with or without proximal LAD artery disease*
CABG I B (353,412,959,985–987)
IIa—It is reasonable to choose CABG over PCI in patients with complex 3-vessel CAD
(e.g., SYNTAX score 22) who are good candidates for CABG.
B (964,980,987–989)
PCI IIb—Of uncertain benefit B (366,959,980,985,987)
2-vessel disease with proximal LAD artery disease*
CABG I B (353,412,959,985–987)
PCI IIb—Of uncertain benefit B (366,959,985,987)
2-vessel disease without proximal LAD artery disease*
CABG IIa—With extensive ischemia B (327,990–992)
IIb—Of uncertain benefit without extensive ischemia C (987)
PCI IIb—Of uncertain benefit B (366,959,985,987)
1-vessel proximal LAD artery disease
CABG IIa—With LIMA for long-term benefit B (412 987,993,994)
PCI IIb—Of uncertain benefit B (366,959,985,987)
1-vessel disease without proximal LAD artery involvement
CABG III: Harm B (306,327,412,985,990,995–998)
PCI III: Harm B (306,327,412,985,990,995–998)
LV dysfunction
CABG IIa—EF 35% to 50% B (365,412,999–1002)
CABG IIb—EF 35% without significant left main CAD B (355,365,410,412,999–1002)
PCI Insufficient data N/A
Survivors of sudden cardiac death with presumed ischemia-mediated VT
CABG I B (350,1003,1004)
PCI I C (1003)
No anatomic or physiological criteria for revascularization
CABG III: Harm B (306,327,412,985,990,995–998)
PCI III: Harm B (306,327,412,985,990,995–998)
*In patients with multivessel disease who also have diabetes mellitus, it is reasonable to choose CABG (with LIMA) over PCI (30,991,1005–1011) (Class IIa; LOE: B).
CABG indicates coronary artery bypass graft; CAD, coronary artery disease; COPD, chronic obstructive pulmonary disease; COR, class of recommendation; EF, ejection fraction; LAD, left anterior
descending; LIMA, left internal mammary artery; LOE, level of evidence; LV, left ventricular; N/A, not available; PCI, percutaneous coronary intervention; SIHD, stable ischemic heart disease; STEMI,
ST-elevation myocardial infarction; STS, Society of Thoracic Surgeons; SYNTAX, Synergy between Percutaneous Coronary Intervention with TAXUS and Cardiac Surgery; TIMI, Thrombolysis In Myocardial
Infarction; UA/NSTEMI, unstable angina/non–ST-elevation myocardial infarction; UPLM, unprotected left main disease; and VT, ventricular tachycardia.
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the decision to treat with GDMT without revascularization,
involving an interventional cardiologist, a cardiac surgeon,
and (often) the patient’s general cardiologist, followed by
discussion with the patient about treatment options, is
optimal. Particularly in patients with SIHD and unpro-
tected left main and/or complex CAD for whom a revas-
cularization strategy is not straightforward, an approach has
been endorsed that involves terminating the procedure after
diagnostic coronary angiography is completed; this allows a
thorough discussion and affords both the interventional
cardiologist and cardiac surgeon the opportunity to discuss
revascularization options with the patient. Because the STS
score and the SYNTAX score have been shown to predict
adverse outcomes in patients undergoing CABG and PCI,
respectively, calculation of these scores is often useful in
making revascularization decisions (949,950,953–957).
5.2. Revascularization to Improve Survival:
Recommendations
Left Main CAD Revascularization
CLASS I
1. CABG to improve survival is recommended for patients with signif-
icant (50% diameter stenosis) left main coronary artery stenosis
(73,381,412,959–962). (Level of Evidence: B)
CLASS IIa
1. PCI to improve survival is reasonable as an alternative to CABG in
selected stable patients with significant (50% diameter stenosis)
unprotected left main CAD with: 1) anatomic conditions associated
with a low risk of PCI procedural complications and a high likelihood
of good long-term outcome (e.g., a low SYNTAX score [22], ostial
or trunk left main CAD); and 2) clinical characteristics that predict a
significantly increased risk of adverse surgical outcomes (e.g.,
STS-predicted risk of operative mortality 5%) (949,953,955,958,
963–979). (Level of Evidence: B)
. PCI to improve survival is reasonable in patients with UA/NSTEMI
when an unprotected left main coronary artery is the culprit lesion
and the patient is not a candidate for CABG (949,968–971,976–
Table 19. Revascularization to Improve Symptoms With Signifi
hysiological (FFR <0.80) Coronary Artery Stenoses
Clinical Setting
1 significant stenoses amenable to revascularization and unacceptable a
GDMT
1 significant stenoses and unacceptable angina in whom GDMT cannot
because of medication contraindications, adverse effects, or patient pre
Previous CABG with 1 significant stenoses associated with ischemia and
angina despite GDMT
Complex 3-vessel CAD (e.g., SYNTAX score >22) with or without involvem
proximal LAD artery and a good candidate for CABG
Viable ischemic myocardium that is perfused by coronary arteries that are
to grafting
No anatomic or physiological criteria for revascularization
CABG indicates coronary artery bypass graft; CAD, coronary artery disease; COR, class of recomm
N/A, not available; PCI, percutaneous coronary intervention; SYNTAX, Synergy between Percutane979,981). (Level of Evidence: B)3. PCI to improve survival is reasonable in patients with acute STEMI
when an unprotected left main coronary artery is the culprit lesion,
distal coronary flow is less than TIMI (Thrombolysis In Myocardial
Infarction) grade 3, and PCI can be performed more rapidly and
safely than CABG (965,982,983). (Level of Evidence: C)
CLASS IIb
1. PCI to improve survival may be reasonable as an alternative to
CABG in selected stable patients with significant (50% diameter
stenosis) unprotected left main CAD with: a) anatomic conditions
associated with a low to intermediate risk of PCI procedural com-
plications and an intermediate to high likelihood of good long-term
outcome (e.g., low–intermediate SYNTAX score of 33, bifurcation
left main CAD); and b) clinical characteristics that predict an in-
creased risk of adverse surgical outcomes (e.g., moderate–severe
chronic obstructive pulmonary disease, disability from previous
stroke, or previous cardiac surgery; STS-predicted risk of opera-
tive mortality 2%) (949,953,955,958,963–979,984). (Level of
Evidence: B)
CLASS III: Harm
1. PCI to improve survival should not be performed in stable patients
with significant (50% diameter stenosis) unprotected left main
CAD who have unfavorable anatomy for PCI and who are good
candidates for CABG (73,381,412,949,953,955,959–964). (Level
of Evidence: B)
Non–Left Main CAD Revascularization
CLASS I
1. CABG to improve survival is beneficial in patients with significant
(70% diameter) stenoses in 3 major coronary arteries (with or
without involvement of the proximal LAD artery) or in the proximal
LAD artery plus 1 other major coronary artery (353,412,959,985–
987). (Level of Evidence: B)
2. CABG or PCI to improve survival is beneficial in survivors of sudden
cardiac death with presumed ischemia-mediated ventricular tachy-
cardia caused by significant (70% diameter) stenosis in a major
coronary artery. (CABG Level of Evidence: B [350,1003,1004]; PCI
Level of Evidence: C [1003])
CLASS IIa
1. CABG to improve survival is reasonable in patients with significant
Anatomic (>50% Left Main or >70% Non–Left Main CAD) or
COR LOE References
despite 1—CABG A (366,407,1012–1020)
1—PCI
lemented
ces
IIa—CABG C N/A
IIa—PCI C N/A
ceptable IIa—PCI C (1021–1024)
IIb—CABG C (1025)
f the IIa—CABG preferred
over PCI
B (980,987–989)
menable IIb—TMR as an
adjunct to CABG
B (923,927,929,1026,1027)
III: Harm—CABG C N/A
III: Harm—PCI C N/A
n; FFR, fractional flow reserve; GDMT, guideline-directed medical therapy; LOE, level of evidence;
ronary Intervention with TAXUS and Cardiac Surgery; and TMR, transmyocardial revascularization.cant
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testing, abnormal intracoronary hemodynamic evaluation, or20%
perfusion defect by myocardial perfusion stress imaging) or target
vessels supplying a large area of viable myocardium (327,990–
992). (Level of Evidence: B)
2. CABG to improve survival is reasonable in patients with mild–
moderate LV systolic dysfunction (EF 35% to 50%) and significant
(70% diameter stenosis) multivessel CAD or proximal LAD coro-
nary artery stenosis, when viable myocardium is present in the
region of intended revascularization (365,412,999–1002). (Level of
Evidence: B)
3. CABG with a left internal mammary artery (LIMA) graft to improve
survival is reasonable in patients with significant (70% diameter)
stenosis in the proximal LAD artery and evidence of extensive
ischemia (412,987,993,994). (Level of Evidence: B)
. It is reasonable to choose CABG over PCI to improve survival in
patients with complex 3-vessel CAD (e.g., SYNTAX score 22), with
or without involvement of the proximal LAD artery who are good
candidates for CABG (964,980,987–989). (Level of Evidence: B)
. CABG is probably recommended in preference to PCI to improve
survival in patients with multivessel CAD and diabetes mellitus,
particularly if a LIMA graft can be anastomosed to the LAD artery
(991,1005–1008,1008–1011). (Level of Evidence: B)
CLASS IIb
1. The usefulness of CABG to improve survival is uncertain in patients
with significant (70%) diameter stenoses in 2 major coronary arter-
ies not involving the proximal LAD artery and without extensive
ischemia (987). (Level of Evidence: C)
. The usefulness of PCI to improve survival is uncertain in patients
with 2- or 3-vessel CAD (with or without involvement of the proximal
LAD artery) or 1-vessel proximal LAD disease (366,959,985,987).
(Level of Evidence: B)
. CABG might be considered with the primary or sole intent of
improving survival in patients with SIHD with severe LV systolic
dysfunction (EF35%) whether or not viablemyocardium is present
(355,365,410,412,999–1002). (Level of Evidence: B)
. The usefulness of CABG or PCI to improve survival is uncertain in
patients with previous CABG and extensive anterior wall ischemia
on noninvasive testing (1021–1025,1029–1032). (Level of Evi-
dence: B)
CLASS III: Harm
1. CABG or PCI should not be performed with the primary or sole intent
to improve survival in patients with SIHD with 1 or more coronary
stenoses that are not anatomically or functionally significant (e.g.,
70% diameter non–left main coronary artery stenosis, FFR0.80,
no or only mild ischemia on noninvasive testing), involve only the
left circumflex or right coronary artery, or subtend only a small area
of viable myocardium (306,327,412,985,990,995–998). (Level of
Evidence: B)
5.3. Revascularization to Improve Symptoms:
Recommendations
CLASS I
1. CABG or PCI to improve symptoms is beneficial in patients with 1 or
more significant (70% diameter) coronary artery stenoses ame-
nable to revascularization and unacceptable angina despite GDMT(366,407,1012–1018,1020,1033). (Level of Evidence: A)CLASS IIa
1. CABG or PCI to improve symptoms is reasonable in patients with 1
or more significant (70% diameter) coronary artery stenoses and
unacceptable angina for whom GDMT cannot be implemented
because of medication contraindications, adverse effects, or patient
preferences. (Level of Evidence: C)
2. PCI to improve symptoms is reasonable in patients with previous
CABG, 1 or more significant (70% diameter) coronary artery
stenoses associated with ischemia, and unacceptable angina de-
spite GDMT (1021,1023,1024). (Level of Evidence: C)
. It is reasonable to choose CABG over PCI to improve symptoms in
patients with complex 3-vessel CAD (e.g., SYNTAX score 22), with
or without involvement of the proximal LAD artery, who are good
candidates for CABG (964,980,987–989). (Level of Evidence: B)
CLASS IIb
1. CABG to improve symptoms might be reasonable for patients with
previous CABG, 1 or more significant (70% diameter) coronary
artery stenoses not amenable to PCI, and unacceptable angina
despite GDMT (1025). (Level of Evidence: C)
. TMR performed as an adjunct to CABG to improve symptoms may
be reasonable in patients with viable ischemic myocardium that is
perfused by arteries that are not amenable to grafting (923,
927,929,1026,1027). (Level of Evidence: B)
CLASS III: Harm
1. CABG or PCI to improve symptoms should not be performed in
patients who do not meet anatomic (50% diameter left main or
70% non–left main stenosis diameter) or physiological (e.g.,
abnormal FFR) criteria for revascularization. (Level of Evidence: C)
5.4. CABG Versus Contemporaneous
Medical Therapy
In the 1970s and 1980s, 3 RCTs established the survival
benefit of CABG compared with contemporaneous (al-
though minimal by current standards) medical therapy
without revascularization in certain subjects with stable
angina: the Veterans Affairs Cooperative Study (1035),
European Coronary Surgery Study (986), and CASS
(1036). Subsequently, a 1994 meta-analysis of 7 studies that
randomized a total of 2,649 patients to medical therapy or
CABG (412) showed that CABG offered a survival advan-
tage over medical therapy for patients with left main or
3-vessel CAD. The studies also established that CABG is
more effective than medical therapy for relieving anginal
symptoms. These studies have been replicated only once
during the past decade. In MASS II (Medicine, Angio-
plasty, or Surgery Study II), patients with multivessel CAD
who were treated with CABG were less likely than those
treated with medical therapy to have a subsequent MI, need
additional revascularization, or experience cardiac death in
the 10 years after randomization (1016).
Surgical techniques and medical therapy have improved
substantially during the intervening years. As a result, if
CABG were to be compared with GDMT in RCTs today,
the relative benefits for survival and angina relief observed
several decades ago might no longer be observed. Con-
versely, the concurrent administration of GDMT may
substantially improve long-term outcomes in patients
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medical therapy alone. In the BARI 2D (Bypass Angio-
plasty Revascularization Investigation 2 Diabetes) trial of
patients with diabetes mellitus, no significant difference in
risk of mortality in the cohort of patients randomized to
GDMT plus CABG or GDMT alone was observed,
although the study was not powered for this endpoint,
excluded patients with significant left main CAD, and
included only a small percentage of patients with proximal
LAD artery disease or LVEF 0.50 (408). The PCI and
CABG guideline writing committees endorse the perfor-
mance of the ISCHEMIA trial, which will provide con-
temporary data on the optimal management strategy (med-
ical therapy or revascularization with CABG or PCI) of
patients with SIHD, including multivessel CAD, and mod-
erate to severe ischemia.
5.5. PCI Versus Medical Therapy
Although contemporary interventional treatments have
lowered the risk of restenosis compared with earlier tech-
niques, meta-analyses have not shown that the introduction
of bare metal stents (BMS) confers a survival advantage over
balloon angioplasty (1037–1039) or that the use of DES
confers a survival advantage over BMS (138,1040).
No study to date has demonstrated that PCI in patients
with SIHD improves survival rates (138,366,408,959,
985,987,1041–1044). Neither COURAGE (366) nor
BARI 2D (408), which treated all patients with contem-
porary optimal medical therapy, demonstrated any sur-
vival advantage with PCI, although these trials were not
specifically powered for this endpoint. Although 1 large
analysis evaluating 17 RCTs of PCI versus medical
therapy (including 5 trials of subjects with ACS) found a
20% reduction in death with PCI compared with medical
therapy (1043), 2 other large analyses did not (138,1042).
An evaluation of 13 studies reporting the data from 5,442
patients with nonacute CAD showed no advantage of
PCI over medical therapy for the individual endpoints of
all-cause death, cardiac death or MI, or nonfatal MI
(1044). Evaluation of 61 trials of PCI conducted over
several decades shows that despite improvements in PCI
technology and pharmacotherapy, PCI has not been
demonstrated to reduce the risk of death or MI in
patients without recent ACS (138).
The findings from individual studies and systematic
reviews of PCI versus medical therapy can be summarized as
follows:
• PCI reduces the incidence of angina (366,407,1016,
1020,1033,1045).
• PCI has not been demonstrated to improve survival in
stable patients (138,1041,1042).
• PCI may increase the short-term risk of MI (366,
397,1041,1045).
• PCI does not lower the long-term risk of MI
(138,366,397,408,1041,1042).5.6. CABG Versus PCI
The results of 26 RCTs comparing CABG and PCI have
been published: Of these, 9 compared CABG with balloon
angioplasty (30,368,1017,1046 –1059), 14 compared
CABG with BMS implantation (1022,1054,1060–1076),
and 3 compared CABG with DES implantation (950,
1077,1078).
5.6.1. CABG Versus Balloon Angioplasty or BMS
A systematic review of the 22 RCTs comparing CABG
with balloon angioplasty or BMS implantation concluded
the following (1079):
1. Survival was similar for CABG and PCI (with balloon
angioplasty or BMS) at 1 year and 5 years. Survival was
similar for CABG and PCI in subjects with 1-vessel
CAD (including those with disease of the proximal
portion of the LAD artery) or multivessel CAD.
2. Incidence of MI was similar at 5 years after randomiza-
tion.
3. Procedural stroke occurred more commonly with CABG
than with PCI (1.2% versus 0.6%).
4. Relief of angina was accomplished more effectively with
CABG than with PCI 1 year after randomization and 5
years after randomization.
5. During the first year after randomization, repeat coro-
nary revascularization was performed less often after
CABG than after PCI (3.8% versus 26.5%). This was
also demonstrated after 5 years of follow-up (9.8% versus
46.1%). This difference was more pronounced with
balloon angioplasty than with BMS.
A collaborative analysis of data from 10 RCTs comparing
CABG with balloon angioplasty (6 trials) or with BMS
implantation (4 trials) (1080) permitted subgroup analyses
of the data from the 7,812 patients. No difference was noted
with regard to mortality rate 5.9 years after randomization
or the composite endpoint of death or MI. Repeat revascu-
larization and angina were noted more frequently in those
treated with balloon angioplasty or BMS implantation
(1080). The major new observation of this analysis was that
CABG was associated with better outcomes in patients with
diabetes mellitus and in those 65 years of age. Of interest,
the relative outcomes of CABG and PCI were not influ-
enced by other patient characteristics, including the number
of diseased coronary arteries.
The aforementioned meta-analysis and systematic review
(1079,1080) comparing CABG and balloon angioplasty or
BMS implantation were limited in several ways:
1. Many trials did not report outcomes for other important
patient subsets. For example, the available data are
insufficient to determine if race, obesity, renal dysfunc-
tion, PAD, or previous coronary revascularization af-
fected the comparative outcomes of CABG and PCI.
2. Most of the patients enrolled in these trials were male,
and most had 1- or 2-vessel CAD and normal LV
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unlikely to derive a survival benefit and less likely to
experience complications after CABG (412).
. The patients enrolled in these trials represented only a
small fraction (generally5% to 10%) of those who were
screened. For example, most screened patients with
1-vessel CAD and many with 3-vessel CAD were not
considered for randomization.
ee Online Data Supplements 5 and 6 for additional data on
ABG versus PCI.
.6.2. CABG Versus DES
lthough the results of 9 observational studies comparing
ABG and DES implantation have been published
964,1081–1088), most of them had short (12 to 24
onths) follow-up periods. In a meta-analysis of 24,268
atients with multivessel CAD treated with CABG or DES
1089), the incidences of death and MI were similar for the
procedures, but the frequency with which repeat revascu-
arization was performed was roughly 4 times higher after
ES implantation. Only 1 large RCT comparing CABG
nd DES implantation has been published. The SYNTAX
rial randomly assigned 1,800 patients (of a total of 4,337 who
ere screened) to receive DES or CABG (949,950,980).
ACE, a composite of death, stroke, MI, or repeat
evascularization during the 3 years after randomization,
ccurred in 20.2% of CABG patients and 28.0% of those
ndergoing DES implantation (p0.001). The rates of
eath and stroke were similar; however, MI (3.6% for
ABG, 7.1% for DES) and repeat revascularization (10.7%
or CABG, 19.7% for DES) were more likely to occur with
ES implantation (980).
In SYNTAX, the extent of CAD was assessed by using
he SYNTAX score, which is based on the location,
everity, and extent of coronary stenoses, with a low score
ndicating less complicated anatomic CAD. In post hoc
nalyses, a low score was defined as 22; intermediate, 23
o 32; and high, 33. The occurrence of MACE correlated
ith the SYNTAX score for DES patients but not for those
ndergoing CABG. At 12-month follow-up, the primary
ndpoint was similar for CABG and DES in those with a
ow SYNTAX score. In contrast, MACE occurred more
ften after DES implantation than after CABG in those
ith an intermediate or high SYNTAX score (950). At 3
ears of follow-up, the mortality rate was greater in subjects
ith 3-vessel CAD treated with PCI than in those treated
ith CABG (6.2% versus 2.9%). The differences in MACE
etween those treated with PCI or CABG increased with
n increasing SYNTAX score (Figure 12) (980).
Although the utility of using a SYNTAX score in
veryday clinical practice remains uncertain, it seems rea-
onable to conclude from SYNTAX and other data that
utcomes of patients undergoing PCI or CABG in those
ith relatively uncomplicated and lesser degrees of CAD are gomparable, whereas in those with complex and diffuse
AD, CABG appears to be preferable (949,980).
ee Online Data Supplements 6 and 7 for additional data
omparing CABG with DES.
5.7. Left Main CAD
5.7.1. CABG or PCI Versus Medical Therapy for
Left Main CAD
CABG confers a survival benefit over medical therapy in
patients with left main CAD. Subgroup analyses from
RCTs performed 3 decades ago included 91 patients with
left main CAD in the Veterans Administration Cooperative
Study (961). A meta-analysis of these trials demonstrated a
66% reduction in RR of death with CABG, with the benefit
extending to 10 years (412). The CASS Registry (381)
contained data from 1,484 patients with 50% diameter
tenosis left main CAD initially treated surgically or nonsur-
ically. Median survival duration was 13.3 years in the surgical
roup and 6.6 years in the medical group. The survival benefit
f CABG over medical therapy appeared to extend to 53
symptomatic patients with left main CAD in the CASS
egistry (962). Other therapies that subsequently have been
hown to be associated with improved long-term outcome,
uch as the use of aspirin, statins, and internal mammary
rtery grafting, were not widely used in that era.
RCTs and subgroup analyses that compare PCI with
edical therapy in patients with “unprotected” left main
AD do not exist.
.7.2. Studies Comparing PCI Versus CABG for
eft Main CAD
f all subjects undergoing coronary angiography, approxi-
ately 4% are found to have left main CAD (1090), 80%
f whom have significant (70% diameter) stenoses in
ther epicardial coronary arteries.
Published cohort studies have found that major clinical
utcomes are similar with PCI or CABG 1 year after
evascularization and that mortality rates are similar at 1, 2,
nd 5 years of follow-up; however, the risk of needing
arget-vessel revascularization is significantly higher with
tenting than with CABG.
In the SYNTAX trial, 45% of screened patients with
nprotected left main CAD had complex disease that
revented randomization; 89% of these underwent CABG
949,950). In addition, 705 of the 1,800 patients who were
andomized had revascularization for unprotected left main
AD. The majority of patients with left main CAD and a
ow SYNTAX score had isolated left main CAD or left
ain CAD plus 1-vessel CAD; the majority of those with
n intermediate score had left main CAD plus 2-vessel
AD; and most of those with a high SYNTAX score had
eft main CAD plus 3-vessel CAD. At 1 year, rates of
ll-cause death and MACE were similar for the 2 groups
949). Repeat revascularization rates were higher in the PCI
roup than the CABG group (11.8% versus 6.5%), but
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versus 0.3%). At 3 years of follow-up, the incidence of death
in those undergoing left main CAD revascularization
with low or intermediate SYNTAX scores (32) was
3.7% after PCI and 9.1% after CABG (p0.03), whereas
in those with a high SYNTAX score (33), the incidence
of death after 3 years was 13.4% after PCI and 7.6% after
CABG (p0.10) (949). Because the primary endpoint of
SYNTAX was not met (i.e., noninferiority comparison of
CABG and PCI), these subgroup analyses need to be
considered in that context.
In the LE MANS (Study of Unprotected Left Main
Stenting Versus Bypass Surgery) trial (958), 105 patients
with left main CAD were randomized to receive PCI or
CABG. Although a low proportion of patients treated with
PCI received DES (35%) and a low proportion of patients
treated with CABG received internal mammary grafts
(72%), the outcomes at 30 days and 1 year were similar
between the groups. In the PRECOMBAT (Premier of
Randomized Comparison of Bypass Surgery versus Angio-
plasty Using Sirolimus-Eluting Stent in Patients with Left
Main Coronary Artery Disease) trial of 600 patients with
left main disease, the composite endpoint of death, MI, or
stroke at 2 years occurred in 4.4% of patients treated with
PCI and 4.7% of patients treated with CABG, but
ischemia-driven target-vessel revascularization was more
often required in the patients treated with PCI (9.0% versus
4.2%) (984).
The results from these 3 RCTs suggest (but do not
definitively prove) that major clinical outcomes in selected
atients with left main CAD are similar with CABG and
CI at 1- to 2-year follow-up, but repeat revascularization
ates are higher after PCI than after CABG. RCTs with
xtended follow-up of 5 years are required to provide
efinitive conclusions about the optimal treatment of left
ain CAD. In a meta-analysis of 8 cohort studies and 2
CTs (973), death, MI, and stroke occurred with similar
requency in the PCI- and CABG-treated patients at 1, 2,
nd 3 years of follow-up. Target-vessel revascularization was
erformed more often in the PCI group at 1 year (OR:
.36), 2 years (OR: 4.20), and 3 years (OR: 3.30).
ee Online Data Supplements 8 to 13 for additional data
omparing PCI with CABG for left main CAD.
.7.3. Revascularization Considerations for
eft Main CAD
lthough CABG has been considered the “gold standard”
or unprotected left main CAD revascularization, more
ecently PCI has emerged as a possible alternative mode of
evascularization in carefully selected patients. Lesion loca-
ion is an important determinant when PCI is considered
or unprotected left main CAD. Stenting of the left main
stium or trunk is more straightforward than treating distal
ifurcation or trifurcation stenoses, which generally requires
greater degree of operator experience and expertise (1091).In addition, PCI of bifurcation disease is associated with
higher restenosis rates than when disease is confined to the
ostium or trunk (971,1092). Although lesion location influ-
ences technical success and long-term outcomes after PCI,
location exerts a negligible influence on the success of
CABG. In subgroup analyses, patients with left main CAD
and a SYNTAX score 33 with more complex or extensive
CAD had a higher mortality rate with PCI than with
CABG (949). Physicians can estimate operative risk for all
CABG candidates by using a standard instrument, such as
the risk calculator from the STS database. The above
considerations are important factors when choosing among
revascularization strategies for unprotected left main CAD
and have been factored into revascularization recommenda-
tions. Use of a Heart Team approach has been recom-
mended in cases in which the choice of revascularization
is not straightforward. As discussed in Section 5.9.5, the
ability of the patient to tolerate and comply with DAPT
is also an important consideration in revascularization
decisions.
The 2005 PCI guideline (987) recommended routine
angiographic follow-up 2 to 6 months after stenting for
unprotected left main CAD. However, because angiography
has limited ability to predict stent thrombosis and the
results of SYNTAX suggest good intermediate-term results
for PCI in subjects with left main CAD, this recommen-
dation was removed in the 2009 STEMI/PCI focused
update (3).
Experts have recommended immediate PCI for unpro-
tected left main CAD in the setting of STEMI (983). The
impetus for such a strategy is greatest when left main CAD
is the site of the culprit lesion, antegrade coronary flow is
diminished (e.g., TIMI flow grade 0, 1, or 2), the patient is
hemodynamically unstable, and it is believed that PCI
can be performed more quickly than CABG. When
possible, the interventional cardiologist and cardiac sur-
geon should decide together on the optimal form of
revascularization for these subjects, although it is recog-
nized that these patients are usually critically ill and
therefore not amenable to a prolonged deliberation or
discussion of treatment options.
5.8. Proximal LAD Artery Disease
A cohort study (985) and a meta-analysis (412) from the
1990s suggested that CABG confers a survival advantage
over contemporaneous medical therapy for patients with
disease in the proximal segment of the LAD artery. Cohort
studies and RCTs (412,1050,1062,1063,1065,1077,1093–
1095) as well as collaborative analyses and meta-analyses
(1080,1096–1098) showed that PCI and CABG result in
similar survival rates in these patients.
See Online Data Supplements 6 and 14 for additional data on
proximal LAD artery disease.
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Choice of Revascularization
5.9.1. Completeness of Revascularization
Most patients undergoing CABG receive complete or
nearly complete revascularization, which seems to influence
long-term prognosis positively (1099). In contrast, complete
revascularization is accomplished less often in subjects
receiving PCI (e.g., in 70% of patients), and the extent to
which the absence of complete initial revascularization
influences outcome is less clear. Rates of late survival and
survival free of MI appear to be similar in patients with and
without complete revascularization after PCI. Nevertheless,
the need for subsequent CABG is usually higher in those
whose initial revascularization procedure was incomplete
(compared with those with complete revascularization) after
PCI (1100–1102).
5.9.2. LV Systolic Dysfunction
Several older studies and a meta-analysis of the data from
these studies reported that patients with LV systolic dys-
function (predominantly mild to moderate in severity) had
better survival with CABG than with medical therapy alone
(365,412,999–1002). For patients with more severe LV
systolic dysfunction, however, the evidence that CABG
results in better survival compared with medical therapy is
lacking. In the STICH trial of subjects with LVEF 35%
with or without viability testing, CABG and GDMT
resulted in similar rates of survival (death from any cause,
the study’s primary outcome) after 5 years of follow-up. For
several secondary outcomes at this time point, including
1) death from any cause or hospitalization for heart failure,
2) death from any cause or hospitalization for cardiovascular
causes, 3) death from any cause or hospitalization for any
cause, or 4) death from any cause or revascularization with
PCI or CABG, CABG was superior to GDMT. Although
the primary outcome (death from any cause) was similar in
the 2 treatment groups after an average of 5 years of
follow-up, the data suggest the possibility that outcomes
would differ if the follow-up were longer in duration; as a
result, the study is being continued to provide follow-up for
up to 10 years (355,410).
Only very limited data comparing PCI with medical
therapy in patients with LV systolic dysfunction are avail-
able (1002). In several ways, these data are suboptimal, in
that many studies compared CABG with balloon angio-
plasty, many were retrospective, and many were based on
cohort or registry data. Some of the studies demonstrated a
similar survival rate in patients having CABG and PCI
(988,1080,1103–1105), whereas others showed that those
undergoing CABG had better outcomes (964). The data
that exist at present on revascularization in patients with
CAD and LV systolic dysfunction are more robust for
CABG than for PCI, although data from contemporary
RCTs in this patient population are lacking. Therefore, the
choice of revascularization in patients with CAD and LVsystolic dysfunction is best based on clinical variables (e.g.,
coronary anatomy, presence of diabetes mellitus, presence of
CKD), magnitude of LV systolic dysfunction, patient pref-
erences, clinical judgment, and consultation between the
interventional cardiologist and the cardiac surgeon.
5.9.3. Previous CABG
In patients with recurrent angina after CABG, repeat
revascularization is most likely to improve survival in sub-
jects at highest risk, such as those with obstruction of the
proximal LAD artery and extensive anterior ischemia
(1021–1025,1029–1032). Patients with ischemia in other
locations and those with a patent LIMA to the LAD artery
are unlikely to experience a survival benefit from repeat
revascularization (1023).
Cohort studies comparing PCI and CABG among post-
CABG patients report similar rates of mid- and long-term
survival after the 2 procedures (1022,1024,1025,1029,
1031,1032,1106). In the patient with previous CABG who
is referred for revascularization for medically refractory
ischemia, factors that may support the choice of repeat
CABG include vessels unsuitable for PCI, number of
diseased bypass grafts, availability of the internal mammary
artery for grafting chronically occluded coronary arteries,
and good distal targets for bypass graft placement. Factors
favoring PCI over CABG include limited areas of ischemia
causing symptoms, suitable PCI targets, a patent graft to the
LAD artery, poor CABG targets, and comorbid conditions.
5.9.4. Unstable Angina/Non–ST-Elevation
Myocardial Infarction
The main difference between management of the patient
with SIHD and the patient with UA/NSTEMI is that the
impetus for revascularization is stronger in the setting of
UA/NSTEMI, because myocardial ischemia occurring as
part of an ACS is potentially life threatening, and associated
anginal symptoms are more likely to be reduced with a
revascularization procedure than with GDMT (1107–
1109). Thus, the indications for revascularization are
strengthened by the acuity of presentation, the extent of
ischemia, and the ability to achieve full revascularization.
The choice of revascularization method is generally dictated
by the same considerations used to decide on PCI or CABG
for patients with SIHD.
5.9.5. DAPT Compliance and Stent Thrombosis:
Recommendation
CLASS III: Harm
1. PCI with coronary stenting (BMS or DES) should not be performed if
the patient is not likely to be able to tolerate and comply with DAPT
for the appropriate duration of treatment based on the type of stent
implanted (1110–1113). (Level of Evidence: B)
The risk of stent thrombosis is increased dramatically in
patients who prematurely discontinue DAPT, and stent
thrombosis is associated with a mortality rate of 20% to 45%
(1110). Because the risk of stent thrombosis with BMS is
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recommended minimum duration of DAPT therapy for
these individuals. Consensus in clinical practice is to treat
DES patients for 12 months with DAPT to avoid late
(after 30 days) stent thrombosis (1110,1114). Therefore, the
ability of the patient to tolerate and comply with 30 days
of DAPT with BMS treatment and 12 months of DAPT
with DES treatment is an important consideration in
deciding whether to use PCI to treat patients with CAD.
5.10. Transmyocardial Revascularization
A single randomized multicenter comparison of TMR (with
a holmium:YAG laser) plus CABG and CABG alone in
patients in whom some myocardial segments were perfused
by arteries considered not amenable to grafting (1026)
showed a significant reduction in perioperative mortality
rate (1.5% versus 7.6%, respectively), and the survival
benefit of the TMR–CABG combination was present after
1 year of follow-up (1026). At the same time, a large
retrospective analysis of data from the STS National Car-
diac Database, as well as a study of 169 patients from the
Washington Hospital Center who underwent combined
TMR–CABG, showed no difference in adjusted mortality
rate compared with CABG alone (1027,1115). In short, a
TMR–CABG combination does not appear to improve
survival compared with CABG alone. In selected patients,
however, such a combination may be superior to CABG
alone in relieving angina.
5.11. Hybrid Coronary Revascularization:
Recommendations
CLASS IIa
1. Hybrid coronary revascularization (defined as the planned combina-
tion of LIMA-to-LAD artery grafting and PCI of1 non-LAD coronary
arteries) is reasonable in patients with 1 or more of the following
(1116–1122) (Level of Evidence: B):
a. Limitations to traditional CABG, such as heavily calcified proxi-
mal aorta or poor target vessels for CABG (but amenable to PCI);
b. Lack of suitable graft conduits;
c. Unfavorable LAD artery for PCI (i.e., excessive vessel tortuosity or
chronic total occlusion).
CLASS IIb
1. Hybrid coronary revascularization (defined as the planned combina-
tion of LIMA-to-LAD artery grafting and PCI of1 non-LAD coronary
arteries) may be reasonable as an alternative to multivessel PCI or
CABG in an attempt to improve the overall risk–benefit ratio of the
procedures. (Level of Evidence: C)
Hybrid coronary revascularization, defined as the planned
combination of LIMA-to-LAD artery grafting and PCI of
1 non-LAD coronary arteries (1123), is intended to
combine the advantages of CABG (i.e., durability of the
LIMA graft) and PCI (1124). Patients with multivessel
CAD (e.g., LAD and 1 non-LAD stenoses) and an
indication for revascularization are potentially eligible for
this approach. Hybrid revascularization is ideal in subjects in
whom technical or anatomic limitations to CABG or PCI
alone may be present and for whom minimizing theinvasiveness (and therefore the risk of morbidity and mor-
tality) of surgical intervention is preferred (1118) (e.g.,
patients with severe preexisting comorbidities, recent MI, a
lack of suitable graft conduits, a heavily calcified ascending
aorta, or a non-LAD coronary artery unsuitable for bypass
but amenable to PCI, and situations in which PCI of the
LAD artery is not feasible because of excessive tortuosity or
chronic total occlusions).
Hybrid coronary revascularization may be performed in a
hybrid suite in one operative setting or as a staged procedure
(i.e., PCI and CABG performed in 2 different operative
suites, separated by hours to 2 days, but typically during the
same hospital stay). Because most hospitals lack a hybrid
operating room, staged procedures are usually performed.
With the staged procedure, CABG before PCI is preferred,
because this approach allows the interventional cardiologist
to 1) verify the patency of the LIMA-to-LAD artery graft
before attempting PCI of other vessels and 2) minimize the
risk of perioperative bleeding that would occur if CABG
were performed after PCI (i.e., while the patient is receiving
DAPT). Because minimally invasive CABG may be associ-
ated with lower graft patency rates compared with CABG
performed through a midline sternotomy, it seems prudent to
angiographically image all grafts performed through a mini-
mally invasive approach to confirm graft patency (1118).
To date, no RCTs involving hybrid coronary revascular-
ization have been published. Over the past 10 years, several
small, retrospective series of hybrid revascularization using
minimally invasive CABG and PCI have reported low
mortality rates (0% to 2%) and event-free survival rates of
83% to 92% at 6 to 12 months of follow-up. The few series
that have compared the outcomes of hybrid coronary revas-
cularization with standard CABG report similar outcomes
at 30 days and 6 months (1116–1122).
5.12. Special Considerations
In addition to patients’ coronary anatomy and LV function
and whether they have undergone prior revascularization,
clinical features such as the existence of coexisting chronic
conditions might influence decision making. However, the
paucity of information about special subgroups represents
one of the greatest challenges in developing evidence-based
guidelines applicable to large populations. As is the case for
many chronic conditions, studies specifically geared toward
answering clinical questions about the management of
SIHD in women, older adults, and individuals with diabetes
mellitus or CKD are lacking. Moreover, clinicians are often
guided by misconceptions and biases that serve to deprive
patients of potentially beneficial therapies. ACCF/AHA
guidelines for the management of patients with UA/NSTEMI
(4,4a) address special subgroups by recommending that
diagnostic, pharmacological and revascularization strategies
be congruent with those in men, the young, and those
without diabetes mellitus. This section echoes those man-
agement recommendations. Although this section will
briefly review some special considerations in diagnosis and
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should be to apply the recommendations in this guideline
consistently among groups.
5.12.1. Women
Women generally have a lower incidence of SIHD than
men until older age, but their outcomes after MI are worse
(1125). Microvascular disease, typically with preserved LV
function, is more common among women, particularly those
who are younger, whereas obstructive epicardial CAD is less
prevalent. Up to 50% of women with typical or atypical
anginal symptoms undergoing cardiac catheterization are
found not to have obstructive CAD (1126,1127). Contrary
to earlier perceptions, the prognosis of women with chest
pain and nonobstructive disease is not necessarily better
(1128,1129). As women age, the prevalence of obstructive
CAD increases.
Stable angina is the most frequent initial manifestation of
SIHD in women, as opposed to AMI and sudden death in
men (35,1130). Atypical chest pain and angina-equivalent
symptoms such as dyspnea are more common in women,
although women still present with similar patterns, dura-
tion, and frequency of symptoms. The lower prevalence of
obstructive disease in conjunction with technical challenges
makes the interpretation of ischemia on imaging studies
somewhat more difficult. Accumulating evidence suggests
that vascular reactivity related to abnormalities in microvas-
cular and endothelial function and possibly plaque erosion
or distal microembolization contribute to ischemia to a
greater extent in women than in men (75).
On exercise testing, ST-segment changes are less accurate
for the detection of CAD in women than in men (175),
although marked ST-segment changes (a visual interpreta-
tion 1 mm of horizontal or downsloping ST-segment
depression or elevation for60 to 80 ms after the end of the
RS complex) remain diagnostic for all patients. Chal-
enges with exercise testing in women include their generally
ower physical work capacity and the high prevalence of
besity, diabetes mellitus, frailty, and other comorbid con-
itions. Numerous reports (14,315,1131,1132) and an ex-
ert consensus statement (175) have examined the diagnos-
ic accuracy of the exercise ECG and various imaging
odalities in large cohorts of women. Overall, most reports
ocument an improvement in diagnostic accuracy with
maging when compared to a standard exercise ECG (175),
lthough that improvement does not necessarily translate
nto improved clinical outcomes (147). From a meta-
nalysis, the diagnostic sensitivity and specificity were 72%
nd 88% for women undergoing dobutamine stress echo-
ardiography (149). From a small controlled clinical trial,
iagnostic specificity was improved considerably when using
ated Tc-99m myocardial perfusion SPECT over Tl-201
yocardial perfusion SPECT (92% versus 67%) because of
mproved image quality (1133). Overall, sensitivity and
pecificity of myocardial perfusion SPECT were reported as
8% and 96% for women (86,175,1134). For CMR, one study reported a diagnostic sensitivity and specificity of 92%
nd 80% with vasodilator stress magnetic resonance myo-
ardial perfusion (281).
In part related to differing pathophysiology and clinical
resentation, substantial differences in provision of clinical
are have been observed between men and women with
AD (1135). Despite increasing recognition of the risks of
orsening IHD and attendant complications in women, the
requency with which they are prescribed important risk-
odifying therapies such as statins, aspirin, and beta block-
rs after episodes of ACS remains significantly lower than
mong men (1136,1137). Among patients with documented
IHD, however, the differences between men and women
ppear to be much smaller with regard to prescription of
hese therapies (1138).
Data from COURAGE suggest that the benefits of
DMT alone in comparison with GDMT plus PCI were
imilar for men and women (366,1138). Moreover, the
utcomes of revascularization appear to be less favorable
mong women than men (1139–1142), although very few
omen were enrolled in COURAGE. In various risk
odels, the odds of in-hospital death after PCI have ranged
rom 25% to 80% higher for women than for men (1143–
147), although this trend might have improved in recent
ears after the higher incidence of diabetes mellitus and
ypertension in women is taken into account (1148). The
isk of procedural complications also appears to be signifi-
antly higher in women (1149). Although fewer data on the
xperience of women after CABG are available, in the New
ork State registry, the odds of in-hospital death for women
ere 2-fold higher than for men (1149,1150). On the basis
f these observations, the initial approach to therapy for
omen with SIHD should be to prescribe a full regimen of
DMT and to reserve consideration of revascularization for
atients who do not obtain a satisfactory response or who
xperience unacceptable adverse effects. On the basis of the
igher risk associated with PCI in women, it might be
easonable to adopt a more conservative approach in under-
aking this procedure than in men, although the general
rinciple of using revascularization in patients whose symp-
oms are refractory to medical therapy and who are not
atisfied with their current level of angina persists.
.12.2. Older Adults
n older adults, often defined as 75 years of age, coronary
tenoses are likely to be more diffuse and more severe, with
higher prevalence of 3-vessel and left main disease. Several
actors complicate the diagnosis and treatment of SIHD in
his age group. Common coexisting conditions of the
ulmonary, gastrointestinal, and musculoskeletal systems
an cause chest pain, making diagnosis more difficult, even
n patients with documented IHD. Physiological changes in
lder adults, including alterations in cardiac output through
arious mechanisms, muscle loss and deconditioning, neu-
opathies, lung disease, and degenerative joint disease, make
tress testing more difficult. Thus, many elderly patients are
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required by standard exercise ECG protocols (118,1151).
For patients who are unable to exercise, pharmacological
stress imaging is indicated. Although the majority of inves-
tigations have focused on prognosis by markers of ischemia
in the elderly, the results generally reveal a similar accuracy
of testing when compared with younger individuals present-
ing with SIHD (1152–1155).
Baseline ECG changes, arrhythmias, and LV hypertro-
phy, which are more common in older adults who have
accumulated cardiac comorbidities, also limit the value of
stress testing (1156,1157). The higher prevalence of SIHD
in older adults results in more tests that are falsely negative,
and the prognostic value of the Duke treadmill score in
older adults might be limited (1158).
Data based on RCTs to guide therapy in older adults are
relatively sparse because of the common exclusion of older
patients from early clinical trials. Several studies have shown
less frequent use of evidence-based therapies in older adults,
such as early invasive procedures, anticoagulants, beta
blockers, and glycoprotein IIb/IIIa inhibitors (1156,
1159,1160). The findings are likely related to several factors.
Pharmacotherapy is more difficult in older adults because of
changes in drug bioavailability and elimination. Drug–drug
interactions are more common because of polypharmacy. A
more conservative approach to coronary angiography is
often appropriate given the higher risk of contrast-induced
nephropathy in older adults (1161). Moreover, the risks of
morbidity and mortality associated with CABG are in-
creased in older adults.
Despite the complexities and concerns related to evalu-
ating and treating elderly patients with SIHD, findings
from the COURAGE trial indicated that initial medical
therapy was not significantly less effective than medical
therapy plus PCI in relieving angina (73% in the GDMT
group at 60 months, versus 80% in the medical therapy–
plus–PCI group) (1162). Although the mortality rate was
50% higher among patients 65 years of age than among
younger patients, there were no significant differences be-
tween the 2 treatment groups in either patients younger or
older than 65 years. Furthermore, although the incidence of
MI and stroke was also higher in older patients, there were
no significant differences between treatment groups. In the
TIME (Trial of Invasive versus Medical Therapy in the
Elderly) trial, 301 patients 75 years of age with chronic
angina with CCS Class II or higher despite treatment with
2 antianginal drugs were randomized to GDMT or to an
invasive strategy of coronary angiography followed by revas-
cularization with PCI or CABG, if feasible (1163). Patients
who were assigned to the early revascularization group
experienced greater improvement in symptoms at 6 months.
This difference disappeared by 12 months, at which time
both groups had shown a 2-class improvement in their CCS
scores and similar results on other quality-of-life measures.
It should be noted that 45% of the group assigned tomedical therapy ultimately underwent revascularization be-
cause of refractory symptoms.
Considerable evidence indicates that elderly patients have
higher mortality following PCI and CABG than do
younger patients, and the risk appears to rise monotonically
when 65 years of age (1144–1147,1164–1166). Com-
pared with patients 65 years of age, adjusted odds of
short-term mortality after PCI among patients between the
ages of 60 and 80 have ranged from 2.2 to 7.6 in various
registries, and the odds of death among those 80 years
have ranged from 2.7 to 13. Unfortunately, far fewer data
are available on the outcomes of elderly patients undergoing
CABG, and much of it could be outdated. On the basis of
data from 16,120 patients entered into the New York State
registry, the odds of in-hospital mortality rose 8% per year
of age 60 years (OR: 1.08; 95% CI: 1.06 to 1.09) (1150).
On the other hand, in an analysis of 505,645 records from
the registry maintained by the STS, age was not found to be
a predictor of mortality (1167). In older studies, elderly
patients were reported to have favorable results after CABG
(1168,1169), and long-term survival rates for elderly pa-
tients with SIHD treated medically versus surgically were
similar (406).
Older adults constitute a growing proportion of patients
with SIHD. On the basis of the available data, it is
recommended that management by GDMT be the initial
approach in most patients. Given concerns about higher
mortality rate, particularly in patients 75 or 80 years of
age, decisions to recommend revascularization should be
undertaken only after careful consideration of patient pref-
erences, functional capacity, quality-of-life and end-of-life
issues, as well as therapeutic alternatives (4,4a).
5.12.3. Diabetes Mellitus
Type 1 and type 2 diabetes mellitus are associated with a
greater risk of SIHD, and the effects of other risk factors
such as hypercholesterolemia are magnified (1170). Cardio-
vascular mortality rate is 3-fold higher in men with diabetes
mellitus and between 2- and 5-fold higher in women with
diabetes than in patients without diabetes mellitus
(1171,1172). Sudden cardiac death occurs more frequently
in patients with diabetes mellitus. Although direct evidence
is lacking, asymptomatic ischemia could be more prevalent
in patients with diabetes mellitus, possibly because of
autonomic neuropathy (1173).
The risk of death in a patient with SIHD and diabetes
mellitus has been equated to the risk of death in a patient
with SIHD and a previous MI (1171,1174). Aggressive
management of cardiovascular risk factors, including hyper-
cholesterolemia, hypertension, smoking, low physical activ-
ity, and obesity, is essential, along with appropriate glycemic
control.
Among patients with IHD, the presence of concomitant
diabetes mellitus increases the risk of adverse events, irre-
spective of whether the patient is treated medically or with
revascularization. Two studies have suggested that survival
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after bypass surgery than with medical therapy, although
these results are based on subgroup analyses from observa-
tional data (991,1175). Of 2 studies comparing PCI and
medical therapy in patients with diabetes mellitus, one
reported longer survival (1175), but the other did not (991).
A subgroup analysis of data from the BARI trial sug-
gested that patients with diabetes mellitus who underwent
CABG with 1 arterial conduit had improved survival
compared with those who underwent PCI (368). Several
retrospective cohort studies have compared outcomes
among patients with diabetes mellitus undergoing PCI
versus CABG. Three observational studies have reported a
survival advantage for CABG over PCI, whereas a fourth
found no significant difference, and no studies located
reported better outcomes after PCI.
In the BARI 2D study, 2,368 patients with type 2
diabetes mellitus and SIHD were initially selected as can-
didates for either PCI or CABG on the basis of clinical and
angiographic assessment and then were randomly assigned
to undergo either prompt revascularization with intensive
medical therapy or intensive medical therapy alone and to
undergo either insulin-sensitization or insulin-provision
therapy (408). The study was not designed to compare PCI
with CABG. At 5 years, overall survival was similar between
the revascularization and medical-therapy groups (88.3%
versus 87.8%), as was the incidence of MACE (77.2%
versus 75.9%) (409). Patients with the most severe CAD
were assigned to the CABG stratum and those with the
least severe CAD to the PCI stratum. In the PCI stratum,
there was no significant difference in primary endpoints
between the revascularization group and the medical-
therapy group. In the 763 patients randomized to the
CABG stratum, survival was similar but AMI less frequent
among those assigned to revascularization plus intensive
medical therapy compared with intensive medical therapy
(10.0% versus 17.6%; p0.003), and the composite end-
points of all-cause death or MI (21.1% versus 29.2%;
p0.010) and cardiac death or MI (p0.03) were also less
frequent. Compared with those selected for PCI, patients in
the CABG stratum had more 3-vessel disease (20% versus
52%), more total occlusions (32% versus 61%), more prox-
imal LAD stenoses 50% (10% versus 19%), and a signif-
icantly higher myocardial jeopardy score (409).
One-year follow-up data from the SYNTAX study dem-
onstrated a higher rate of repeat revascularization in patients
with diabetes mellitus treated with PCI than in those
treated with CABG, driven by a tendency for higher repeat
revascularization rates in those with higher SYNTAX scores
undergoing PCI (1006).
A large meta-analysis that included the BARI trial but
not BARI 2D failed to identify any significant difference in
mortality rate after CABG versus PCI for patients with
diabetes mellitus (1079). In a more recent, collaborative
analysis that pooled patient-level data from 10 randomized
trials (again, not including BARI 2D), Hlatky and col-leagues found that of the 1,233 patients with diabetes
mellitus, 23% of those assigned to CABG died, compared
with 29% of those assigned to PCI (1080). By contrast, of
the 6,561 patients without diabetes mellitus, 13% and 14%
died, respectively (p0.014 for interaction). The interaction
between diabetes mellitus and treatment remained highly
significant after adjustment for multiple patient character-
istics and after exclusion of patients enrolled in the BARI
2D trial.
Some evidence indicates that the presence of diabetes
mellitus adversely affects the outcomes of revascularization.
An analysis of the 2009 data on 7,812 patients (1,233 with
diabetes mellitus) in 10 RCTs demonstrated a worse long-
term survival rate in patients with diabetes mellitus after
balloon angioplasty or BMS implantation than after CABG
(1080). Analyses from 3 registries found significantly ele-
vated adjusted ORs for short-term mortality after PCI that
ranged from 1.25 to 1.54 in relation to patients without
diabetes mellitus (1144,1146,1165). Data from the STS
registry indicated that patients with diabetes mellitus on oral
therapy had an adjusted OR of 1.15 for death within 30 days
(95% CI: 1.09 to 1.21), as well as significantly higher odds
of stroke, renal failure, or sternal wound infection than those
of patients without diabetes mellitus (1167). For patients on
insulin, the adjusted OR for death within 30 days was 1.50
(95% CI: 1.42 to 1.58), and the risks for other complications
were also correspondingly higher.
In summary, in subjects requiring revascularization for
multivessel CAD, current evidence supports diabetes mel-
litus as an important factor to consider when deciding on a
revascularization strategy, particularly when complex or
extensive CAD is present (Figure 14).
The basis of the currently available data, an intensive
approach to reducing cardiovascular risk and symptoms in
patients with diabetes mellitus by using GDMT should be
the initial approach. For patients whose symptoms are
inadequately managed or who experience intolerable adverse
effects, revascularization should be considered. CABG
might be associated with lower risk of mortality in patients
with diabetes mellitus and multivessel disease than PCI, but
this remains uncertain. The ongoing FREEDOM (Future
Revascularization Evaluation in patients with Diabetes mel-
litus: Optimal management of Multivessel disease) trial
could help resolve this question (1177).
5.12.4. Obesity
Obese individuals frequently have reduced physical work
capacity and exaggerated dyspnea on exertion. Furthermore,
weight limits of exercise and imaging equipment preclude
testing the very obese (1178,1179). Because of limitations in
exercise testing and challenges with imaging through in-
creased breast tissue or chest girth, reduced diagnostic
accuracy has been reported for obese patients (1180). Because
of breast tissue artifact, myocardial perfusion PET is more
accurate than myocardial perfusion SPECT for the obese
patient (191,193,323), although attenuation-correction algo-
terven
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sion SPECT accuracy (187,188). Intravenous contrast en-
hancement improves image quality in obese patients and
results in improved diagnostic certainty for stress echocardiog-
raphy (181).
5.12.5. Chronic Kidney Disease
CKD confers greater risk for developing SIHD, for its
progression, and for poor outcomes after interventions for
AMI (1181–1183). The mortality rate for patients on
hemodialysis is 20% per year, and approximately 50% of
deaths among these patients are due to a cardiovascular
cause (27,1184). To avoid worsening underlying kidney
disease, physicians should consider creatinine clearance in
pharmacotherapy and should apply risk scores for predicting
the likelihood of contrast-induced nephropathy (1161,1185)
in conjunction with the use of renal protective strategies
such as isosmolar contrast agents during angiography
(3,4,4a).
Unfortunately, studies evaluating the outcomes of revas-
cularization in patients with renal disease have not applied a
consistent definition of renal disease. Only one study iden-
tified by the writing committee used the Kidney Disease
Outcome Quality Definition of renal disease grades: Stage
1, creatinine clearance of 90 to 120 mL/min; Stage 2, 60 to
89 mL/min; Stage 3, 30 to 59 mL/min; Stage 4, 15 to 29
mL/min; and Stage 5, 15 mL/min or ongoing dialysis
(1186). Others studies simply described patients as receiving
dialysis (1187,1188) or defined renal disease as any creati-
nine clearance 60 mL/min (1189,1190) or any serum
creatinine above approximately 2.3 mg/dL (1191,1192).
Ongoing studies are beginning to use the AKIN (Acute
Kidney Injury Network) or RIFLE (Risk, Injury, Failure,
Loss, and End-stage) criteria and should ensure more
consistency in the study of periprocedural complications of
percutaneous revascularization.
Among patients who were enrolled in the COURAGE
trial, the presence of CKD was associated with odds of 1.48
for death, MI, or new heart failure relative to patients
without kidney disease (1193). Medical therapy, however,
Figure 14. One-Year Mortality Rates in Randomized Trials of Patie
(Experimental) With CABG (Control)
An OR 1 suggests an advantage of CABG over PCI. ARTS1 indicates Arterial Revas
gation I (1005); CARDia, Coronary Artery Revascularization in Diabetes (1176); CI, c
Study II (1008); OR, odds ratio; SYNTAX, Synergy between Percutaneous Coronary Inwas effective and associated with the same BP and lipidlevels as in patients without CKD. Patients with CKD also
experience significant and sustained improvement in angina
with both PCI and GDMT, and there was no significant
interaction between the presence of CKD and treatment
assignment in survival rate, incidence of AMI, or improve-
ment in symptoms.
To date, randomized comparisons of coronary revascu-
larization (with CABG or PCI) and medical therapy in
patients with CKD have not been reported. Some, but not
all, observational studies or subgroup analyses have demon-
strated an improved survival rate with revascularization
compared with medical therapy in patients with CKD and
multivessel CAD (1191,1193,1194), despite the fact that
the incidence of periprocedural complications (e.g., death,
MI, stroke, infection, renal failure) is higher in patients with
CKD than in those without renal dysfunction. In 2 cohort
studies involving patients with a spectrum of kidney disease
ranging from mild to severe, adjusted survival was superior
for those who underwent bypass surgery compared with
those who received only medical therapy (1191,1194). In 1
study, survival after PCI was improved (compared with
medical therapy) in patients with mild, moderate, or severe
kidney disease but not in those with end-stage kidney
disease. The other study yielded opposite results, with
longer survival after PCI in patients with end-stage renal
disease but not in those with mild, moderate, or severe
kidney disease.
Some studies have shown that CABG is associated with
a greater survival benefit than PCI among patients with
severe renal dysfunction (1187–1192,1194). Five studies
have suggested that survival is prolonged among patients
with CKD after CABG compared with after PCI
(1187,1188,1191,1192,1194), whereas 3 other studies indi-
cated that survival is similar after either of the 2 revascular-
ization strategies, regardless of the severity of underlying
renal disease (1189,1190,1192).
5.12.6. HIV Infection and SIHD
HIV infection appears to be associated with an increased
risk of premature coronary and cerebrovascular atheroscle-
ith Diabetes and Multivessel CAD, Comparing PCI
ation Therapy Study I (1033); BARI I, Bypass Angioplasty Revascularization Investi-
ce interval; DM, diabetes mellitus; MASS II, Medicine, Angioplasty, or Surgery
tion with TAXUS and Cardiac Surgery; and W, weighted (1006).nts W
culariz
onfidenrosis, which is often accelerated, diffuse, and circumferen-
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initial manifestation (1197). The etiology is likely multifac-
torial and related to both the underlying infection and
antiretroviral therapy. The former appears to promote
proliferation of smooth muscle cells and elastin leading to
luminal obstruction, although there is poor correlation
between CD4 cell counts and severity of CAD. Of the
therapeutic agents used to treat HIV infection, protease
inhibitors in particular have been epidemiologically linked
to dyslipidemia and insulin resistance (1198–1200). The
protease inhibitors amprenavir/fosamprenavir with or with-
out ritonavir and lopinavir with ritonavir have the strongest
association with risk of AMI, although saquinavir and
nelfinavir do not appear to be associated with MI
(1201,1202). The nucleoside reverse-transcriptase inhibitors
didanosine and abacavir also are associated with risk of AMI
(1202). Other agents, such as nonnucleoside reverse-
transcriptase inhibitors (nevirapine and efavirenz), entry
inhibitors, and integrase inhibitors, do not appear to be
associated with an increased risk of IHD.
Despite the increase in prevalence of IHD among pa-
tients with HIV, the absolute increase in incidence of AMI
is relatively low, and overall mortality does not appear to be
increased (1198,1203). It is likely that this reflects the
otherwise enormous benefit conferred by treatment with
highly active antiretroviral therapy in the course of HIV
infection. Nonetheless, patients receiving highly active an-
tiretroviral therapy should be assessed for cardiovascular risk
factors and monitored for signs and symptoms of IHD. It is
prudent to recommend a healthy diet, regular physical
activity, and avoidance of smoking. Patients with hypercho-
lesterolemia should be managed in a fashion similar to other
patients at risk for IHD (1204).
5.12.7. Autoimmune Disorders
Connective tissue disease represents a less well-studied issue
in SIHD. In rheumatoid arthritis, findings from at least one
study show increased inflammation in the coronary artery
walls, with increased frequency of vulnerable plaques
(1205). Accelerated atherosclerosis in systemic lupus ery-
thematosis, due to impaired endothelial function and novel
atherogenic and thrombotic risk factors, requires special
attention inasmuch as the adjusted rate of SIHD in systemic
lupus erythematosis is 50-fold higher than in patients
without it (1206,1207). A younger population is more
frequently affected in systemic lupus erythematosis (1208),
and coronary artery spasm is a frequent complication in
connective tissue disease (1209).
5.12.8. Socioeconomic Factors
Low socioeconomic status is highly associated with the risk
of cardiovascular disease (1210). Men 30 to 59 years of age
with low socioeconomic status are at 55% higher risk of
death due to IHD than are those of higher status (RR: 1.55;
95% CI: 1.51 to 1.60), and the risk is2-fold higher among
women (RR: 2.13; 95% CI: 1.98 to 2.29) (1211).In addition to lower socioeconomic status being associ-
ated with a higher prevalence of IHD, it has been amply
demonstrated that patients of lower socioeconomic status
and those who are members of an ethnic or racial minority
(in particular African Americans and Hispanics) are less
likely to receive a wide variety of diagnostic and therapeutic
interventions. These disparities have been observed with
regard to cardiac procedures as well as access to cardiologists
(1212). Moreover, African Americans and Hispanics are
10% to 40% less likely to receive outpatient secondary
prevention therapies for cardiovascular disease (1213). Al-
though lower rates of diagnostic and interventional services
have not been adequately explained (1214,1215), it is clear
that individuals of lower socioeconomic status and ethnic
minorities typically have fewer healthcare resources, have
worse general health and cardiac risk profiles, and are less
knowledgeable about SIHD symptoms. Healthcare provid-
ers and systems should strive to eliminate or ameliorate
barriers to care for patients who have SIHD and are of low
socioeconomic class or ethnic minorities.
5.12.9. Special Occupations
Although not recommended for the general population,
routine surveillance with functional testing is recommended
in a few occupations in which the presence of even asymp-
tomatic cardiac disease could endanger others, such as
commercial pilots, police, firefighters, and bus drivers. The
general parameters of test performance noted above apply in
these circumstances, with the caveat that most of these
individuals are at low risk and therefore could be more likely
to have false positive results.
6. Patient Follow-Up: Monitoring of
Symptoms and Antianginal Therapy
The goals of clinical follow-up of patients with SIHD are to
maximize function and to minimize long-term mortality
and morbidity. In this context, the primary goal of
follow-up testing should be to reassess residual or new
ischemic burden in the setting of persistent or worsening
(but not unstable) symptoms. Thus, follow-up assessment
and testing will vary according to the clinical status of the
patient and with the evolution of evidence-based practice.
Unnecessary testing should be avoided. For patients with
SIHD who show no change in symptoms or functional
capacity, periodic follow-up serves multiple purposes:
• Ongoing reassessment of adherence to and effective-
ness of the therapeutic regimen, including clinical
response, occurrence of adverse effects, and treatment
goals, on the basis of evolving scientific evidence and
preferences of the patient.
• Evaluation of the effectiveness of interventions to
modify risk factors such as exertional hypertension.
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conditions that could directly or indirectly affect the
management of stable cardiac ischemia.
Patients with SIHD who have accelerating symptoms or
decreasing functional capacity require prompt reassessment.
Patients with SIHD who develop new ACS should be
evaluated and treated according to established guidelines
(3,4,4a,9,10). Patients who have been treated for an ACS
(i.e., AMI or UA) within the previous 6 months and who
develop chest pain within 30 days of the AMI should be
evaluated according to the STEMI or UA/NSTEMI guide-
lines as warranted (2–4,4a). Patients who have undergone
revascularization with either PCI or CABG within 6
months should be monitored according to the PCI and
CABG guidelines (9,10). Patients with SIHD should be
evaluated before elective or emergent surgery according to
established perioperative guidelines (4,4a,9,10).
6.1. Clinical Evaluation, Echocardiography During
Routine, Periodic Follow-Up: Recommendations
CLASS I
1. Patients with SIHD should receive periodic follow-up, at least annu-
ally, that includes all of the following (Level of Evidence: C):
a. Assessment of symptoms and clinical function;
b. Surveillance for complications of SIHD, including heart failure
and arrhythmias;
c. Monitoring of cardiac risk factors; and
d. Assessment of the adequacy of and adherence to recommended
lifestyle changes and medical therapy.
. Assessment of LVEF and segmental wall motion by echocardiogra-
phy or radionuclide imaging is recommended in patients with new
or worsening heart failure or evidence of intervening MI by history or
ECG. (Level of Evidence: C)
CLASS IIb
1. Periodic screening for important comorbidities that are prevalent in
patients with SIHD, including diabetes mellitus, depression, and
CKD, might be reasonable. (Level of Evidence: C)
2. A resting 12-lead ECG at 1-year or longer intervals between studies
in patients with stable symptoms might be reasonable. (Level of
Evidence: C)
CLASS III: No Benefit
1. Measurement of LV function with a technology such as echocardi-
ography or radionuclide imaging is not recommended for routine
periodic reassessment of patients who have not had a change in
clinical status or who are at low risk of adverse cardiovascular
events (117). (Level of Evidence: C)
Standard risk-assessment tools that have been developed
from clinical and laboratory evaluation of ambulatory pop-
ulations with suspected CAD, as discussed in detail in
Section 2 of this guideline, include patients who have
noncardiac causes of presenting symptoms. However, the
performance of these same tools in predicting short-term
and long-term risk for coronary mortality and coronary
events might vary in patients with known SIHD as com-
pared with patients without known disease who present
with chest pain syndromes that might or might not repre- rsent angina. Although mortality and morbidity rates intui-
tively might be considered to be higher in patients with
documented as opposed to suspected CAD, evidence-based
medical management, including adherence to appropriate
lifestyle changes, and possibly appropriate revascularization
in patients with ACS or patients identified as high risk with
worsening clinical status or persistent symptoms despite
GDMT, might explain the generally low mortality risk that
has been found in several studies of patients with established
SIHD (57,58,366,1216,1217). The incidence of adverse events
during longitudinal follow-up of SIHD has declined and can be
expected to vary with evolving medical management and with
accruing information about the outcomes of revascularization
(295,898,1163,1217–1219).
Although data on serial testing are limited, one approach
o identifying candidates for follow-up testing is to apply
rognostic scores for detection of patients with SIHD who
re at high risk of MACE. The findings of studies that have
xamined the prognostic value of testing among patients
ith known stable CAD who are receiving contemporary
DMT (306,1220–1223) could provide clues for identify-
ng candidates and appropriate intervals for follow-up test-
ng. In the TIBET (Total Ischemic Burden European Trial)
tudy group, which comprised 682 patients with stable
ngina and positive exercise ECG tests, adverse outcome
as predicted by time to ischemia during exercise, prior
nfarction or prior CABG, ECG evidence for LV hyper-
rophy, and LV enlargement by echocardiography (58).
asily available clinical characteristics have been the stron-
est predictors of risk during follow-up of patients with
IHD in other studies. The Euro Heart Survey found that
score based on the cumulative presence of comorbidity,
iabetes mellitus, severity of angina, onset of recurrent
ymptoms 6 months previously, abnormal ventricular
unction, and resting ECG repolarization abnormalities was
ssociated with an increase in the 1-year risk of death or
onfatal infarction that ranged nearly 100-fold (from 0.5%
o 47%) among3,000 outpatients (57). The ACTION (A
oronary Disease Trial Investigating Outcome with Nifed-
pine Gastrointestinal Therapeutic System) trial derived a
linical risk score that separated 5-year risk of death, MI, or
troke from 4% to 35% in 7,300 patients with stable
ngina on the basis of commonly available clinical variables.
n order of decreasing importance, the variables included
ge, LVEF, smoking, white blood cell count, presence of
iabetes mellitus, casual (any time of day without regard to
ime since the last meal) blood glucose concentration,
reatinine, prior stroke, frequent angina, findings at coro-
ary angiography, lipid-lowering treatment, QT interval on
he resting ECG, systolic hypertension, number of drugs
sed for angina, prior infarction, and sex (1216). Because
he populations enrolled in these studies varied and the
esults have not been independently validated, additional
rospective studies of patients with established SIHD are
equired to establish appropriate follow-up evaluation strat-
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in stable patients (307,320,1223,1224).
6.2. Follow-Up of Patients With SIHD
Standard risk assessment tools that have been developed from
clinical and laboratory evaluation of ambulatory populations
with suspected CAD, as discussed in detail in Section 2 of this
guideline, include patients who have noncardiac causes of
presenting symptoms. Estimates of the likelihood of future
cardiac events using the Framingham score (508,1225), which
was derived from populations that included large numbers of
low-risk individuals without disease in their low-risk subsets,
are not generally useful when applied to patients with known
SIHD. In fact, prediction of risk for coronary mortality and
coronary events during short-term and long-term follow-up of
patients with SIHD differs from risk stratification in less-
ascertained populations with chest pain syndromes. Although
mortality and morbidity rates intuitively might be considered
to be higher in patients with documented as opposed to
suspected IHD, several circumstances serve to confound this
assumption. Patients at highest risk, for example, are often
identified and aggressively treated during the course of ACS or
during initial risk assessment of chest pain. After being treated,
asymptomatic patients are typically at low risk for adverse
events. Moreover, patients with recognized SIHD could be
more likely to receive and adhere to effective therapies than are
those whose disease has not been documented. Finally, patients
who have been stable for long periods of time could be less
prone to development of ACS than are newly ascertained
patients with SIHD. Thus, evidence-based medical manage-
ment, including adherence to appropriate lifestyle changes and
possibly appropriate revascularization in patients with ACS or
patients identified as high risk with worsening clinical status or
persistent symptoms despite GDMT, could explain the gen-
erally low mortality risk that has been found in several studies
of patients with established but stable SIHD
(57,58,366,1216,1217). Moreover, large trials conducted dur-
ing the past decade have shown a declining mortality rate
among pa t i en t s w i th e s t ab l i shed SIHD
(295,898,1163,1217,1218). Accordingly, risk could change
with advances in therapy and patient management, and these
advances could alter risk-prediction models.
A key component in following up patients with SIHD is
to systematically and reproducibly monitor their symptoms
and functional status. This should be done, at a minimum,
yearly and ideally at each visit. Even though the CCS
classification system is the most common metric with which
to quantify patients’ symptoms and function, as noted
previously, it is limited by being from the physician’s
perspective rather than the patient’s. Moreover, it has
limitations in its reproducibility and interrater reliability. To
obtain a valid, reliable, reproducible, and sensitive assess-
ment of patients’ symptoms, function, and quality of life
from patients’ perspectives, the SAQ can be used
(435,1226). The SAQ is a 19-item, self-reported question-
naire that takes approximately 5 minutes for most patientsto complete and explicitly quantifies patients’ angina fre-
quency, recent changes in their angina, their physical
limitations due to angina, their satisfaction with treatment,
and their perceptions of how their angina limits their quality
of life. Scores on the SAQ have been shown to be associated
with subsequent survival. ACS admissions and costs
(246,247,1227) can be integrated into prognostic models to
identify patients warranting more aggressive treatment be-
cause of an adverse prognosis. In the CADENCE (Coro-
nary Artery Disease in General Practice) study, conducted
in 207 primary care clinics throughout Australia (1228),
Beltrame and colleagues found wide variation in anginal
symptoms according to the SAQ. Routine use of the SAQ
has been endorsed as a performance measure of quality in
SIHD (407,436).
6.2.1. Focused Follow-Up Visit: Frequency
Patients with SIHD should receive regular follow-up to
monitor symptoms and progression or complications of
disease. Regular visits with a healthcare provider are also
necessary to evaluate patients’ adherence to and effectiveness
of therapy as well as occurrence of any adverse effects.
Although there are scant data on which to base a definitive
recommendation, the writing committee recommends a
clinical follow-up evaluation every 4 to 12 months. A more
precise interval cannot be recommended because many
factors influence the length of the follow-up period, includ-
ing sharing of care by family physicians, internists, and
cardiologists, which will vary with regional practice patterns,
patient preference, and physician availability. During the first
year of therapy, evaluations every 4 to 6 months are recom-
mended. After the first year of therapy, evaluations every 6 to
12 months are recommended if the patient is stable and reliable
enough to call or make an appointment when symptoms or
functional capacity become worse. Limited data from observa-
tional studies indicate that outcomes might be better for
patients who receive follow-up from a cardiologist
(1229,1230). When patients are managed jointly by their
primary care physician and cardiologist, effective communica-
tion between physicians is essential. This ultimately will be
facilitated by effective implementation of accessible electronic
medical records. Periodic office visits can be supplemented by
telephone, e-mail, or other types of contact between the patient
and the healthcare team.
6.2.2. Focused Follow-Up Visit: Interval History and
Coexisting Conditions
Although follow-up of patients with SIHD often is focused
on periodic testing, the most crucial element is a careful
interval history. Key elements of the history are:
• Changes in physical activity or symptoms;
• Response to therapy, adverse effects, and adherence to
recommendations; and
• Development of relevant, new chronic conditions orchanges in existing conditions.
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are important markers for increased risk in patients with
SIHD, particularly with increasing age and additional co-
morbidities. The evaluation of symptoms should be detailed
and directed, as many patients are reluctant to volunteer
such information. It should be noted whether patients have
reduced their activity, perhaps in an effort to ameliorate
anginal symptoms or as a symptom of ventricular dysfunc-
tion. The adverse prognostic importance of frequent, typical
angina in patients with SIHD is evident in both older and
newer studies of risk (57,126,127,1231,1232). Motivation
and compliance with risk-reduction measures should be
carefully assessed. In particular, assistance with smoking
cessation by means of a structured program might be
necessary for some patients. Careful attention must be paid
to concomitant conditions, such as hypertension, diabetes
mellitus, dyslipidemia, heart failure, and depression.
6.2.3. Focused Follow-Up Visit: Physical Examination
The physical examination should be directed according to the
patient’s history. Every patient should have weight, BP, and
heart rate measured. BMI and waist circumference can provide
signs of additional risk. Signs of heart failure, such as elevated
jugular venous pressure, hepatojugular reflux, pulmonary crack-
les, new murmurs or gallops, or edema, should be sought. The
vascular examination should identify any change in peripheral
pulses or new bruits. Coexistence of SIHD with extracranial
carotid disease makes palpation and auscultation of the carotid
arteries particularly important, and examination of the abdo-
men should include special attention to bruits or abnormally
prominent pulsations of the abdominal aorta.
6.2.4. Focused Follow-Up Visit: Resting 12-Lead ECG
An ECG is necessary when there is a change in anginal
pattern, symptoms or findings suggestive of a dysrhythmia
or conduction abnormality, and near or frank syncope. It is
important to recognize that periodic recording of the
standard 12-lead ECG has clinical value that is independent
of diagnostic and prognostic content: It provides a baseline
waveform against which tracings taken during symptoms
reasonably can be compared. Because many patients with
SIHD have resting repolarization abnormalities, absence of
a timely tracing for comparison with a tracing taken during
atypical symptoms can lead to overdiagnosis of acute isch-
emia (1233,1234). Conversely, repolarization abnormalities
during symptoms that might be new or significantly more
marked can also be consistent with old disease and lead to
underdiagnosis or undertreatment of unstable disease
(1235). New repolarization abnormalities during serial study
have been shown to predict cardiovascular events during the
longitudinal study of hypertensive patients in the Framingham
Heart Study (318). A study of hypertensive patients that
included a subgroup with established SIHD also demonstrated
an increased risk of cardiovascular endpoints after the devel-
opment of new repolarization changes during serial evaluation
(318,1236). Although there are no prospective randomizeddata demonstrating that intervention based on routine, peri-
odic evaluation of the ECG alone will alter outcomes in
patients with SIHD, pending such evidence, the clinical value
of a change in the resting ECG is widely accepted. In patients
with established SIHD, a change in a periodically obtained
ECG can be the only evidence of intercurrent silent infarction,
inadequately treated hypertension, or complex arrhythmia that
would modify treatment. The timing between routine record-
ings of the 12-lead ECG that would be required and adequate
to accomplish these purposes has not been established, but a
consensus recommendation based on expert opinion and com-
mon practice would be not greater than once yearly for stable
patients with SIHD, as well as at the time of any clinical
change.
6.2.5. Focused Follow-Up Visit:
Laboratory Examination
Patients not known to have diabetes mellitus should have a
fasting blood glucose measurement every 3 years to detect
new-onset diabetes mellitus, and those with established
diabetes mellitus should have glycosylated hemoglobin mea-
sured at least annually to assess glycemic control. A lipid
profile should be obtained as clinically warranted. Long-
term studies (up to 7 years) demonstrate sustained benefit
from continued therapy (18,318). Measurement of creati-
nine kinase also could be appropriate at these times. In
circumstances in which the patient is not concurrently
followed up by a primary care physician, measurements of
hemoglobin, thyroid function, serum electrolytes, and renal
function should be obtained annually, or sooner when
prompted by a change in symptoms or signs.
6.3. Noninvasive Testing in Known SIHD
For any patients with known SIHD who have recurrent but
stable symptoms after having been symptom free for a
period of time on GDMT or after revascularization and
who do not fall into any of the categories listed in the
previous paragraph, the concepts underlying the recommen-
dations for “Noninvasive Testing for Diagnosis of SIHD”
from Section 2.2 generally apply, with the modifications and
special consideration discussed below.
6.3.1. Follow-Up Noninvasive Testing in Patients
With Known SIHD: New, Recurrent, or Worsening
Symptoms Not Consistent With Unstable Angina:
Recommendations
See Table 20 for a summary of recommendations from this
section.
6.3.1.1. PATIENTS ABLE TO EXERCISE
CLASS I
1. Standard exercise ECG testing is recommended in patients with
known SIHD who have new or worsening symptoms not consistent
with UA and who have a) at least moderate physical functioning and
no disabling comorbidity and b) an interpretable ECG (114,145–
147). (Level of Evidence: B)
iograph
ailable
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patients with known SIHD who have new or worsening symptoms
not consistent with UA and who have a) at least moderate physical
functioning or no disabling comorbidity but b) an uninterpretable
ECG (172,276,278,284,306,313,314,320,324,327–329,1237–
1240). (Level of Evidence: B)
CLASS IIa
1. Exercise with nuclear MPI or echocardiography is reasonable in pa-
tients with known SIHD who have new or worsening symptoms not
consistent with UA and who have a) at least moderate physical func-
tioning and no disabling comorbidity, b) previously required imaging
with exercise stress, or c) known multivessel disease or high risk for
multivessel disease (1241,1242). (Level of Evidence: B)
CLASS III: No Benefit
1. Pharmacological stress imaging with nuclear MPI, echocardiog-
raphy, or CMR is not recommended in patients with known SIHD
who have new or worsening symptoms not consistent with UA
and who are capable of at least moderate physical functioning or
Table 20. Follow-Up Noninvasive Testing in Patients With Know
Not Consistent With UA
Test
Exercise
Status
ECG
Interpretable
Able Unable Yes No
Patients able to exercise*
Exercise ECG X X I
Exercise with nuclear MPI or
Echo
X X I
Exercise with nuclear MPI or
Echo
X Any IIa
Pharmacological stress
nuclear MPI/Echo/CMR
X X III: N
Patients unable to exercise
Pharmacological stress
nuclear MPI or Echo
X Any I
Pharmacological stress CMR X Any IIa
Exercise ECG X X III: N
Irrespective of ability to exercise
CCTA Any Any IIb
CCTA Any Any IIb
CCTA
Any Any
III: N
*Patients are candidates for exercise testing if they are capable of performing at least moderat
living) and have no disabling comorbidity. Patients should be able to achieve 85% of age-predic
CABG indicates coronary artery bypass graft surgery; CCTA, cardiac computed tomography ang
Echo, echocardiography; LOE, level of evidence; MPI, myocardial perfusion imaging; N/A, not avhave no disabling comorbidity (333). (Level of Evidence: C)6.3.1.2. PATIENTS UNABLE TO EXERCISE
CLASS I
1. Pharmacological stress imaging with nuclear MPI or echocardi-
ography is recommended in patients with known SIHD who
have new or worsening symptoms not consistent with UA and
who are incapable of at least moderate physical functioning or
have disabling comorbidity (148–150,152–156). (Level of Evi-
dence: B)
CLASS IIa
1. Pharmacological stress imaging with CMR is reasonable in patients
with known SIHD who have new or worsening symptoms not con-
sistent with UA and who are incapable of at least moderate physical
functioning or have disabling comorbidity (280,281,283). (Level of
Evidence: B)
CLASS III: No Benefit
1. Standard exercise ECG testing should not be performed in pa-
tients with known SIHD who have new or worsening symptoms
HD: New, Recurrent, or Worsening Symptoms
LOE References Additional Considerations
B (114,145–147)
B (172,276,278,284,306,
313,314,320,324,
327–329,1237–1240)
B (1241,1242) ● Prior requirement for imaging
with exercise
● Known or at high risk for
multivessel disease
efit C (333)
B (148–150,152–156)
B (280,281,283)
efit C N/A
B (1244–1248) Patency of CABG or coronary stent
3 mm diameter
B (158,161,1244) In the absence of known
moderate or severe calcification
and intent to assess coronary
stent 3 mm in diameter
efit B (1244–1248) Known moderate or severe native
coronary calcification or
assessment of coronary stent
3 mm in diameter in patients
who have new or worsening
symptoms not consistent with
UA
cal functioning (i.e., moderate household, yard, or recreational work and most activities of daily
ximum heart rate.
y; CMR, cardiac magnetic resonance; COR, class of recommendation; ECG, electrocardiogram;
; SIHD, stable ischemic heart disease; and UA, unstable angina.n SI
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b) have an uninterpretable ECG. (Level of Evidence: C)
6.3.1.3. IRRESPECTIVE OF ABILITY TO EXERCISE
CLASS IIb
1. CCTA for assessment of patency of CABG or of coronary stents 3
mm or larger in diameter might be reasonable in patients with
known SIHD who have new or worsening symptoms not consistent
with UA, irrespective of ability to exercise (1244–1248). (Level of
Evidence: B)
2. CCTA might be reasonable in patients with known SIHD who have
new or worsening symptoms not consistent with UA, irrespective of
ability to exercise, in the absence of known moderate or severe
calcification or if the CCTA is intended to assess coronary stents less
than 3 mm in diameter (158,161,1244). (Level of Evidence: B)
CLASS III: No Benefit
1. CCTA should not be performed for assessment of native coronary
arteries with known moderate or severe calcification or with
coronary stents less than 3 mm in diameter in patients with
known SIHD who have new or worsening symptoms not consis-
tent with UA, irrespective of ability to exercise (1244–1248).
(Level of Evidence: B)
See Online Data Supplement 1 for additional data on nonin-
vasive testing in known SIHD: recurrent or worsening
symptoms.
Strategies for the selection and use of noninvasive testing
in the evaluation of new or worsening symptoms in patients
with documented SIHD are similar to those in suspected
SIHD. As always, in patients with interpretable rest ECGs
who are capable of exercise, treadmill exercise ECG testing
remains the first choice. Whenever possible, initial and
follow-up testing should be performed with the same stress
and imaging techniques so that any interval change can be
attributed more reliably to alterations in clinical status rather
than mere differences in technique. Loss of the ability to
exercise on follow-up testing, in and of itself, suggests
deterioration in functional and clinical status. In general, the
diagnostic accuracy of stress testing is similar in patients
with and without known SIHD (Section 2.2.3). A few
meta-analyses examining the effect of prior MI on diagnos-
tic accuracy have found that the specificity of exercise ECG
was higher in mixed populations (145), whereas the diag-
nostic performance of exercise echocardiography was re-
duced. In contrast, the specificity of exercise SPECT was
increased because of the predictive value of total stress
perfusion abnormalities, which includes both the risk of
ischemia plus infarcted myocardium (91). Although CMR
LGE imaging detects MI, current evidence indicates that
assessment of myocardial ischemia provides incremental
diagnostic (1249) and prognostic value above LGE detec-
tion of infarction (284) in patients with or without known
SIHD.
In contrast to stress testing, the diagnostic value of
CCTA differs in patients with and without known CAD.
Limitations of image quality relating to coronary calcifica-
tion, coronary stents, or vascular clips can reduce diagnostic haccuracy, and revascularization also affects results. The large
caliber of venous conduits facilitates the assessment of
patients who have undergone CABG with CCTA and has
sensitivities of 89% to 98% and specificities of 89% to 97%
for the identification of50% diameter stenoses in grafts on
invasive coronary angiography (1244–1246). The accurate
evaluation of coronary stents with CCTA depends on the
material and diameter of the stent, with image artifacts
related to the stents’ metallic structure preventing assess-
ment of 9% to 11% of stents (1247,1248). Typically, stents
3 mm in diameter can be assessed (1248), with sensitiv-
ities for detecting a 50% diameter in-stent restenosis on
invasive coronary angiography of 86% to 94% and specific-
ities of 91% to 93%.
6.3.2. Noninvasive Testing in Known SIHD—
Asymptomatic (or Stable Symptoms): Recommendations
See Table 21 for a summary of recommendations from this
section.
CLASS IIa
1. Nuclear MPI, echocardiography, or CMR with either exercise or
pharmacological stress can be useful for follow-up assessment at
2-year or longer intervals in patients with SIHD with prior evidence of
silent ischemia or who are at high risk for a recurrent cardiac event
and a) are unable to exercise to an adequate workload, b) have an
uninterpretable ECG, or c) have a history of incomplete coronary
revascularization (10,12,15). (Level of Evidence: C)
CLASS IIb
1. Standard exercise ECG testing performed at 1-year or longer inter-
vals might be considered for follow-up assessment in patients with
SIHD who have had prior evidence of silent ischemia or are at high
risk for a recurrent cardiac event and are able to exercise to an
adequate workload and have an interpretable ECG. (Level of Evi-
dence: C)
2. In patients who have no new or worsening symptoms or no prior
evidence of silent ischemia and are not at high risk for a recurrent
cardiac event, the usefulness of annual surveillance exercise ECG
testing is not well established. (Level of Evidence: C)
CLASS III: No Benefit
1. Nuclear MPI, echocardiography, or CMR, with either exercise or
pharmacological stress or CCTA, is not recommended for follow-up
assessment in patients with SIHD, if performed more frequently
than at a) 5-year intervals after CABG or b) 2-year intervals after PCI
(10,12,15). (Level of Evidence: C)
See Online Data Supplement 1 for additional data on noninva-
ive testing in known SIHD: asymptomatic (or stable symptoms).
.3.3. Factors Influencing the Use of
ollow-Up Testing
he appropriateness of performing noninvasive testing in
atients who either are asymptomatic or have stable symp-
oms (i.e., routine surveillance testing) depends on factors
elated to the likelihood of significant findings, such as the
atient’s risk for rapidly advancing disease, propensity to
ave silent ischemia, and length of time since revasculariza-
hocard
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insufficient to support routine, repeat testing in asymptom-
atic individuals. However, evidence exists that persistent
ischemia on testing is a prognostically poor finding. Explor-
atory data from a small cohort of 314 patients with SIHD
enrolled in the COURAGE trial nuclear substudy revealed
that a reduction in the ischemic myocardium is associated
with an (unadjusted) reduction in the incidence of death or
MI combined (306). In the BARI 2D trial, at 1 year of
follow-up, more extensive and severe stress myocardial
perfusion SPECT abnormalities were associated with
higher rates of death or MI (276).
There are, however, several circumstances in which a
decision to perform follow-up testing is thought to be
warranted in the absence of a change in clinical status,
although data supporting this approach are limited. These
circumstances include, but are not limited to, evaluation of
incomplete revascularization, assessment of the adequacy of
medical therapy by provocative exercise testing, a substantial
change in risk profile, or the need to reevaluate coronary
status in anticipation of major noncardiovascular surgery
when the patient’s exercise capacity is limited or unknown
(although revascularization in this circumstance has not
been shown to reduce the risk of perioperative cardiovascu-
lar complications), as detailed in the ACCF/AHA Periop-
erative Cardiovascular Evaluation and Care for Noncardiac
Surgery Guideline (1250). Care should be taken when
interpreting paired testing results to incorporate not only
the change in the extent and severity of ischemia but also the
workload at onset and total exercise capacity achieved, as
these factors relate to the patient’s symptom burden and
functional correlates in daily life. Outside of such special
circumstances, routine periodic testing is not recommended
Table 21. Noninvasive Testing in Known SIHD: Asymptomatic (
Test
Exercise
Status
ECG
Interpretable
Pretest ProbabiAble* Unable Yes No
Exercise or pharmacological
stress with nuclear MPI,
Echo, or CMR at 2-y
intervals
X X Prior evidence of
or high risk fo
cardiac event.
listed in additi
considerations
Exercise ECG at 1-y
intervals
X X An
Exercise ECG X X No prior evidence
ischemia and
of recurrent ca
Exercise or pharmacological
stress with nuclear MPI,
Echo, or CMR or CCTA
Any Any An
*Patients are candidates for exercise testing if they are capable of performing at least moderat
living) and have no disabling comorbidity. Patients should be able to achieve 85% of age-predic
CABG indicates coronary artery bypass graft surgery; CCTA, cardiac computed tomography
tomography angiography; CMR, cardiac magnetic resonance; ECG, electrocardiogram; Echo, ec
percutaneous coronary intervention; and SIHD, stable ischemic heart disease.in patients who are at low risk for progression or had overtsymptoms on initial presentation (i.e., those without known
silent ischemia) or very early after revascularization. In
addition to a lack of evidence for testing to detect ischemia,
currently there is also little research to support exercise stress
testing for risk assessment in asymptomatic patients with
known CAD, except for cardiac rehabilitation and exercise
prescription purposes (Section 4.4.1.4).
6.3.4. Patient Risk and Testing
By using clinical, noninvasive, and invasive data acquired
during the initial evaluation and subsequently, recommen-
dations about stress testing in patients with known SIHD
can be formulated on the basis of the following consider-
ations: In the absence of a change in clinical status, patients
with a low projected annual mortality rate (1%) are those
with low-risk Duke treadmill scores, either without imaging
or with negative imaging findings, whose 4-year cardiovas-
cular survival rate approximates 99%. The low-risk category
also includes patients with normal stress imaging who lack
adverse prognostic characteristics, such as diabetes mellitus
or prior MI. Younger women without diabetes mellitus or a
prior MI who have normal stress nuclear MPI remain at
very low risk for as long as 7 to 9 years (307), depending on
specific clinical characteristics, and probably do not require
repeat stress imaging during that period in the absence of
changes in clinical status (307).
Data are more limited with regard to the value of serial
testing strategies in patients at intermediate risk of cardiac
mortality (1% to 3% per year). Follow-up testing probably
should be performed only if decisions about a change in
pharmacological management, level of exercise, or revascu-
larization will be influenced directly by the test result or if
the patient has persistent symptoms despite adequate
table Symptoms)
Ischemia COR LOE References Additional Considerations
ischemia
rent
criteria
IIa C (10,12,15) a) Unable to exercise to adequate
workload or
b) Uninterpretable ECG or
c) History of incomplete
coronary revascularization
IIb C N/A a) Prior evidence of silent
ischemia OR
b) At high risk for recurrent
cardiac event
lent
high risk
event.
IIb C N/A For annual surveillance
III: No Benefit C (10,12,15) a) 5-y intervals after CABG, or
b) 2-y intervals after PCI
cal functioning (i.e., moderate household, yard, or recreational work and most activities of daily
ximum heart rate.
aphy; CMR, coronary magnetic resonance; COR, class of recommendation; CCTA, computed
iography; LOE, level of evidence; MPI, myocardial perfusion imaging; N/A, not available; PCI,or S
lity of
silent
r recur
Meets
onal
.
y
of si
not at
rdiac
y
e physi
ted ma
angiogrGDMT. Thus, in the patient with known SIHD, the goal
farctio
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burden after optimization of GDMT or the consideration
of revascularization as a result of failed optimal medical
management. Furthermore, to be considered significant,
findings should be outside the expected range of variability
of test results, which is approximately 5% for stress nuclear
MPI (306,366), such that patients move into a higher or
lower risk category.
Even for high-risk patients, the value of annual exercise
testing (or serial exercise testing at alternative intervals) in
the absence of a change in symptoms has not been studied
adequately. Yearly exercise testing could be useful in pa-
tients with SIHD who have 3% risk of mortality per year,
because a marked decrease in exercise capacity or a marked
increase in ischemic burden can warrant reevaluation of the
medical regimen or interventional plan. Examples of such
patients are those with a high-risk Duke treadmill score,
patients with an EF 50% and significant CAD in 1
major vessel, patients with diabetes mellitus, and those with
multivessel disease who have not undergone CABG. Some
data also suggest that ischemic burden might be useful in
targeting ischemia-guided revascularization. In a substudy
of the COURAGE trial, the overall event-free survival rate
was 86.6% in patients with 5% reduction in ischemic
myocardium versus 75.3% in those without significant
reduction in ischemic burden after 6 to 18 months (unad-
justed p0.037; adjusted p0.26) (306). Although this trial
substudy was not powered to examine differences in clinical
outcomes, the results are similar to the BARI 2D trial, in
which patients with high myocardial jeopardy scores ran-
Figure 15. Incidence of Cardiac Death or Nonfatal MI During Follo
Adapted with permission from Hachamovitch et al. (327). MI indicates myocardial indomized to CABG had fewer cardiovascular events (AMIand composite endpoint of all-cause mortality or MI and
cardiac death or MI) than those with high scores who
received only medical therapy (276,409).
6.3.5. Stability of Results After Normal Stress Testing
in Patients With Known SIHD
The durability of information gained from a stress test
over time varies widely according to the characteristics of
the patients and the type of test performed. Among
patients with several clinical risk factors and negative
stress imaging studies, the relative hazard for cardiac
death or MI can increase after a 2-year follow-up time
period, whereas among other groups, the risk remains low
through 2 years and can be safely assumed to remain low
for an extended period of time. In 1 large single-site
study, the factors associated with an earlier increase in
risk included diabetes mellitus, male sex, increased age
(i.e., 70 years), a history of previous MI or revascular-
ization, and having undergone a pharmacological stress
test rather than an exercise test (327) (Figure 15). The
relationships were, however, complex and covarying.
Importantly, among patients who were younger and
female and did not have diabetes mellitus or a history of
MI or revascularization, the annual risk of adverse
cardiovascular events was predicted to remain 1% for as
long as 9 years, on the basis of hard events observed
during the 2-year follow-up period. In contrast, in an
80-year-old man with a normal pharmacological stress
study, the risk of an adverse event rose to 1% in 1 year
After a Normal Stress MPI
n; MPI, myocardial perfusion imaging.w-Upafter an index-negative perfusion evaluation.
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With Known CAD
The interpretation of repeat testing should be based on a
threshold change value that exceeds the expected variability
in test results, even in patients at high risk for recurrent
events, and especially in those with no interval clinical
change (1244). Although the variability of exercise and
stress testing results is not well established (306,1251),
factors such as differences in day-to-day operations in the
same laboratory, interobserver variability, and differences
between practices in different imaging laboratories are
important contributory factors in observed differences in
serial testing. A 5% change in the percent of ischemic
myocardium (based on extent and severity) has been sug-
gested by some investigators as a threshold that indicates
clinically significant change for stress nuclear MPI
(306,1251). The findings from different exercise or stress
imaging modalities (echocardiography versus nuclear MPI)
can be even more difficult to compare, such that clinicians
should use the same imaging modality over time whenever
possible. Despite these concerns, significant changes in risk
category (such as shifting to a lower- or higher-risk patient
subset) may be used to guide interpretability of interval
change in repeat testing (306,333), and the presence of
significant interval change can alter risk assessment. For
example, in the ACME (Angioplasty Compared to Medi-
cine) trial, patients whose exercise nuclear MPI normalized
after 6 months of randomized treatment had an improved
survival rate (92%) compared with those with persistent
ischemia (82%, p0.02) (333). The ongoing technical
evolution within imaging modalities is, in part, aimed at
minimizing intraobserver, interobserver, and intertest vari-
ability.
6.3.7. Future Developments
Numerous opportunities to improve the diagnosis and
management of SIHD remain. Large registries have the
potential to improve the diagnosis of IHD and to assess risk
according to clinical information and results from noninva-
sive testing. Risk-assessment strategies from older databases
should be updated with modern information and statistical
techniques. Technical development across all cardiac imag-
ing modalities continues to evolve rapidly, often outpacing
the ability to perform rigorous clinical validation and appli-
cation. Current and anticipated technical developments of
CT scanners and software are intended to improve the
spatial and temporal resolution of cardiac CT images while
reducing the radiation dose received from a typical exami-
nation. They include wider detector arrays that allow higher
numbers of simultaneously acquired image slices, faster
x-ray tube rotation times, and the use of alternative image
reconstruction techniques that target image noise, all of
which could improve the diagnostic value of CCTA in
currently challenging scenarios, such as calcified coronary
arteries and coronary stents. The improvement also will ofoster the study and clinical use of newer applications of
cardiac CT, such as coronary plaque characterization, late
enhancement imaging for the detection of myocardial scar,
and MPI to detect myocardial ischemia (1252). Efforts
currently under way to obtain perfusion information from
CCTA images are promising (196–201), with one report
also calculating FFR with CCTA (195). Moreover, plaque
quantification software is in development and could further
guide accurate detection of atherosclerotic disease burden
(1253).
Several new developments in stress nuclear MPI have occurred,
including new radioisotopes: 1) an F18 PET perfusion agent (in
Phase III trials), which will allow exercise PET testing;
2) 123I-beta-methyl-iodophenylpentadecanoic acid SPECT, with
the unique ability to document metabolic alterations representing
prior ischemic episodes (i.e., ischemic memory); and 3) 123I-
abeled meta-iodobenzylguanidine SPECT, which could be
elpful for assessment of arrhythmic risk in SIHD patients
1254). Several new SPECT cameras also have been intro-
uced into the marketplace and offer the opportunity for
mproved image quality within a substantially shorter time
eriod and with a lower radiation dose (1255,1256). Several
tudies have correlated atherosclerotic plaque characteristics
ith the extent of ischemic myocardium by stress nuclear
PI (202–206,215). Finally, the diagnostic and prognostic
alue of PET flow reserve data is currently under intense
nvestigation (185,1257).
Echocardiography, being the most portable and widely
vailable stress imaging technique, has developed novel
ethods that are promising in the assessment of SIHD
atient. Speckle-tracking echocardiography provides a
-dimensional, angle-independent, real-time evaluation of
yocardial strain and has been shown to detect myocardial
schemia incremental to wall motion analysis (1258,1259).
ecent reports of contrast echocardiography MPI during
asodilating stress indicate that it is a potentially robust and
linically viable tool in detection of CAD (1260). Finally,
-dimensional techniques can provide an improved assess-
ent of cardiac size and function in patients with SIHD.
Increasing recognition of the ability of CMR to accu-
ately assess abnormal myocardial physiology of CAD by
ombined imaging of rest and stress ventricular function,
erfusion, and myocardial viability is expected to increase its
se in SIHD (172,1261,1262). With rapid data acquisition
y parallel imaging, real-time cine, or sub-second single-
hot imaging methods, a diagnostically adequate CMR can
e obtained without the need for patient breath-holding or
CG gating (1263). A routine CMR assessment of CAD
an be achieved in 30 minutes. These developments likely
ill improve diagnostic consistency and patient throughput
f CMR. CMR myocardial perfusion and LGE imaging for
schemia and scar, respectively, have improved image quality
t 3.0T field strength compared to 1.5T and have been
hown to improve diagnostic accuracy in detecting CAD
1264). Whole-heart 3-dimensional coronary magnetic res-
nance angiography with navigator respiratory-gating has
e128 Fihn et al. JACC Vol. 60, No. 24, 2012
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clinical trials (1265,1266).
Further studies on lipid management are warranted to
ascertain the optimal drug regimens for patients with
SIHD. Questions remain as to the optimal dose of statins
and the effectiveness of combining lipid-lowering medi-
cations. In addition, studies that establish the effective-
ness of CABG in comparison with contemporary
GDMT are necessary, as are studies that better define the
relative benefits of different revascularization techniques.
(Figure 13).
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